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Abstract
To explore the regulation and function of the serotonin transporter (5-HTT),
transgenic (Tg) mice that over express the human 5-HTT were made. A 500Kb
modified yeast artificial chromosome (YAC35D8) containing the human 5-HTT
gene and its 5' regulatory sequence was injected into fertilized mouse oocytes, and
Tg offspring were identified by PCR. Analysis by in situ hybridisation showed that
h5-HTT mRNA is over-expressed in the cortex, hippocampus and mesencephalic
raphe nuclei of these animals. RNase protection and RT-PCR showed that the
human 5-HTT is expressed in these regions at levels comparable to, or greater than,
that of the endogenous 5-HTT whilst the mouse 5-HTT RNA remained unaltered.
[3H]-Citalopram, a high affinity 5-HTT ligand, was used to measure the protein
expression. [3H]-citalopram binding showed a higher Kd value (/3<0.02) and a 2.3 -
3.5 fold increase in binding site density (R<0.01) in cortical membranes from Tg
mice compared to controls. In addition, the Hill coefficient was less than 1
(consistent with the presence of two binding sites corresponding to the human and
mouse 5-HTT).
Using HPLC, tissue extracts from the brainstem, hippocampus, midbrain,
hypothalamus cerebellum and basal ganglia were analysed for 5-HT, DOPAC and
5-HIAA. The transgenic mice show a drop in 5-HT levels in all areas except the
cerebellum (-17 to -40%) and a slight increase in 5-HIAA levels (6-17%); although
this was only significant in the cortex (42% p<0.05). Thus the 5-HIAA to 5-HT ratio
was increased by 27-76% in transgenic animals (p<0.005).
Irwin screening for behavioural abnormalities discovered no overt phenotype in
transgenic mice. Mice were then treated with MDMA, a psychoactive chemical that
acts at the 5-HTT, in a ramped dosing regime (1,3,10,30 mg/kg) one dose per day
and horizontal, locomotor activity and body temperature recorded using telemetry
equipment. Drug naive transgenic mice were less active during the dark period of
the diurnal cycle. There was a shift in the response curve for MDMA suggesting that
transgenic mice have an increased sensitivity to MDMA. Transgenic mice showed
an altered thermoregulatory response, with a pronounced hypothermia (reaching
-8°C in one case) occurring within 7 hrs of administration of the 10 mg/kg dose of
MDMA in contrast to a slight hyperthermia in wild-type animals.
In conclusion these mice show a moderate over-expression of the human 5-HTT,
which results in significant alterations in the metabolism of 5-HT. This may provide
a useful animal model of the neurochemical disturbances occurring in affective
disorder in man.
I hereby confirm that the work in this thesis is all my own with the
exception of the MDMA behavioural studies which were done in
collaboration with Dr Hugh Marston, FINE, Edinburgh,.
None of this work has been submitted , in whole or in part, for any
other degree program.
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Genetic variability is an area of huge interest in the search for causes, treatments and
prevention of disease, including disorders such as depression and anxiety. These
disorders are believed to involve disturbances in the availability of neurotransmitters,
particularly of 5-Hydroxytryptamine (5-HT or serotonin). An important aspect of the
regulation of this transmitter is the specific 5-HT transporter protein (5-HTT), which
removes the transmitter from the synapse. The expression of this protein can be
influenced by individual genetic make-up or by experimental manipulation of the
genome. Inserting or deleting specific sequences ofDNA within the mouse genome
creates an animal model for understanding gene function and the effects of enhanced
or diminished expression of an individual gene. Such an animal model provides an
excellent method to analyse the effect of changing one element in a complex system.
Transgenic technology where protein expression can be moderately changed by
inserting extra copies of a gene is a particularly useful and powerful tool for studying
the ramifications of genetic variability on whole systems. In fact, one of the reasons
that the 5-HT system is still poorly understood is because of its complexity. In
addition to the transporter there are 14 known 5-HT receptor subtypes, which are
expressed both pre- and post-synaptically.
Because the 5-HT transporter plays such an important role in regulating 5-HT, this
study will examine the effects of increased 5-HTT expression in transgenic mice at
two levels: locally on the 5-HT system and systemically on animal behaviour and
physiology. A mouse model with extra copies of the gene for the 5-HT transporter
may be particularly significant in view of recent evidence suggesting that the 5-HTT
is increased in depressed patients (Dahlstrom et al., 2000).
The 5-HT system is well known, even to the general public, as the target of the
antidepressant Prozac (fluoxetine) and because of its association with the effects,
both positive and negative, of the popular recreational drug 'Ecstasy' (MDMA or
1
(±) 3,4-methylenedioxymethamphetamine). This study will therefore also examine
the effects of increased 5-HTT expression on behavioural responses to MDMA.
The following pages of this introduction will present the areas of the 5-HT system
most relevant to 5-HTT activity: 5-HT synthesis and regulation, the actions and
regulation of the 5-HTT, 5-HT neuroanatomy and projections, the role of 5-HT and
5-HTT in relevant disease states, and the rationale for using a transgenic animal
model.
1.1 The 5-HT system
In evolutionary terms 5-HT is one of the oldest transmitters in the human brain. The
serotonergic system is involved in both neuronal development and in many functions
of the central nervous system (CNS), including cognition, emotion, and possibly
motor function. Serotonergic inputs from the raphe nuclei of the brainstem project
throughout the forebrain and to the spinal cord.
The first identification of the substance now known as 5-HT (serotonin) was as a
serum factor that caused vasoconstriction (Brodie, 1900). As a serum tonic factor, it
was named 'serotonin' (Page, 1976). A substance found in the chromaffin cells of
the enteric nervous system, which caused smooth muscle contraction (Vialli, 1933),
was called enteramine. When isolated as the factor released from platelets during
blood clotting, this substance was identified chemically as 5-Hydroxytryptamine
(Page, 1976). The two substances serotonin and enteramine were found to be
identical by Erspamer et al in the 1950's (Erspamer, 1963). Since the mid-twentieth
century, the terms serotonin and 5-Hydroxytryptamine have been used
interchangeably. The presence of 5-HT in the brain was first reported in 1953 by
Twarog and Page (Twarog, 1988).
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1.1.1 5-HT synthesis
The synthesis and metabolism of 5-HT is well documented and is tightly regulated
(Figure 1.1.). 5-Hydroxytryptamine is synthesised from the essential amino acid
tryptophan, obtained from the diet. The availability of tryptophan, which is
transported across the blood-brain barrier by a neutral amine transporter (Blasberg
and Lajtha, 1966), is a rate-limiting factor in the two-step process of 5-HT synthesis
(Grahame-Smith, 1964; Hamon and Glowinski, 1974). First the 5' position of the
indole ring of the tryptophan molecule is hydroxylated by tryptophan hydroxylase
(TPH) in the cytoplasm of the cell, a process which requires NADPH, reduced
pteridin, and oxygen as cofactors (Joh et ah, 1975). The expression of this enzyme is
specific to 5-HT neurons, and its activity is the rate-limiting step in the synthesis of
5-HT (Hamon et ah, 1981). Second, the resulting product, 5-Hydroxytryptophan, is
rapidly decarboxylated by the enzyme L-aromatic amino acid decarboxylase to form
5-Hydroxytryptamine (5-HT). This non-specific enzyme, which modifies most L-
form amino acids, is found in high abundance in catecholamine neurons where it is
also involved in the synthesis of noradrenaline (NA) and dopamine (DA).
Tryptophan hydroxylase activity is regulated at many levels (Joh, 1998). At the level
of protein regulation, this enzyme's activity is regulated by phosphorylation of the
non-active form of TPH to the active enzyme by both Ca2+/calmodulin-
dependent (Hamon et ah, 1981; Kuhn and Lovenberg, 1982) and cAMP-dependent
(Foguet et ah, 1993) protein kinases. The activity of cAMP protein kinases is
dependent upon cAMP formation by adenylate cyclase, which is regulated by several
5-HT receptor subtypes, which in turn regulate 5-HT synthesis. 5-HTia receptors are
negatively linked to both adenylate cyclase and to Gi-protein regulated K+- or Ca2+
channels, and so may act through either protein kinase system (Starke et ah, 1989;
Williams et ah, 1988). 5-HTib receptors are also linked to the adenylate cyclase
second messenger system. The stimulation of 5-HTia receptors by agonists
decreases 5-HT synthesis, but blockade of 5-HTia receptors only marginally
increases 5-HT synthesis (Larsson et ah, 1998; Stenfors et ah, 2000). The terminal
autoreceptor 5-HTib also inhibits 5-HT synthesis. Stimulation of the 5-HTib
3





Figure1.1PathwaysfoSynthesif5-HTandi smajorMetabolites (adaptedfromWren2000J h(1998))
receptor markedly inhibits synthesis and the blockade of 5-HTib receptors increases
synthesis, indicating that endogenous 5-HT does exert a tonic effect on synthesis via
this receptor (Moret and Briley, 1997a; Moret and Briley, 1997b; Stenfors et ah,
2000; Stenfors et ah, 2001). Both 5-HTia and 5-HTib receptors can regulate
synthesis independently under experimental conditions (Barton and Hutson, 1999),
but they are probably not the only receptors involved physiologically. Selective
serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants increase
extracellular 5-HT and inhibit neuronal firing and 5-HT synthesis (Aghajanian, 1972;
Carlsson and Lindqvist, 1978; Corrodi and Fuxe, 1969; Fuller et al., 1974; Gartside
et ah, 1995; Hjorth, 1993; Hjorth and Sharp, 1993; Hjorth et ah, 1995; Invernizzi et
ah, 1992; Svensson, 1978). This acute effect is dependent on the presence of 5-HT
and is not prevented by blocking 5-HTja, 5-HTib or a combination of both receptors
(Moret and Briley, 1997a; Stenfors et ah, 2001). This last observation suggests that
another as yet undefined mechanism exists by which 5-HT release inhibits 5-HT
synthesis.
1.1.2 S-WTmetabolism
In addition to being regulated by changes in synthesis, 5-HT levels may be affected
by changes in 5-HT metabolism. 5-HT is metabolised by the monoamine
oxidase/aldehyde dehydrogenase pathway (Weissbach, 1961).
Of the two forms ofMAO that are expressed differentially in the brain (Westlund et
ah, 1985), only the clorgyline-sensitive MAO-A is expressed in 5-HT neurons
(Johnston, 1968). MAO-A, which is located on the outer mitochondrial membrane
(Schnaitman and Pedersen, 1968), converts cytoplasmic 5-HT by oxidative
deamination to 5 -Hydroxyindole acetaldehyde. NAD+-sensitive aldehyde
dehydrogenase then converts the 5-Hydroxyindole acetaldehyde to 5-Hydroxyindole
acetic acid (5-HIAA) the major metabolite of 5-HT (Duncan and Sourkes, 1974). A
minor metabolite, 5-Hydroxytryptophanolcan, is produced from 5-Hydroxyindole
acetaldehyde by metabolism by NADPH-sensitive aldehyde reductase (Cheifetz and
Warsh, 1980). In the pineal gland and the retina 5-HT is also metabolised, via
5
N-acetyl serotonin, to produce melatonin, which is important in the co-ordination of
circadian activity (Feldstein and Williamson, 1968; Klein et ah, 1971). Regulation of
5-HT metabolism is thus largely dependent upon the activity of MAO-A, which is
influenced by the availability of its substrate 5-HT, but enzyme activity may also be
controlled by other feedback mechanisms. For instance, preliminary evidence
suggests that MAO-A transcription and therefore 5-HT metabolism may be genotype
specific. Human volunteers with a promoter polymorphism that increases MAO-A
transcription have altered levels of 5-HT and dopamine metabolites in the CSF. This
effect was genotype and gender specific with women showing increased monoamine
metabolism whilst men had the opposite trend (Jonsson et ah, 2000).
1.2 The 5-Hydroxytryptamine transporter (5-HTT)
The existence of the 5-HTT and other monoamine transporters has been known since
the 1960's. These transporters are part of a Na+/Cf dependent transporter family,
usually referred to as the NET/GAT family after the first cloned proteins from this
family (the norepinephrine transporter, NET, and the GABA transporter GAT)
(Blakely et ah, 1991). This family includes the proteins that transport the biogenic
amines noradrenaline (NET), dopamine (the dopamine transporter (DAT), and 5-HT
(the 5-HTT). These transporters, located on the plasma membrane, have a high
sequence homology and a putative structure with 12 transmembrane domains (Figure
1.2).
1.2.1 The mechanism of5-HT uptake
The recapture of released neurotransmitter via the plasma membrane is the first of
two steps required for neurotransmitter recycling. Figure 1.3 outlines this uptake
mechanism. The second step in the transport process sequesters cytoplasmic
transmitters within vesicles via VMAT2 in preparation for their release by
exocytosis. A brief discussion of the biogenic amine transporters and the vesicular
monoamine transporter (VMAT), which is involved in 5-HT transmission, is given
below.
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Figure 1.3 Diagram of a serotonergic neuron showing (A) factors involved in neuronal firing and somatic regulation and (B) synaptic
transmission (adapted from Blier&De Montigny 1998)
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As mentioned above, dopamine, noradrenaline and 5-HT are the main substrates for
the DAT, NET and 5-HTT respectively, and these transporters are primarily
restricted to their specific amine neuron type (Blakely et al., 1994; Lester et al.,
1996; Lorang et al., 1994). All the monoamine transporters can transport other
substrates in addition to their own .The DAT and NET transport their own substrates
with an affinity of about lpM though the NET can also transport DA with equal
affinity. The 5-HTT has a slightly higher affinity for its substrate, in the range of
about 300-500 nM. In addition to the endogenous substrates the monoamine
transporters can transport neurotoxins such as amphetamine and MDMA. Various
drugs such as cocaine and a wide range of specific inhibitors can also block
transporters. Some inhibitors have a range of targets, for example Nomifensine has a
high affinity for both DAT and NET. Desmethylimipramine (DMI) and nisoxetine
however are selective for NET whilst Citalopram, clomipramine, paroxetine and
fluoxetine are considered serotonin specific re-uptake inhibitors (SSRIs) due to their
higher affinity for the 5-HTT. In addition there is some species variability in the
affinity of inhibitors for the 5-HTT. These drugs will be used in this thesis research
for pharmacological analysis of transgenic protein expression to confirm the
expression of the human protein. This process is discussed in greater depth in
Chapter 4.
Monoamine transport is Na+ and CI" dependent and occurs by secondary active
transport. The electrochemical gradient for this secondary active transport is
generated by the plasma membrane Na+/K+ ATPase (Kanner and Schuldiner, 1987).
The outwardly directed K+ gradient coupled with the inwardly directed Na+ and CI"
gradients provides the driving force for 5-HT transport across the plasma membrane
(Rudnick and Clark, 1993). The ionic dependence of monoamine transport appears
to vary between transporters, at least in stably transfected cells (Blakely et al., 1994).
Dopamine requires two Na+ ions for co-transport, whilst noradrenaline and 5-HT use
only one Na+ ion. All three transporters also co-transport a single CI" ion (Blakely et
al., 1994).
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The most widely known theoretical model for transporter activity is that proposed by
Rudnick and Clark (1993: Figure 1.4). These authors suggested that the 5-HTT
forms two channel-like states, open and closed, which differ only in the accessibility
of its central binding site. The model follows the gate-lumen-gate theory, behaving
like a channel with a gate at each face, but only one gate can be open at any point in
time. However, more recent evidence has suggested that there is more to the
transport process than a simple carrier-mediated response. Electrophysiological
studies using the dopamine transporter have uncovered a Na+ current that the
currents generated by co-transported ions could not explain.
Two different antidepressant-sensitive Na+ fluxes were detected using both Xenopus
oocytes (Lester et ah, 1994; Lin et ah, 1996; Mager et ah, 1994; Zahniser et ah,
1998) and mammalian cells (Galli et ah, 1996; Galli et ah, 1995; Galli et ah, 1997).
The one is associated with the transport cycle and the second with a leak current in
the absence of substrate. Two reviews of these data (Lester et ah, 1996; Sonders and
Amara, 1996) suggest that transporters have a channel-like activity, possibly through
the formation of a pore-like multimeric structure, whilst other evidence suggests that
the transporter-associated leak current is due to both gates remaining open (Cao et
ah, 1998). The role of these currents in the transport process is still unclear and a
fascinating area of investigation.
1.2.2 Regulation of5-HT transporter function
The activity of the 5-HTT is regulated by extracellular factors such as amounts of
5-HT. 5-HTT levels are decreased (Benmansour et ah, 1999) following prolonged
treatment with SSRIs, possibly due to the effect of increased extracellular 5-HT,
(Pineyro et ah, 1994). Transporter activity can also be modulated by intracellular
messenger systems, such as the protein kinase C pathway, which can be activated by
neuronal receptors, and transcription factors such as retinoic acid receptors.
In human chorionic JAR cells, 5-HTT activity is modulated by chronic exposure to
treatments that elevate cAMP, including cholera toxin (Cool et ah, 1991). Inhibitors
10
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of transcription and translation could prevent this effect, which had a delay of several
hours. The human 5-HTT RNA increased in parallel with the 5-HTT protein,
indicating a transcription-mediated increase (Ramamoorthy et al., 1993b). However,
a non-cAMP-dependent pathway was also present (Lester et al., 1996; Ramamoorthy
et al., 1995a; Ramamoorthy et al., 1995b; Sonders and Amara, 1996). In addition to
regulation of transcription, 5-HTT function is regulated at the protein level. 5-HTT
activity can be regulated by the activation of both protein kinase A and protein
kinase C (PKC) pathways (Blakely et al., 1998; Qian et al.,1997). Platelet, endothelial
and brain 5-HTT are down-regulated within minutes by PKC activation (Anderson
and Home, 1992; Myers et al., 1989). The down-regulation of 5-HT uptake in
HEK293 cells by PKC occurs via a specific reduction in cell-surface protein (Qian et
al., 1997). PKC induced down regulation could be due to phosphorylation of the
transporter inducing protein translocation or to phosphorylation of other proteins
causing alterations in intracellular trafficking. The 5-HTT has many putative
phosphorylation sites on both the NH2 and COOH termini and both termini can be
phosphorylated by purified protein kinases suggesting a role for direct
phosphorylation (Blakely et al., 1993; Blakely et al., 1998; Ramamoorthy et al.,
1998). The rapid kinase-mediated regulation of 5-HT uptake activity, is concurrent
with 5-HTT phosphorylation and is paralleled by reductions in 5-HTT surface
abundance due to intemalisation of the 5-HTT (Qian et al., 1997) suggesting a link
between phosphorylation and intemalisation. Recent evidence shows that 5-HT and
other 5-HTT substrates inhibit PKC-induced phosphorylation of the 5-HTT and
reduce loss of cell surface protein (Ramamoorthy and Blakely, 1999). This effect is
abolished by the presence of antidepressants and may be a method to link 5-HTT
expression to extracellular amine concentration. However recent studies on
monoamine transporters also suggest that cell surface protein expression is more
dynamic than previously thought and suggest the existence of additional, as yet
undefined, regulatory mechanisms (Blakely et al., 1998).
5-HTT activity can also be regulated by rapid elevation/depletion of intracellular
Ca2+ (Nishio et al., 1995), treatment with calmodulin inhibitors (Jayanthi et al.,
1994), and by NOS/cGMP pathways (Launay et al., 1994; Miller and Hoffman,
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1994). These alterations affect Vmax of the 5-HTT activity, not its affinity for 5-HT,
though parallel effects of modulators on vesicular amine pools may be occurring in
these studies and obscuring measurements.
Transporter function is regulated in vivo via steroid hormones (McQueen et ah,
1997) and pharmaceutical^ through the direct action of uptake inhibitors, which
bind to a site on the 5-HTT that is closely related to the transmitter binding site, thus
inhibiting transport (Graham et al., 1989). Chronic treatment with these agents
probably causes a decrease in 5-HTT density and desensitises the transporter
(Pineyro et al., 1994), as well as reducing 5-HTT mRNA levels (Lesch et al., 1993),
suggesting action at the level of gene transcription. However, which intracellular
mechanism meditates this action is unknown. Some evidence suggests that the
5-HTjb receptor has a modulating effect on 5-HTT function via a direct G-protein
mechanism (Daws et al., 2000). As with the regulatory effect of 5-HT, this
modulation is important in the maintenance of 5-HT homeostasis (Daws et al., 2000).
1.3 5-HT neurotransmission
In atypical 5-HT synapse (shown in Figure 1.3) the 5-HT nerve terminal is found in
close proximity to its postsynaptic target neuron. Upon firing 5-HT is released into
the synaptic cleft from the presynaptic neuron, the signal is then terminated by
transport of 5-HT back into the cell by the 5-HTT. Once returned to the cytoplasm
the 5-HT is either degraded by the monoamine oxidase pathway or taken up into
vesicles by the vesicular monoamine transporter (VMAT) where it is stored with the
specific 5-HT binding protein (Levi and Raiteri, 1993; Rudnick and Wall, 1992;
Tamir and Gershon, 1990). When the neuron is stimulated, the arrival of the action
potential results in the depolarisation of the nerve terminal, which in turn causes the
opening of voltage-sensitive Ca2+ channels and subsequent Ca2+ entry. The increase
in intracellular Ca2+ induces exocytosis from secretory vesicles docked at the plasma
membrane. However this exocytotic process is not the only mechanism for 5-HT
release; another mechanism, particularly for release stimulated by drugs such as the
amphetamines, is a carrier-mediated process. This process is Na+- but not Ca2+-
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dependent and, unlike exocytosis, relies on a cytoplasmic rather than vesicular
transmitter pool. Since this process is not modulated by terminal 5-HT receptors and
is blocked by re-uptake inhibitors, it probably involves 5-HT transporter activity
(Levi and Raiteri, 1993; Rudnick and Wall, 1992).
Vesicular monoamine transporters differ from the plasma membrane transporters in
that they translocate transmitters from the cytoplasm into vesicles, against a
concentration gradient, in preparation for regulated release by exocytosis. A single
vesicular transport protein, the VMAT2, is responsible for the re-uptake of all
monoamine transmitters (DA, NA and 5-HT). The affinities of these transmitters for
the VMAT2 is similar, with 5-HT having a slightly higher affinity (0.2 p,M; (Liu and
Edwards, 1997). The VMAT2 is also sensitive to reserpine and tetrabenzine (Liu and
Edwards, 1997; Masson et ah, 1999).
The VMAT couples efflux of two H+ ions to the uptake of each molecule of 5-HT
(Rudnick and Clark, 1993). The driving force for this vesicular transport is created
by an ATP-driven H+ pump, which acidifies the vesicle interior and creates a
transmembrane electrical potential. The exchange of one amine substrate for the
equivalent of two H+ ions allows a 10-fold H+ concentration gradient (one pH unit)
to lead to a 100-fold gradient of neurotransmitter (Rudnick and Clark, 1993). This
pH gradient is a stronger driving force than membrane potential, with only one
charge crossing the membrane with each catalytic cycle (Rudnick and Clark, 1993).
As shown in Figure 1.3, 5-HT neurotransmission is a highly regulated process. The
main autoregulatory effect of 5-HT on its own release is inhibitory. 5-HT is released
from the terminal and the somatodendritic area of 5-HT neurons and has a profound
effect on its own neurotransmission, via receptor-mediated regulation. 5-HT,
released from the neuron or from axons of other neurons innervating the cell,
activates receptors on the soma and on the synaptic terminal. These receptors induce
a decrease in neuronal firing or somatodendritic release (5-HTia) or 5-HT release
from nerve terminals (5-HTibAd)- The activation of 5-HTjA receptors probably
alters the propensity of a neuron to fire through altering the balance of currents
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across the membrane. Indeed 5-HTia receptors have been shown to reduce a high-
threshold Ca2+ current (Penington and Fox, 1994; Penington and Kelly, 1990;
Penington et ah, 1991) and to increase conductance to K+ ions (Aghajanian and
Lakoski, 1984; Penington et ah, 1993). Stimulation of 5-HTib receptors, however,
acts through second messenger systems to inhibit adenylate cyclase and consequently
reduces cAMP thus inhibiting release. In addition to the autoreceptors, other
receptors such as the alpha2-adrenergic receptors located on the 5-HT nerve
terminals also inhibit 5-HT release (Araneda and Andrade, 1991; Maura et ah, 1982).
All of these factors contribute to the inhibition of 5-HT neurotransmission.
Once in the synaptic cleft, 5-HT interacts with a wide variety of postsynaptic
receptors leading to a cascade of events involving second messenger coupling to
intracellular mechanisms and resulting in either excitatory or inhibitory postsynaptic
potentials. In some cell types more than one receptor subtype is present, sometimes
with apparently opposite actions on neuronal activity. The paradoxical presence of
two serotonin receptors mediating opposite effects on membrane excitability in the
same cell provides a flexible mechanism by which serotonin might regulate neuronal
activity. As an example, studies on cortical pyramidal cells exposed to extracellular
5-HT found that 5-HT simultaneously inhibited neurotransmission via 5-HTia
receptors and stimulated activity through 5-HTa receptors resulting in an altered
response to strong, but not weak excitatory stimuli (Araneda and Andrade, 1991).
5-HT neurotransmission is therefore influenced by many factors. Drugs can activate
any of the 5-HT autoreceptors; drugs can block or alter 5-HT uptake (SSRIs) or
vesicular transport (reserpine); monoamine oxidase can de-aminate 5-HT; and
genetic factors can affect any of the variables involved. The 5-HT transporter is
crucial as it is the only mechanism that terminates the 5-HT signal and recycles
5-HT; 5-HTT knockout reduces 5-HT concentrations by 65-90% of control (Bengel,
1998). The ramifications of over-expressing the 5-HTT on the 5-HT system are thus
likely to be diverse.
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1.4 5-HT receptors
A recently published article offers an excellent and comprehensive review of the
5-HT receptor field (Barnes and Sharp, 1999). The following is a brief summary of
current knowledge with particular emphasis on the receptor types involved in
regulating 5-HT neurons and which may be altered by overexpression of the 5-HTT.
All the known and well-defined 5-HT receptors, except for the 5-HT3 receptor
(Maricq et ah, 1991), are from the G-protein coupled receptor family. The sequences
of the many known members of this family vary significantly in their degree of
homology with each other, but share a common feature: the presence of seven
putative hydrophobic transmembrane domains. These domains have been implicated
by site-directed mutagenesis experiments in specific agonist recognition (Chanda et
ah, 1993). The amino terminus is predicted to be external, whilst the carboxyl
terminus is predicted to be intracellular. The carboxyl terminus, along with the
predicted third intracellular loop, probably interacts with the G-protein and
determines the recognition specificity. The binding of agonist to the receptor causes
the heterotrimeric G-protein complex to dissociate into its subunits, the GTP-binding
a-subunit and the Py subunit complex, both of which may interact with effector
enzymes or ion channels within the cell to generate a response. Each receptor
activates only certain types ofG-proteins that will, in turn, influence only a subset of
possible effector systems. The system activated by a particular receptor is therefore
dependent on the G-protein and signal transduction mechanisms available in the cell
type. This specificity is important as many of the signal transduction mechanisms
postulated for 5-HT receptors are derived from experiments in heterologous
expression systems and may not correspond to those seen in vivo. Table 1.1





5-HT 2C Phospholipase C(+)
5-HT 2B Phospholipase C(+)
5-HT 1A Adenylyl cyclase (-)
5-HT 1B Adenylyl cyclase (-)
5-HT 1D Adenylyl cyclase (-)
5-htiE Adenylyl cyclase (-)
5-ht i f Adenylyl cyclase (-)
5-ht5A Adenylyl cyclase (-)
5-ht5B ?
5-HT7 Adenylyl cyclase (+)
5-HT4 Adenylyl cyclase (+)
5-ht6 Adenylyl cyclase (+)
5-HT3 Ligand gated ion channel
Table 1.1 5-HT receptors and their second messenger systems
(+) represents stimulation (-) represents inhibition and ? represents unknown.
Information taken from Barnes and Sharp (1999)
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1.5 Anatomy of the 5-HT system
The neuroanatomy of the 5-HT system consists of two main pathways - the
ascending and descending pathways, which originate in the raphe areas of the
brainstem (Figure 1.5). Although 5-HT neurons represent a tiny proportion (<0.5%)
of the total number of neurons in the brain, they project throughout the brain and as
such are involved in many brain functions.
Originally the 5-HT containing cell bodies were classified into nine distinct cell
groups (B1-B9) (Dahlstrom and Fuxe, 1964; Dahlstrom et al., 1965), which can be
divided into two distinct divisions (Ungerstedt, 1971). B1-B3, the more caudal
group, give rise to axons that descend to innervate the ventral and dorsal horns and
the lateral column of the spinal cord. The rostral divisions in the raphe project to the
forebrain and are most relevant to the neurochemistry analysed in this thesis. They
consist of cell bodies in the caudal linear nucleus and the dorsal and median raphe
nuclei (DRN and MRN, respectively), corresponding to B6-B9 (Tork, 1990). These
nuclei have a wide pattern of innervation projecting to several different areas of the
pre frontal and cerebral cortex as well as parts of the limbic system, basal ganglia
and diencephalon (Steinbusch, 1981; Steinbusch et ah, 1981).
Evidence from anterograde labelling and immunofluorescence studies indicates that
in the rat, and almost certainly in the mouse and primate, the raphe nuclei have at
least two populations of neurons (D and M), which differ in their areas of
innervation, morphology and, nucleus of origin (Azmitia and Gannon, 1986;
Molliver, 1987). The difference in morphology between projections from the two
nuclei has been implicated in the apparent differences in neurotoxicity of chemical
agents such as MDMA and p-chloroamphetamine (Gartside et ah, 1997; Mamounas
and Molliver, 1988; O'Hearn et ah, 1988). Fibres that arise from the DRN are very
fine, have frequently branching axons, and typically have small, pleomorphic
varicosities that are granular or fusiform in shape (type D fibres). The D fibres
project most heavily to frontal cortex and striatum, particularly to the associative and
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limbic areas concentrated in layers III-IV (Azmitia et al., 1978; Jacobs and Azmitia,
1992). The fibres from the DRN are susceptible to both PCA and MDMA toxicity
(Kosofsky and Molliver, 1987; Mager et al., 1994; Mamounas and Molliver, 1988;
Molliver, 1987). In contrast axons arising from cells in the median raphe nucleus
were found to be concentrated in particular areas of limbic cortex such as dentate
gyrus, posterior cingulate, and entorhinal areas as well as in parietal cortex (Azmitia
et al., 1978; Jacobs and Azmitia, 1992) and are characterized by large, spherical
varicosities (type M axons) and by variations in axonal diameter. These coarser
projections are more resistant to neurotoxins than the finer D fibres. As the mood-
altering substances MDA, MDMA, and PCA act specifically upon 5-HT axon
terminals from the dorsal raphe nucleus these neurons may be preferentially involved
in the control of affective state (Kosofsky and Molliver, 1987; Mamounas and
Molliver, 1988; Molliver, 1987).
5-HT projections have been reported from the B1-B3 regions of the rat and primate
medulla via the ventromedial pathway to the ventral horn and the lateral pathway to
the central grey area of spinal cord (Azmitia and Gannon, 1986; Dahlstrom and
Fuxe, 1964). The 5-HT input to the spinal cord has been investigated using
immunocytochemistry and the retrograde cell marker horseradish peroxidase
(Bowker et al., 1982a; Bowker et al., 1982b) Whilst 5-HT immunoreactivity was
found throughout the spinal grey area (most densely in the laminae I-IIa of the dorsal
horn and laminae VIII and IX of the ventral horn), the major serotonergic input was
from cell groups B1-B3, with B5, B7, and B9 having a smaller input to the cervical
regions of the cord (Bowker et al., 1982a; Bowker et al., 1982b).
1.6 The indoleamine/monoamine hypothesis of depressive disorders
Recent technological advances in imaging techniques have made it easier to study
the living human brain; however, they still have only limited efficacy and so most
evidence for the role of 5-HT in depression is still circumstantial or based on model
systems. The monoamine theory of depression, which was first suggested by
Schildkraut in 1965, is based on the ability of reserpine to induce a depressive
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syndrome and biochemical evidence such as changes in the levels of 5-HT and its
metabolites in the cerebrospinal fluid (CSF) of depressed patients (Bryer et al., 1992;
Martensson et al., 1989). This theory stated that depression was caused by a
functional deficit of the monoamine systems and that mania resulted from an excess
(Schildkraut, 1965). Several lines of evidence support this theory. Most drugs with
antidepressant actions, including the earliest tricyclic antidepressants (TCAs), such
as imipramine, block the reuptake of 5-HT in addition to their effects on other
monoamines. It was then observed that the clinical efficacy of the TCAs was relative
to their ability to inhibit the 5-HTT (DMI < imipramine < clomipramine) but not to
the inhibition of other monoamine transporters suggesting that inhibition of 5-HT
uptake might be responsible for the mood-altering effects of these drugs (Carlsson,
1969; Carlsson et al., 1969; Carlsson et al., 1968; Lapin and Oxenkrug, 1969). This
observation led to the development of the indoleamine theory of depression, which
hypothesized that 5-HT neurotransmission was decreased in depressed patients
(Carlsson, 1969; Carlsson et al., 1969; Carlsson et al., 1968; Lapin and Oxenkrug,
1969) and led to the development of the most recent class of antidepressants, specific
serotonin reuptake inhibitors such as fluoxetine. Further support for the indoleamine
theory comes from studies of biochemical abnormalities in the CSF, blood or urine
of depressed patients. Concentrations of 5-HT and its metabolite 5-HIAA have been
found to be lower in the hindbrain of suicide victims suffering from depression,
compared to sudden death victims (Lloyd et al., 1974; Shaw et al., 1967). Similarly,
5-HIAA concentrations were altered in the CSF of depressed patients (Dencker et al.,
1966), particularly among those with a history of suicide attempts (Asberg et al.,
1986; Coppen et al., 1967; Hertz and Sulman, 1968). Precursors of 5-HT, tryptophan
and 5-Hydroxytryptophan (Coppen et al., 1967; Hertz and Sulman, 1968) have been
shown to have antidepressant effects, suggesting that 5-HT availability is one
important factor in depression. More recently studies on a subset of depressed
patients in remission found that a low tryptophan diet caused immediate relapse into
depression. This relapse was reversed by tryptophan supplementation (Delgado et al.,
1990). Thus 5-HT availability an essential factor in at least some forms of
depression. In depressed patients, neuroendocrine responses to L-tryptophan are
altered (Price et al., 1991) and the hypothalamus-pituitary-adrenal axis (Calogero et
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al., 1990; Lopez et al., 1997), which has been implicated in depression, is
hyperactive. These effects are reversed by antidepressant treatment, but do not
return to normal until clinical recovery is complete (Barden et al., 1995). 5-HT
receptors, particularly those in platelets, have also been implicated in the
pathophysiology of depression (Owens and Nemeroff, 1994). These 5-HT2 receptors
are increased in depressed patients whilst 5-HTT levels decrease. Both return to
normal on clinical improvement (Owens and Nemeroff, 1994). Thus there is
considerable evidence that alterations in the 5-HT system are symptomatic of
depression and occur on a time course that does not preclude a causal nature.
1.6.1 5-HTT expression in depression
As antidepressant drugs act on the 5-HTT, considerable emphasis has been placed on
the role of the 5-HTT in depression. 5-HTT levels in depressed patients have been
measured by post-mortem autoradiography and by positron emission tomography
(PET) studies in living patients. Both techniques have several problems. In post¬
mortem studies the tissue may be degraded, and the medical history and effects of
drug treatments during life must be taken into consideration. An additional problem
among various studies is the classification of depression, which varies from major
depression to bi-polar disorder to suicide (Malison et al., 1998; Staley et al., 1998).
It is therefore hardly surprising that the reported findings show little consensus.
Several authors report reduced diffuse 5-HTT expression in the post-mortem
forebrain tissue of depressed patients (see, for example, Mann et al., 2000), but other
studies find no correlation between depression and 5-HTT levels in the DRN (see,
for example, Bligh-Glover et al., 2000)
Recent innovations in PET and single photon emission tomography (SPET) scanning
have allowed measurements of 5-HTT levels in living depressed patients (Malison et
al., 1998; Staley et al., 1998). These authors found a reduction in the density of
5-HTT sites in the brainstem of unipolar depressed patients. Contrary to this study,
(Dahlstrom et al., 2000) used SPET with 123iodine-labelled 23-carbomethoxy-
3P3(iodophenyl) tropane [123I]beta-CIT as a tracer for monoamine transporters in
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drug-nai've children and adolescents and found an increase in hippocampal/midbrain
5-HTT availability in depressed patients. The contrast between these studies can
easily be explained by the possibility of prior drug treatment in the adult study and
the different aetiologies for adolescent and adult unipolar depression. In addition,
the use of radioactivity in the SPET studies restricted the available controls to other
adolescents with psychiatric disease. Whilst this limitation was controlled for, it is
always possible that a further factor such as dopaminergic disturbances complicated
the result.
Two polymorphisms in the 5-HTT gene have been proposed to influence expression
levels and to play a role in determining susceptibility to affective disorders. The first
is a functional deletion/insertion in the promoter region (5-HTTLPR) with short and
long variants (Heils et al., 1996), whose long form increases 5-HTT expression and
whose short form reduces transcriptional efficiency (Lesch et al., 1996). Whether or
not this polymorphism is significant is controversial; work from Lesch's group and
another (Kunugi et al., 1997) have found a link between genetic status and affective
disorder. The polymorphism has been linked in its short form with bipolar and
unipolar disorders (Collier et al., 1996), bipolar only (Kunugi et al., 1997) and
anxiety (Lesch et al., 1996). Post-mortem studies (Mann et al., 2000) have recently
shown a link between major depression and the short allele. However, several
studies have found no link between the short allele and affective disorder (Hoehe et
al., 1998; Naylor et al., 1998) or 5-HTT levels in the human prefrontal cortex or
hippocampus (Hoehe et al., 1998; Mann et al., 2000; Naylor et al., 1998). The
contradictions among these studies may be explained by the small sample sizes used,
which may have concealed significant findings. Evidence also suggests that the
associations between 5-HTT expression and depression are race- (Kunugi et al.,
1997) and gender-specific (Oruc et al., 1997), indicating the need for a large multi¬
ethnic analysis.
The second polymorphism in the 5-HTT gene is a variable number tandem repeat
(VNTR) in the second intron, consisting of three alleles containing, respectively, 9
(STin2.9), 10 (STin2.10) and 12 (STin2.12) copies of a repetitive element. The short
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9-copy allele has been linked to affective disorders, unipolar disorder more strongly
than bi-polar (Battersby et ah, 1996; Harmar et ah, 1996; Ogilvie et ah, 1996).. No
evidence suggests that the VNTR would affect 5-HTT expression level (Battersby et
ah, 1996; Harmar et ah, 1996; Ogilvie et ah, 1996), though it may alter regulation.
1.6.2 Effects ofchronic SSRI treatments on 5-HTT and 5-HT
The therapeutic effects of antidepressant treatments have a delay of weeks from the
onset of treatment. It is therefore of interest to study the effect of long-term
treatment with antidepressants on 5-HTT levels Although few studies have examined
the effect of antidepressant treatments on 5-HTT function in vivo, considerable
research has been done on the effect of chronic SSRI treatments on 5-HTT mRNA
and ligand binding. The results of these studies are conflicting, with some studies
finding increases, others no change, and some decreases (Benmansour et ah, 1999).
The reason for these apparent contradictions is probably the wide range of
antidepressants and treatment regimes used in the early studies. Some drugs have a
much shorter half-life than others, for instance citalopram has a half-life of 3 hrs. in
the rat, whilst paroxetine has a half-life nearer one and a half hours. If the drug is
applied by a single intraperitoneal injection every 12 or 24 hours, its serum levels
may fall outside the therapeutic window.
Pineyro et al (1994) hypothesised that a continuous steady state exposure to a drug
was required to alter 5-HTT expression level. More recent studies have taken this
drug exposure into account. Even if a steady drug concentration is not required, it is
still a better model for the situation in depressive patients where treatment regimes
are designed to maintain a steady free serum concentration of drug within the
therapeutic window. Benmansour (Benmansour et al., 1999) used an osmotic mini-
pump to administer paroxetine, the most specific 5-HTT ligand available, sertraline,
and DMI specific to the noradrenaline transporter, and measured the drug serum
concentrations needed to maintain levels similar to those used therapeutically. Under
these circumstances, SSRI treatment reduced 5-HTT ligand binding by 80-90% in
the hippocampus, whilst 5-HTT binding increased by 50%. 5-HTT mRNA level was
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altered only in the DRN, not the MRN. DMI or imipramine, both of which have a
higher affinity for other transporters, reduced 5-HTT binding (Hebert et al., 2001),
whilst fluoxetine reduced noradrenaline receptor and transporter expression. It
would therefore appear that chronic lifetime treatment with 5-HTT inhibitors leads to
down-regulation of transporter expression. This observation raises two interesting
points. Does genetic knockout of the 5-HTT have similar effects on the rest of the
5-HT system as chronic SSRI treatment? Do genetic knockout studies thus offer a
possibility for progress in depression research? As mentioned above, several studies
suggest that polymorphisms that increase 5-HTT expression may be linked with
depression. The possibility that 5-HTT overexpression causes the chemical
imbalances of depression is therefore far from outrageous. Using 5-HTT knockout
mice may be an effective tool for modelling the effects of chronic antidepressant
treatments in humans.
1.7 Transgenic and knockout mice
The term transgenic is often used signify any manipulation of the genome. In this
thesis, however, transgenic will be used only to define mice genetically modified to
contain an additional DNA sequence, which is usually a gene from another species,
most commonly human. These mice provide a way to study the effects of a single
gene on development and behaviour in a whole system and so provide an excellent
method for studying the expression and role of a gene throughout life. Since human
disease may be caused by genetic factors that are present throughout life, transgenic
mice provide a better model for studying genetic susceptibility to human disease
when compared to pharmacological manipulations that are limited to a small window
of time.
A knockout (KO) mouse is one that has been modified to remove a functional gene,
either by mutation of the promoter sequence, which prevents gene transcription, or
by removal of a coding exon to produce a non-functional transcript.
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1.7.1 Techniques for generating transgenic mice
Extra DNA sequences can be inserted into the mouse genome through several
mechanisms. The most common method is to inject a DNA construct containing the
sequence of interest into the early-fertilized mouse embryo. A variety of DNA
vectors may be used in such studies, but artificial chromosome vectors derived from
yeast (YAC) or bacteria (PAC or BAC) have advantages since they permit very large
DNA sequences, likely to include all of the regulatory DNA sequences of the gene of
interest, to be expressed in transgenic mice.
1.7.2 Use of transgenic mice as models
Transgenic mice are extremely useful as models for gene function. They provide an
in vivo system for studying changes in expression that occur throughout the life span
and a method of analysing the function of single genes. However, there are several
caveats to interpreting results from these studies. Firstly, there is always a possibility
that inserting extra DNA will overtly alter other gene expression by accidentally
knocking out another gene. Other more subtle effects on gene expression might
include the inhibition of a promoter or regulatory transcription site or the disturbance
of a regulatory system by altering the proximity of a modulatory site to its gene of
action.
1.7.3 5-HT and development
The serotonin system is one of the earliest neurotransmitter systems expressed in
mammalian development (embryonic day 12 in rats and days 11-12 in mice). The
expression of this system at the same time as neuronal growth and differentiation has
led to the suggestion that 5-HT may be involved as a signalling chemical for
serotonergic development (Lauder, 1990). The projection of serotonergic neurons
from the brainstem nuclei throughout the brain appears early in development. 5-HT
has been shown to be mitogenic for both neuronal and other cell types and to control
the growth and development of neuronal growth cones (Ivgy-May et al., 1994) in a
highly controlled and protected manner. 5-HT has also been shown to induce
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neurogenesis and neuronal differentiation (Lauder, 1993; Whitaker-Azmitia et al.,
1996) affect cranial neural crest migration (Moiseiwitsch and Lauder, 1995), and
induce synaptogenesis (Ivgy-May et al., 1994; Whitaker-Azmitia et al., 1996).
The serotonin transporter, 5-HTT, appears with a time course very similar to that of
5-HT (Zhou et al., 2000). The 5-HTT is expressed mainly in the raphe system, but
also transiently in the cortex, striatum, substantia nigra and thalamus (Bruning and
Liangos, 1997). Expression of the 5-HTT occurs before synapse formation,
suggesting a role for neurotransmitter transport beyond signal regulation, which is
similar to that seen in non-mammalian species (Lauder, 1993) where 5-HTT acts as a
regulator of growth and motility. Moreover, it is likely that in brain areas where
5-HT is not produced, the transporter may be important for effects of 5-HT on cells
there.
It is therefore likely that any factor which effects 5-HT uptake will have at least a
subtle effect on the developing embryo. Given that SSRIs are known to cross the
placental barrier and that many women take antidepressants during pregnancy, there
is considerable concern as to their possible effects. It is also possible that a genetic
predisposition to high or low levels of 5-HTT could alter neuronal differentiation,
thus influencing the 5-HT or other transmitter system in later life and leading to a
predisposition to depression and/or other diseases linked to 5-HT levels. In this case
the presence of SSRIs during embryogenesis may have beneficial as well as negative
effects.
Similar to 5-HTT knockout mice, the animals over-expressing 5-HTT produced for
this research (see Chapter 2) do not show overt physical phenotypes, indicating that
the increase in 5-HTT does not in itself control neuronal differentiation or cranial
morphogenesis. Nevertheless, more subtle pharmacological and behavioural changes
are seen in the mice that over-express the 5-HTT (see Chapters 3 - 6).
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The increase in the 5-HTT, assuming it occurs throughout development as well as
during adulthood, can be expected to increase 5-HT in areas of the nervous system
where the transporter is the only means by which that area obtains 5-HT. The
likelihood of a regulatory role for axonal and somatic 5-HTT makes its effect(s) on
the 5-HT system more difficult to predict. Possibly the effect is counter-balanced by
alterations in other parts of the system. As it is not yet known whether the 5-HTT
has the same function in adults as in embryos, or even whether all components of the
system such as vesicular storage are present, it is difficult to say whether an increase
or decrease in 5-HT should be expected.
1.7.4 Genetically modified mice and the 5-H T system
Many genes and proteins have been studied using transgenic and knockout mice. In
the serotonergic system knockout mice have been created for the 5-HTT and for
5-HTia, 5-HTib, 5-HT2c receptors. Mice have also been created to over-express the
5-HT3 receptor, which is normally hard to detect in the CNS (Figure 1.6).
1.7.5 5-HTT knockout (KO) mice
There are now several strains of KO mice in which the 5-HTT is not expressed and a
growing body of information about the effects of the gene knockout. Despite the
importance of 5-HTT as a developmental signal, 5-HTT knockout mice survive with
neither a physical phenotype nor anatomical changes compared to wild-type mice
(Bengel, 1998). 5-HTT knockout mice have greatly reduced tissue 5-HT
concentrations (60-80%) (Bengel, 1998). Removing the 5-HTT leads to several
changes in 5-HT neuronal function. The 5-HTia autoreceptor, which controls
neuronal firing, is desensitised (Gobbi et ah, 2001) and reduced in expression in the
dorsal raphe nucleus (Fabre et ah, 2000; Li et ah, 2000), whilst increased in the
hippocampus and unchanged in the forebrain (Fabre et ah, 2000). 5-HTib receptors
are also site-specifically reduced in 5-HTT knockout mice, with reductions in the
substantia nigra but not other brain regions tested (Fabre et ah, 2000). The
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diminished in knockout animals (Li et al., 1999b). In addition to changes in 5-HTi
receptors, the knockout mice have altered 5-HT2 and adenosine receptor expression.
5-HT2 receptors are reduced in most areas, but with additional novel expression in
the striatum (Rioux et al., 1999). Adenosine Al receptors, which are involved in the
regulation of 5-HT release, are altered in the DRN but not projection areas, whilst A2
receptors are altered in the basal ganglia (Mossner et al., 2000). 5-HTT knockout
mice also show an altered response to the stimulatory effects of MDMA, but not
amphetamines, with reduced locomotor stimulation in knockout mice.
Paradoxically, increased activity was also seen in the heterozygote mice during the
first 30 minutes after administration ofMDMA. The 5-HTT knockout is of interest
as a model for antidepressant treatments, where the 5-HTT is blocked. The
therapeutic effects of antidepressants may be mediated by long-term changes in
5-HT levels induced by blockade of the 5-HTT, similar to those seen in the knockout
mice. The changes that induce depression are not replicated in the KO mouse model.
As explained in Section 1.6.1, evidence suggests that the 5-HTT is raised in some
depressed patients (Dahlstrom et al., 2000). Mice that over-express the 5-HTT may
provide a better model for the causes of the chemical changes inducing depression.
1.7.6 The mouse model used in this research
In the research described in this thesis, the transgenic technique is used to further
study the role of the serotonin transporter by introducing the human 5-HT transporter
gene into mice, so that they express greater than normal amounts of the 5-HT
transporter protein. A yeast artificial chromosome (YAC) containing the human
5-HT transporter gene and regulatory regions was created (Chapter 2) and injected
into mouse oocytes. The transgenic mice that developed from these oocytes provide
a model for studying the influence of 5-HTT overexpression on the 5-HT system and
behaviours associated with this overexpression, which has been suggested as a cause
for depression in humans (Dahlstrom et al., 2000). The human transporter gene was
used so that at a future date the transgenic mice could be crossed with knockout mice
to produce animals with only human 5-HTT protein, thus providing a target for
therapeutic drugs to be used in humans.
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This chapter has provided an introduction to the 5-HT system, concentrating on the
areas most relevant to the investigation, and to transgenic technology. Chapter 2
describes the production of the DNA insert and the generation of the mice. Chapters
3 and 4 describe the next stage, confirming that the inserted DNA leads to higher
RNA and protein expression. Chapters 5 and 6 describe the functional consequences




The Modification of Yeast Artificial Chromosome
35D8 and the Generation of 5-HTT Transgenic Mice
2.1 Introduction
This chapter reports the modification of a yeast artificial chromosome (YAC)
containing the human serotonin transporter (5-HTT) gene and the generation of
transgenic mice containing this construct.
Yeast artificial chromosomes are a convenient way of inserting DNA into the
genome of mice in a manner that is dependent on copy number but independent of
position and with an expression pattern as similar as possible to the endogenous gene
(Schedl et ah, 1993b).
A YAC contains an insert of genomic DNA between short and long vector arms.
The 500kb YAC 35D8 used here, identified by screening of the ICRF human YAC
library (Shen et ah, 2000a), contains the 40kb SLC6A4 gene which encodes the
h5-HTT along with its upstream and downstream sequences. The upstream sequence
contains the promoter region for the human gene which confers tissue specific
expression, shown to be contained in 1.4kb of 5' flanking sequence (Heils et ah,
1995) and so should confer a pattern of expression in transgenic animals that
resembles that of the endogenous mouse 5-HTT. There are several polymorphisms
found in the promoter region (see introduction). The YAC used contains the short
form of the short/long promoter polymorphism and the 10 repeat allele of the intron2
9/10/12 polymorphism.
2.1.1 Modification of YAC 35D8 to include marker genes
Before injection into mouse oocytes the YAC 35D8 was modified. A short amino
acid sequence (YPYDVPDYA) corresponding to the influenza virus haemagglutinin
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(HA) epitope tag was inserted at the C-terminus of the open reading frame, together
with the poly-adenylation sequences from SV40, the Yeast ADE2 gene , and the lacZ
reporter gene, which had been inserted downstream of a viral internal ribosomal
entry site (IRES) (Mountford, 1994).
The addition of these sequences was done in an attempt to provide an easier method
to analyse expression than the more traditional in situ hybridisation techniques
(Vassaux and Huxley, 1997). The product of the lacZ reporter gene is the enzyme b-
galactosidase, which can be detected with simple histochemical staining techniques.
The HA epitope tag expressed at the C terminus of the 5-HTT protein can be
detected with commercially available antibodies.
A two stage YAC manipulation system was used to generate transgenic mice by the
method described in Shen et al (2000b). A brief description of the steps involved is
given below. In the first stage, genomic sequences flanking the last exon of the
5-HTT were cloned around an HA-IRES-ZacZ-ZDiE? cassette. After homologous
recombination to incorporate the HA-IRES-lacZ-ADE2 cassette into the YAC 35D8,
in stage two an amplification vector pYAM4 was used to replace the long vector arm
so that the YAC DNA could be amplified when grown in a medium containing
galactose.
The two vectors used -YAC amplification vector pYAM4 and insertion vector
pYIV2- are shown in Figure 2.1.2.1. pYAM4 is a derivative of pBluescript SK" that
contains a 572-bp Smal-Clal fragment linked to a conditional centromere (CEN4)
that can be inactivated by induced transcription from an adjacent GAL1 promoter.
pYAM4 also contains the yeast LYS2 gene and the Escherichia coli hygromycin B
resistance gene driven by the mouse Pgkl promoter. The amplification vector
increases the copy number of inserted YAC per cell by inducing non-segregation of
the YAC DNA when the GAL1 promoter is activated by the use of galactose rather
than glucose in the growth medium.
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Figure2.1.2.1Twost peneticManip lationofYACDNAbyhom log usrecombinatio( ) usingYACamplificationvectorpYAM4(b)ndinsert oVec IV3 c
pYIV2 is a derivative of pGEM-llZf that encodes the lacZ reporter gene. It is
flanked by a viral IRES and poly-adenylation sequences from SV40 together with the
Yeast ADE2 gene which in turn is flanked by unique restriction sequences to
facilitate cloning. pYIV2 does not contain the amino acid sequence for the HA tag
so this had to be inserted into the construct.
Stage 1 - The Insertion of the HA tag into the C terminus ofthe 5-H TTgene
The HA tag was introduced by inserting sequences from the 5-HTT gene into
another construct which already contained the HA tag.
First a BamHI- Xbal fragment containing the VPAC2 receptor with the HA epitope
tag amino acid sequence (EYPYDVPDYASL) at the 3' end was blunt-ended and
cloned into the EcoRV site of pBluekriptSK vector with a previously inactivated
Xhol site to make plasmid VIP2RHAskx
Next, to subclone the 5-HTT sequences, a 5Kb human genomic DNA fragment
containing intron 13 and exon 14 of the 5-HTT gene was cloned into the Notl-Xhol
site of pBluescript (using PCR oligonucleotides ACT GCA TAG CGG CCG CAT
CTT TCA TT GCA TCC CC and TGT GCT CGA GAG CAT TCA AGC GGA
TGT) and then this was used to replace the Notl-Xhol VPAC2 receptor fragment of
VIP2RHAskx to make a vector containing only the 5-HTT intron 13 exon 14 and HA
tag = pInl3-HA, The 5-HTT-HA sequence was isolated as a SacII-ClaI(blunt-
ended) fragment and inserted into the NotI site of pYIV2 which contains the IRES-
lacZ-ADE2 sequence = pInl3-HA-IZA
In order to insert the sequence downstream of the stop codon, exon 14 of the 5-HTT
was isolated by PCR (using PCR oligonucleotides CTC CTC GAG AGG AAA AAG
GCT TCT and TAG GTA CC TGT TCT CTC CTA CGC AGT TT). It was then
inserted into the Xhol-Kpnl site of pBluescript to make p3'5-HTT.
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Finally the intron 13 -HA-IRES-/acZ-ADE2 fragment was isolated by NotI and Sail
digestion of pInl3-HA-IZA and inserted into the NotI and Xhol sites of p3'5-HTT
to produce a construct containing the 5-HTT sequence from intron 13 with the HA-
IRES-/ocZ-ADE2 cassette inserted at the stop codon in exon 14 = pLacZ5-HTT+ .
pZ,«cZ5-HTT+ was linearised with NotI and transformed into yeast clone 35D8 by
homologous recombination. The existence of the ADE2 sequence in the modified
YAC 35D8/D6 was confirmed by Southern hybridisation with an ADE2 probe.
Stage 2 - The Replacement ofthe vector long arm with the amplification vector.
The modified YAC35D8/D6 was transformed with the NotI linearised YAM4
amplification vector. Ura+Ade+Lys+ recombinants were streaked on plates lacking
tryptophan. Lys+Trp- clones were cultured in medium with 2% galactose. The
YAC 35D8/D6 DNA was isolated and purified by pulsed field gel electrophoresis as
described by Schedl et al (1993a).
In addition to this modified construct the unmodified YAC 35D8 containing the
unaltered 5-HTT gene was used at a later date.
2.2 Methods
2.2.1 The Injection of YAC DNA into mouse oocytes and the generation of
transgenic mice
Mice were generated by a variation of the method of Schedl et al (1993a). This
method involves the direct injection of purified, modified YAC DNA into the male
pronucleus of fertilized oocytes. The DNA is incorporated into the genome when the
male and female pro-nuclei fuse. This method has the advantage over the use of the
unpurified yeast genome of easy incorporation of only the target DNA rather than the
entire yeast genome and, unlike methods where DNA is inserted into embryonic
stem cells, generates non-chimeric animals. The large size and low concentration of
YAC in the injected solution usually limits the number of copies of the YAC that are
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incorporated, and so the transgenic animals generated usually contain only one or
two copies of the gene of interest.
CBAxC57BL6 F1 female mice (CharlesRiver, UK, Margate, Kent) were
superovulated and mated 24 hours later. Those which plugged successfully were
killed by cervical dislocation and the fallopian tube and ovary were carefully
dissected and cleaned and placed in M2 medium (Sigma). At this stage of pregnancy
the fertilized oocytes are still in the upper part of the fallopian tube and can be
removed by gently tearing the tissue wall where the tube is swollen or gently
expelled by inserting a mouth pipette into the end of the tube and blowing through.
Fertilized oocytes were cultured for a few hours in M2 medium (Sigma) at 37 °C
before injection. The solution containing the YAC was then micro injected into the
male pronucleus using an Axiovert 100 microscope (Carl Zeiss) and automatic
injector and manipulators (Narashige) with instrument holders from Narashige and
Eppendorf.
The injected embryos were cultured overnight or for a few hours in medium Ml6
(Sigma) and living embryos (those which had completed cell division) gently
inserted into the fallopian tube of pseudopregnant CD1 female mice under general
anaesthetic. About 30 embryos were inserted per mouse using a mouth pipette and a
dissecting microscope attached to a video camera and monitor. Mice were allowed
to recover from the anaesthetic and pregnancy continued. Birth occurred naturally.
Offspring were allowed to reach weaning age when a sample of tail tissue was taken
and transgenic animals identified by PCR.
2.2.2 Analysis ofmiceforpresence ofthe transgene by PCR
Genomic DNA was extracted from samples of tail tissue by digestion with proteinase
K (6mg/10ml) (Boerhinger Mannheim) in a lysis buffer (600pl per sample of 50mM
Tris-HCl pH 8, lOOmM EDTA, lOOmM NaCl, 1% SDS) overnight at 60°C. The
digested sample was spun to remove remaining debris such as hairs and the
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supernatant containing the DNA precipitated in a fresh tube with 0.8 volumes of
isopropanol. Samples were mixed and DNA was precipitated for 20 minutes at room
temperature followed by centrifugation at room temperature for 5 minutes. The
resulting DNA pellet was washed with 70% ethanol and the DNA was re-suspended
in 100 or 200 pi of PCR grade water by incubation at 60°C for 2hrs. or overnight at
4°C and mixed before being used in PCR reactions.
To identify transgenic mice, DNA samples were tested by PCR analysis with several
primer pairs. Primer sequences and conditions are listed in Table 2.2.2.1.
Each mouse was first analysed with primers specific to the 5-HTT gene (exon 1A,
exon IB and 3'UTR). To check how much of the construct was incorporated, the
mice positive for the 5-HTT gene were then tested with primers for the STS markers
near the gene; D1S1294, WI1570, (Shen et al., 2000a) and the long and short arm of
the YAC. All primers were obtained from MWG Biotech AG.
The same primers were used to identify transgenic animals throughout this work and
to genotype the embryos used in the histochemical X-gal staining.
2.2.3 Selection of Transgenic Mice and Colony Maintenance
Those animals positive for YAC DNA were given specific 4 digit numbers in the
form AlOx.x. Each animal was bred with a CBA/C57BL6 wild-type animal and all
offspring of this animal (referred to as a transgenic line) was given the founder's "A
number" in addition to their own identifying number. The offspring were tested as
above. All the lines were found to breed and produce transgenic offspring in the
expected proportion of about 50% of the offspring. The lines which did not contain
the entire 5-HTT gene were discarded.
Breeding was continued to provide sufficient animals for experiments and to
establish a colony. Wherever possible breeding pairs were 3-6 months in age. All
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accidental knockout. Accidental knockout occurs when the injected DNA
incorporates into the middle of another gene and prevents its expression.
Homozygote animals will contain no functional copies of this endogenous gene and
the gene is therefore "knocked out". Any phenotypical effects may be due to this
lack rather than the over expression of the injected DNA. This occurred in the
generation of the MAOA knockout mice which were produced when an injected
interferon gene was incorporated into the MAOA locus (Cases et ah, 1995).
However, breeding for h5HTT homozygotes was carried out and the offspring were
crossed with a wildtype animal to test for homozygosity. Homozygotes were
produced in the ratio expected and bred well. Therefore this is not a life threatening
modification.
2.2.4 Histochemical detection of f-galactosidase activity
The lacZ gene incorporated into the construct should be expressed in the same areas
as the 5-HTT (Vassaux and Huxley, 1997). Its product |3- galactosidase can be
detected by its activity in cleaving X-gal (5-bromo-4-chloro-3indoyl-B-D-galactside)
to produce a precipitable blue-green product.
CD1 female mice were mated with heterozygote male transgenic mice as CD1
animals produce larger litters than F1 animals. The mice were then culled at 12.5,
13.5, 14.5, 18.5 days post fertilisation (E0.5 = date of plug) and the uterus removed
and placed in ice-cold Phosphate Buffered Saline (PBS). Embryos were carefully
removed from the uterus and washed in PBS in a 24 well dish to remove
contaminating fluids. Embryos were then fixed in 4% Paraformaldehyde El2-13 for
3hrs., El4-17 for 4hrs., larger embryos and newborns overnight. A sagittal cut was
made down the midline of large embryos for ease of access to the staining media.
After washing for three periods of 20 minutes in PBS containing 0.01% sodium
deoxycholate (pH adjusted to 8.4 to minimise background staining)) each time,
embryos were transferred to filtered Xgal (5-bromo-4-chloro-3indoyl-|3-D-
galactside) staining solution (lmg/ml X-gal, 5mM K4Fe(CN)6 5mM K.3Fe(CN)6,
2mM MgCH, 0.01% sodium deoxycholate 0.02% NonidetP-40 in PBS) filtered
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through a 0.2 A filter. X-gal was dissolved in DMSO at 40mg/ml. The final
concentration of DMSO in the final solution was less than 1%.
Tissues were incubated at 30°C overnight with gentle shaking for the larger embryos.
The staining solution was then removed and the embryos washed in PBS for a
minimum of 2 hours. After staining the embryos were transferred to increasing
concentrations of glycerol: 40% 10 minutes, 80% lOminutes, 80% overnight to clear
then examined and photographed using a Contax 167 MT camera and Kodak colour
film.
New-born pups were culled by schedule one method - Pups were injected with an
overdose of sodium pentobarbitone followed by insertion into ice-cold PBS to
preserve the tissue - then fixed and stained as for 18.5 day embryos.
The pictures used in this chapter are reproductions of the slide obtained by scanning
in combination with Adobe PhotoShop ® software (Adobe systems Inc)
2.2.5 Immunocytochemistryfor HA epitope tag, f-galactosidase and 5-HT
Mice were killed by injection of a lethal dose of sodium pentobarbitone with slow
perfusion of about 50 ml of ice-cold 4% paraformaldahyde in PBS to fix the tissue.
The brains were then dissected rapidly and postfixed for 2 hours at 4°C in
paraformaldehyde (4%) / glutaraldehyde (0.05%), washed briefly in PBS and
incubated overnight in 30% sucrose before sectioning. 30 micrometer sections were
cut on a freezing microtome and thaw mounted on slides. The antibodies and
conditions used for labelling are listed in Table 2.2.4.1
In general sections were allowed to dry for about 30mins then blocked for 30
minutes at room temperature in goat serum diluted in PBS with 0.1% Triton X-100.
After blocking the solution was removed and the slides blotted before the primary
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solution and incubated overnight at 4°C. Incubation was in sealed boxes containing
paper saturated in PBS to prevent the slides drying out
Slides were then washed in PBS for 3 times 30 minutes at room temperature, then
incubated in the secondary antibody for 1 hour at room temperature, then washed 3x
30 minutes in fresh PBS before mounting in xylene.
Fluorescence was viewed using an Axiovert 135M inverted microscope (Carl Zeiss
Ltd, Welwyn Garden City, Hertfordshire, UK) with x40 objective.
Immunofluorescence was observed using an appropriate filter under UV light
(395nm). Antibodies tagged with FITC emitted at a wavelength of 509nm
Fluorescence was photographed with a Contax 167MT camera attached to the
microscope, using the appropriate exposure time and Ektachrome 160T (Kodak, UK)
colour slide film.
2.3 Results
2.3.1 PCR analysis, generation and selection ofdifferent lines
298 oocytes were injected with YAC 35D6 and inserted into CD1 mice. Of these 97
(32%) were born, of which 6 died, and the rest were tested for the presence of the
YAC transgene.
18 of the 97 offspring produced were positive for some part of the YAC (18.6%).
Three founder mice were found to contain the complete YAC (A102.3, A102.5 and
A105). Although this does not rule out splitting of the chromosome during injection,
it makes it unlikely. Shearing forces, which occur during injection, can cause the
large YAC to split into several sections that incorporate into the genome in different
places. In this case the majority of the DNA will be present but non functional, it
also leads to the loss or break of the sequence. If a DNA marker is not detectable it
is probably due to this splitting and those animals will not express the human protein.
Therefore only animals which contain all the 5-HTT gene markers are likely to
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express the protein. Table 2.3.1.1 shows the PCR results. One of the animals had
only one area of the 5-HTT gene and so was culled. Those without 5-HTT gene
incorporation were discarded and work concentrated on those lines with the greatest
incorporation (meaning most complete YAC-in which all the primer sequences were
detected) (Figure 2.3.1.1).
Transmission to the next generation (germline transmission) was obtained from all
the lines maintained. However it became impossible to breed all the remaining lines
due to constraints in the breeding facility so lines that did not contain the complete
gene were also discarded.
Lines A102.3 A102.2 A102.5 A101.2 A104 were maintained in the breeding
programme whilst others were frozen as sperm for use in future studies.
As described below lacZ was not detected in transgenic mice and so the injection
procedure was repeated with the unaltered YAC 35D8 in case the lack of expression
was due to a frame shift, which may also have inactivated the 5-HTT gene. Three
transgenic lines (A145, A145.1 and A145.2) were produced (Figure 2.3.1.2). Since
the levels of expression of the 5-HTT did not obviously differ from those in lines
expressing the modified construct, due to space and time constraints the modified
YAC lines were used rather than breeding the new lines.
2.3.2 X-gal stainingfor Histochemical detection of (3-galactosidase activity
Staining for lacZ expression was unsuccessful. At embryonic day 12.5 there was no
staining at all. Embryos from day 13.5 showed light staining in the choroid plexus
and possibly very lightly in the midbrain. This increased in 14.5- and 15.5-day
embryos to include vertebral and toothgerm staining. An apparent pathway from the
midbrain to the frontal cortex was also visible (Figure 2.3.2.1).
DNA samples were taken by removing one limb from the embryo and extracting the
DNA as described for tailtip samples.
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Analysis of Tail Tip DNA for Transgenic containing
35D8/D6 YAC
Founder Sex Colour A B C D E F G H
TATTOO
No.
14 F Ag +? + A101.3
37 F Ag +? +? + A102.4
60 M B1 + + + - - - - +? A103.1
89 M B1 + + + + +? - +? + A105.2
53 F Ag + + + - + + +? - A103
70 M Ag + + + + + + +? + A104
77 F Ag + + + + + + +? + A 104.1
21 M Ag - + + + + + - + A102
28 M Ag + + + + + - + + A102.2
83 M Ag + + + + + + + + A105
92 ? ? + + + + + + - + Dead
8 M Ag + + + + + +? + + A101.2
36 F Ag + + + + + + + + A102.3
46 M Ag + + + + + + + + A102.5
85 F B1 + +? + + + + + + A105.1
26 M B1 - - +? - + + - + A102.1
24 M B1 - - - - - +? - - Killed
6 M Ag + - +? - - + +? - A101
7 M Ag + + +? - - + + - A101.1
Table 2.3.1.1 PCR analysis of mice generated by microinjection containing the
5-HTT gene
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Figure 2.3.2.1 X-gal staining for p-galactosidase activity in
Transgenic Mouse line A101.2 E14.5. A non-specific pathway
from the midbrain to the cortex is visible
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The staining pattern was then compared to the transgenic status of the animals (Table
2.3.2.1). X-gal staining did not relate to genetic status and so is non-specific. In
adult transgenic brain slices there was no X-gal staining in any region, except
background staining in the ventricles. There was also endogenous staining in the gut.
2.3.3 Immunohistochemistry for f-galactosidase, 5-H T and Haemagglutin-tag in
adult brains
13-galactosidase antibody - There was no staining in any area after 24 hrs. of
incubation with the fluorescence medium at either concentration of 1° antibody. The
slides were therefore left for 24 hrs. and re-examined. There was still no visible
fluorescence.
HA tag- there was no fluorescence after 24hrs. After another 48 hours very faint
fluorescence was seen in the brainstem of transgenic mice. However this was very
diffuse and negligible and so was probably due to background staining as it was also
visible when binding was inhibited by co-incubation with the peptide against which
the antibody was raised.
5-HT - After 24hrs. of development there was some fluorescence in the brains of
transgenic and wild-type mice at both concentrations of 1° antibody. 5-HT
projections are seen in the cortex and lateral ventricle of controls and transgenics and
possible fluorescence in the ventricles of transgenic but not wild-type mice. The
hindbrain of wild-type mice showed some staining in the dorsal raphe area in a
pattern similar to that seen in other work (Bengel et ah, 1997) (data not shown).
2.4 Discussion
The use of YACs to integrate a human gene into the mouse genome provides a
method by which large amounts ofDNA sequence, including most of a gene's long-





















A105.2 1 18.5 d + + + - - - - + + -
2 ?d + + + - a+ - - + -+ -
3 + + + + ++ + - - + + -
4 ?d + + + a? - - - + + -
5 ?d + + a? + - - + + -
6 ?+ + + + - - - - - + - -
7 + + + + - ++ - + faint -
8 ? + + + - - - - + + +
9 not good cut + - ++ + + -
10 " " " + - ++ - + -
11 - .? + + - - + + -
12 - - - + - - - - +
13 - - - + - - - - -




















A101.2 1 13.5 -
2 -
3 ? + - - - - - - ? - +
4 ? + - - - - - - - - - -
5 - + - - - - - - - - - -
6 ? + - - - - - - - - - -
7 ? + - - - - - - - - - -
8 + + - - - - - - - - - -
9 +? + - - - - - - - - - -
10 +? + - - - - - - - - - -
11 - ? - - - - - - - - - +
12 - - - - - - - - - - - -




















A102.5 1 14.5 + + + ? ? + + _? -
2 + + + + - - - + -
3 - + - - - + + - -
4 + + - - ? ? - ? +
5 - +? - - - - - - -
6 + + + - - - - - + +
7 + + - - - - - - +
8 - + - - - - - - -
9 ? + - - - - - - -
10 d + - - - - - - -
11 - + - - - - - - -
12 - + - - - - - - +
Table 2.3.2.1 Results ofX-gal staining in embryos from h5-HTT mice.
Key: (+) staining is present, (-) staining is not present, (9) staining is faint, (d) staining is
diffuse, (?) staining is uncertain, Genetic status was defined by PCR analysis.
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upstream and downstream regulatory sequence have been introduced to a mouse.
The presence of the gene is identified by the PCR results with gene specific primers
and nearby STS markers.
The use of YAC transgenics minimises many of the problems of transgenic
technology as the large size of a DNA sequence maintains the expression patterns to
the correct areas and prevents ectopic expression of the gene. However the large size
also means that shearing of the chromosome is more likely to occur during
microinjection. This can lead to breakage of the YAC and multiple incorporation
sites or to the inactivation of the gene even though all the DNA may be present.
Many of the founder mice have parts of the YAC missing. This is due to
incorporation of some of the sheared parts of the YAC - probably into different sites
in the genome- and loss of some bits of the YAC. Those mice where the markers for
all the 5-HTT sites and the STS markers on either side are present were considered
likely to contain the complete h5-HTT gene. The insertion of DNA into the
pronucleus before cell division also ensures that the transgene is expressed in all
cells rather than in a mosaic pattern. However, the insertion of such a large piece of
DNA into the genome can also have unwanted effects - accidental KO where the
transgene inserts into the middle of another gene effectively knocking it out. For
example, Cases et al (1995) reported a line of transgenic mice in which integration of
an interferon transgene caused a deletion in the gene encoding monoamine oxidase A
(MAO-A), providing an animal model of MAO-A deficiency rather than one for
overexpression of interferon. Placement of the transgene within the genome may
also affect its expression and regulation; thus, wherever possible, several lines of
transgenic animals should be studied to confirm that any alterations seen are due
specifically to the transgene.
The copy number of inserted transgenes is lower with YAC than BACs as the DNA
fragment is much larger (Giraldo and Montoliu, 2001). Normally multiple copies of
transgenes are inserted end to end at the point of entry. In general, copy number
directly relates to expression level and so different lines can show different
phenotypes.
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It was hoped that the incorporation of the HA-IRES-/acZ -ADE2 cassette would
provide an efficient method to analyse the pattern of h5-HTT expression. However
staining for lacZ expression was unsuccessful. There was light staining in embryos
after 13 days which is the expected time of 5-HTT expression in tissues which might
be expected to show the 5-HTT gene (Bruning et al., 1997; Schroeter and Blakely,
1996; Zhou et al., 2000). This proved to be non specific and X-gal staining was not
seen in adult brains. It was possible that this was due to a failure at the level of
incorporation of the lacZ reporter gene into the construct. A single base mis-
incorporation or deletion can cause a frame shift and non-expression. This may have
occurred, in this construct, when the HA sequence was inserted at the stop codon of
the 5-HTT gene from the previous construct. A second possibility is that (3-
galactosidase expression was low, insufficient to detect over the background staining
that is always expected in this type of experiment. |3-galactosidase needs to form a
tetramer for enzymatic activity diffuse low expression may not be sufficient for this
to occur (Hirata et al., 1984; Jacobson et al., 1994; Juers et al., 2000; Kaneshiro et
al., 1975; Pisani et al., 1990).
To answer this question immunofluorescence, which is more sensitive than chemical
staining, was used to identify (3-galactosidase expression and expression of h5-HTT
protein with the HA tag in adult mouse brain sections. However, this was also
unsuccessful under any concentration of 1° or 2° antibodies used. The same
antibodies had previously been used successfully in cell lines in the laboratory.
However, the HA tag was not easily detectable in mice expressing the VIP2 receptor
clone from which the HA-IRES- lacZ -ADE2 cassette was taken. The levels of
expression may be too low to detect over a background of nonspecific staining that
will be present in any such experiment, or the antibody may be inefficient in animal
tissues. An antibody against 5-HT in parallel experiments identified projections in
both wild-type and transgenic mice in the cortex and brainstem. These areas are
consistent with the pattern of 5-HT innervation and with the expression pattern of
5-HTT RNA in other mouse studies (Bengel et al., 1997). This staining in the
expected areas shows that 5-HT neurons are being expressed in these animals and
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confirms that the secondary antibody and technique are functional. This leads to the
conclusion that there was a problem with the incorporation of the marker sequence
into the YAC resulting in loss of activity in the lacZ gene and HA tag expression.
There have been several reports of problems with lacZ expression in transgenic
animals although the reason is often unknown.
This chapter reports the generation of transgenic mice containing the h5-HTT gene
as identified by PCR. However, as neither the (3-galactosidase nor HA markers were
available in these animals in order to study the expression of the human gene in these
animals, two alternative, more traditional, strategies were used. Firstly the RNA was
analysed by RT-PCR , RNase protection analysis , and in situ hybridisation to show
expression and location of the human RNA (Chapter 3). Secondly to show protein




Localization and quantification of RNA expression in
the brain of h5-HTT transgenic mice
3.1 Introduction
3.1.1 5-HTTRNA expression in adult mice
In adult mice 5-HTT RNA is expressed almost exclusively in the midbrain and
hindbrain. It is expressed throughout the mesencephalic raphe nuclei (Bengel et al.,
1997; Schroeter and Blakely, 1996) and is highest in the dorsal and median raphe
nuclei (Bengel et al., 1997). In situ hybridisation and northern hybridization
analyses (Bengel et al., 1997; Blakely et al., 1991; Hansson et al., 1998; Hoffman et
al., 1991; Lesch et al., 1993) do not identify 5-HTT mRNA in any other region of the
adult mouse or rat brain except a very low and diffuse expression in the dentate
gyrus of adult rat hippocampus (Hansson et al., 1998). Using the more sensitive RT-
PCR technique low levels of expression of 5-HTT RNA were found in the frontal
cortex and hippocampus of rats despite the lack of 5-HT cell bodies in these
areas.(Lesch et al., 1993). This has not been repeated and has not been studied in
mice.
3.1.2 RNA expression during development
5-HT has many roles in development (see introduction) (Lauder et al., 1983;
Whitaker-Azmitia, 1991; Whitaker-Azmitia et al., 1996). In the brain specific 5-HT
neurons are first seen at E13 in the rat (Lauder, 1990; Wallace and Lauder, 1983) but
5-HTT RNA is seen, well before the development of synapses, at El0 in the mouse
(Schroeter and Blakely, 1996) and El 1 in the rat (Hansson et al., 1998).
Most of the work on 5-HTT RNA localization during development has been done in
rats. However binding studies using 5-HTT specific ligands in mice show that the
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overall spatiotemporal expression pattern of the serotonin transporter in the mouse
concurs with the localization of serotonin in the rat embryo (Bruning et ah, 1997),
thus where evidence in mice is not available it is feasible to extrapolate from the data
available in rats. In rats 5-HTT RNA is expressed both in cells which synthesise
5-HT and other cell types where serotonin probably has a less traditional
role.(Hansson et ah, 1999; Zhou et ah, 2000). The hippocampus produces 5-HTT
RNA from early embryonic through to postnatal development (Hansson et ah, 1998)
and the piriform cortex, olfactory nucleus and hypothalamus (Hansson et ah, 1998)
and the thalamus and neural crest-derived sensory neurons(Hansson et ah, 1999) also
show 5-HTT RNA activity during ontogeny.
3.1.3 RNA expression patterns and the study ofgene expression.
In modified animals which contain higher levels of h5-HTT DNA the RNA may be
being expressed in tissues which do not normally express 5-HTT or in greater, more
easily detected, concentrations in areas with normally low expression. Analysis of
RNA expression was used to determine gene expression and localization as the
presence of the marker gene lacZ, which would have been used to determine areas
where the transgene was being expressed, was not detectable. RT-PCR provides a
very sensitive method of RNA detection but was difficult to quantify and without
detailed dissection does not provide more than general localization. RNase
protection assays were therefore also used for quantification. In situ hybridization
provides a sensitive method ofRNA localization in tissue sections with a high level
of specificity for either the human or mouse form. This combination of techniques
provides a comprehensive picture of 5-HTT gene expression in these animals.
3.2 Methods of RNA analysis
3.2.1. Extraction ofRNA from tissue samples
Heterozygote h5-HTT mice were killed by cervical dislocation and the brain
removed and dissected immediately. For most studies the areas taken were: the
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cortex to study possible differences between transgenic and wild-type mice,
brainstem/midbrain containing the raphe nuclei, and the cerebellum as a negative
control. A coronal cut was made immediately anterior to the cerebellum and
followed by the separation of the cerebellum from the brainstem. The midbrain was
dissected and pooled with the brainstem sample. A sagittal cut was made down the
midline between the two hemispheres of the cerebral cortex. The cortex was
separated from the hippocampus and striatum and the remaining structures were
discarded. The two halves of the cortex were then pooled. Samples were frozen on
dry ice for later assay or homogenised immediately in RNAzol B (Biogenesis Ltd.
England) using glass homogenisers and extracted according to the manufacturers
instructions. Samples were then precipitated with isopropanol and resuspended in
tissue culture grade water (Sigma) and stored at -70 °C. under ethanol until required.
JAR cells -a human choriocarcinoma cell line expressing the 5-HTT (Cool et al.,
1991)- were used to provide human RNA. RNA was extracted by homogenising the
cells in 2ml of RNAzol B per 10"6 cells and isolated according to the manufacturer's
instructions. Before use RNA was quantified using OD 260/280 ratios of the




RNA samples were transcribed using Omniscript kits (Qiagen) according to the
manufacturer's instructions.
lpg samples of total RNA from different brain regions were transcribed at 37°C. for
1 hour in the presence of RNAse inhibitors. In most experiments the whole cortex,
brainstem and midbrain and cerebellum were used in order to provide sufficient
RNA. In experiments for closer localization in the wild-type samples were taken
from the frontal cortex, basal ganglia, midbrain, brainstem, hypothalamus,
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hippocampus, and cerebellum for analysis. To facilitate comparison the same
dissection was carried out as used when analysing neurochemistry (see section 5.2)
cDNA amplification
For the expression analysis of human 5-HTT half the resulting cDNA was amplified
using 32P end-labelled primers E4 (CTA CCT CAT CTC CTC CTT CAC g (Tm 62.1
oC)) and E7 (TTg TTg TTg AAC TTg TTg TAg C (Tm 54.7 °C)) from the exons 8-
11 region. This pair of primers was selected as the area amplified is of a similar size
in the two species (human 510 bp, mouse 499bp) but contains several differences in
restriction enzyme sites between the two species (see Figure 3.2.2.1).
Primers were labelled by PNK phosphate substitution. 30pmols of each primer were
incubated for 30min at 37°C in the presence of 90 pCi, 30pmols of y[32P]ATP
(Amersham Pharmacia Biotech, UK). Primers were then precipitated in the presence
of 20pg yeast total RNA as a carrier, washed to remove excess label, and
resuspended in tissue-culture-grade water (Sigma). Primers were made up to
sufficient concentration with cold primer and used in PCR reactions.
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10 20 30 40 50 60
I I I I I I
CTACCTCATCTCCTCCTTCACGGACCAGCTGCAAGAACTCTTGGAACACTGGCAACTGCACCAACTAC
• • • • • • ••••••••••••••••••• ••••••••••••••••••••••• •••
CTACCTCATCTCCTCCTTCACGGACCAGCTGCCCTGGACCAGCTGCAAGAACTCCTGGAACACTGGCAACTGCACCAATTAC
I I I I I I I I
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I I I I I I I I I
TTCGCCCAGGACAACATCACCTGGACACTCCATTCCACGTCACCTGCTGAGGAGTTTTACTTGCGCCATGTCCTGCAGATCC
TT("TGfGAGGArAAfATfA(TTGGAfffT(TATTffAfGTf(TfTGrTGAAGAATTTTArAfGCGffAfGTffTGfAGAT(T
I I I I I I I I
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160 170 180 190 700 710 770 730
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ATCAGTCAAAGGGAnTfAGGACTTGGGGACfATfAGfTGGCAGfTGGfTfTGTGfATfATGCTfATnTfAffATTATfTA
A££GG.TCTAAGGGGCTCCAGGACCTGGGGGGCATCAGCTGGCAGCTGGCCCTCTGCATCATGCTGATCTTCACTGTTATCTA
I I I I I I I I
Hpall 170 180 190 200 210 220 230 240
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I I I I I I I I
CTTCAGCATCTGGAAAGGAfilCAAAACGTCTGGCAAGGTGGTGTGGGTGACAGCCACCTTCCCTTACATTGTCCTTTCTGTC
(TTrAGfATfTGGAAAGGfGTfAAGAffTGTGGfAAGGTGGTGTGGGTGAfAGCTAffTTCT CTTATATCAT(TTTTCTGTC
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AGACAGGGGTGTGGGTTGATGCTGCGGCTCAGATCTTTTTCTCTCTTGGCCCGGGGTTTGGGGTTCTCCTGGCGTTTGCTAG
AGACAGGGGTGTGGATAGATGCAGCCGCTCAGATCTTCTTCTCTCTTGGTCCGGGCTTTGGGGTCCTGCTGGCTTTTGCTAG
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Figure 3.2.2.1. Comparison ofMouse (top) and Human (bottom) cDNA




To study the expression of human or mouse RNA the cDNA products were then cut
by restriction endonuclease digestion. The enzymes used and the products created
are described in Table 3.2.2.1.
Restriction enzyme Species cut Product Size
BanI h 341,172 bp
Hinfl m 249,163,87 bp
Hpall h 295,166,52bp
m 447,52 bp
Table 3.2.2.1 Restriction endonucleases used for analysis of RT-PCR and the fragments generated.
(h)= human (m)= mouse
The digested samples were then separated on a 5% non-denaturing acrylamide gel at
80-100 volts until the dye front (65bp) ran off., dried and exposed to Kodak biomax
film with a intensifying screen for at least 48 hrs. or to a phosphoimager cassette.
For Wild-type localization studies PCR with unlabelled E4, E7 primers only
followed the cDNA transcription.
RT-PCR reactions were carried out using a HYBAID Omni-E PCR machine with
Hotlid. PCR reactions were carried out on a HYBAID Omni-gene PCR machine.
Phosphoimaging used a Cyclone phosphoimager storage system with Optiquant
image analysis software (Hewlett Packard,UK). Primers were obtained from MWG
Biotech. (Germany) and Taq Polymerase ,and other reagents from Promega. Image
analysis was done using NIH image 1.62 after scanning using a EPSON II scanner.
Bands were selected visually and the area further defined by intensity greater than
5% over background. Signal density was measured in OD units converted to pCi.pg"1
from standards.
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3.2.3 RNase Protection assay
RNase protection assays are a form of solution hybridisation using a riboprobe
complementary to the sequence of interest and the properties of RNase T and RNase
A1 that digest single stranded RNA and mismatched strands. This allows the
identification of several similar products with the same probe and within the same
experiment.
A cRNA riboprobe containing a 375bp complementary region from exons 8-11 of
the human 5-HTT gene (Figure 3.2.3.1) was generated by synthesising a fragment of
the human cDNA using RT-PCR and inserting this into a T4 vector. This was
linearised using Ncol and transcribed using SP6 enzyme in the presence of excess
32P labelled CTP. The labelled product was purified through a G-50 column
(Boerrhinger- Mannenheim), precipitated and 1 pi counted on a scintillation counter.
lxlO5 dpm of labelled probe per sample was added to a 20pg pellet of sample RNA.
Samples were assayed using the RPAII kit (Ambion) according to the manufacturer's
instructions. Briefly, pellets of freshly precipitated and dried tRNA were incubated
with the labelled cRNA probe overnight at 42 °C to allow hybridisation to occur.
After hybridisation RNase A/Tl was used to digest any single stranded RNA, the
area hybridised to the probe was protected and generated a full-length human 375bp
product. The human probe hybridised to the mouse RNA where there was a 4bp area
of mismatch (Figure 3.2.3.1). This section was also digested by the Rnase,
generating two smaller RNA fragments of 274 and 85 bp. Products were separated
on a 7.5% denaturing acrylamide gel. The gel was dried and exposed to Kodak
biomax film in the presence of an intensifying screen for at least 1 week or to a
phosphoimager cassette.
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Rnase Protection Assay Probe / mouse RNA sequence
1 <71 7(71 R(7l A.0\ ^(71 7(71 S£7l
I I I I I I I I
aacgaagacgtgtccgaggtggccaaagacgcgggccccagcctccttttcatcacatatgcggaggcaatagctaacatgc
• ••••• ••••• ••••••••••••••••• •• ••••••••••• •••••••• ••••• • • •• ••••• •••••••
atgaagatgtgtctgaggtggccaaagacgcaggtcccagcctcctcttcatcacgtatgcagaagcgatagccaacatgc
I I I I I I I I
1 £71 7(3 R£7l A(7l R(71 A(7> 7(71 R(7l
90 100 110 120 130 140 150 160
I I I I I I I I
cagcatccacattctttgccatcatcttcttcctcatgttaatcacgctgggtttggatagcacgtttgcaggcctggaagg
cagcgtccactttctttgccatcatcttctttctgatgttaatcacgctgggcttggacagcacgtttgcaggcttggaggg
I I I I I I I I
Q£7l 1(71(71 11(71 17(71 1 R0I 1 AO 1^(71 1 ££71
170 180 190 200 210 220 230 240
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tgtgatcacagctgtgttggatgagtttcctcacatctgggccaagcgcagggaatggtttgtgctcatcgtggtcatcact
ggtgatcacggctgtgctggatgagttcccacacgtctgggccaagcgccgggagcggttcgtgctcgccgtggtcatcacc
l I i I I I I i
170 180 190 200 710 770 730 740
750 760 770 780 790 300 310 370
I I I I I I I I
tgcatcttgggatccctgctcacactgacai£Aggaggggcgtatgtggtgaccctgctggaggagtacgccacggggccag
••• •••• ••••••••• •••• ••••• • •••••••• •• ••••••• •••••••••••••• ••••••••••• •
tgcttctttggatccctggtcaccctgaciuxggaggggcctacgtggtgaagctgctggaggagtatgccacggggcccg
I I I I I I I I
250 260 270 280 290 300 310 320
330 340 350 360
l I I l
cagtgctcactgtggctctcatcgaggccgtcgtcgtg
••••••••••••• •• •• ••••• •• •••• ••
cagtgctcactgtcgcgctgatcgaagcagtcgctgt
I I I I
330 340 350 360
Figure 3.2.3.1 comparison of the ribobrobe from the human sequence
and mouse RNA. Sites of sufficient mismatch for RNase digestion are
highlighted.
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3.2.4 In situ hybridisation analysis ofRNA expression and localisation
Preparation ofbrain sections
Six male wild-type C57B16/CBA animals (Charles River) and six male +/-
heterozygous h5-HTT transgenic mice (3-6 months old), on a C57B16/CBA
background, were killed by cervical dislocation. Brains were removed as quickly as
possible; about 7 minutes per mouse, and frozen in an isopentane bath at -30 to -
35°C. for a few minutes until bubbling ceased then transferred to dry ice and stored
at -70°C. until required.
12 micron coronal sections were cut at -20°C. in a cryostat, according to levels in the
mouse brain atlas by Franklin & Paxinos (Franklin, 1997). The levels for coronal
sections used, according to the atlas, are listed in brackets. Frontal cortex (8-12),
striatum (16-20), hippocampus/SNR (26-30), anterior raphe (35) and posterior raphe
(36-38) and thaw mounted on gelatinised slides. Once mounted, sections were
maintained at -20°C then stored at -70°C until required.
For in situ hybridization, slides were pre-treated as follows. Sections were fixed in
4% paraformaldehyde, acetylated for 10 minutes in 0.1M triethanolamine HC1 pH 8,
then dehydrated in increasing concentrations of ethanol and air dried. Sections were
then stored overnight at -20°C.
Hybridisation
Two cDNA probes were used: (1) a probe for the human transporter (obtained from
Qi Pei, Department of Pharmacology Oxford University) which could hybridise with
the mouse transporter under low stringency conditions; and (2) a specific 3' mouse
probe selected from the sequence in the data base for low homology with the human
transporter sequence (obtained from Sigma Genosys Ltd.). The probe information is
listed in table 3.2.4.1
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mouse 40 bp CgTgTCACCAgCTAATgTggCA
gTAACTCCAAgAgAgTTC
42.5 0%
Table 3.2.4.1 Human and mouse probe sequences % mismatch is that compared to the mouse
sequence in experiments where both human and mouse were detected using the same
probe.
The probes were tested in a preliminary experiment for species specificity and in the
presence of the antisense or cold probe. There was no cross hybridisation under the
conditions used.
Probes were end-labelled with 35S (NEN Life Science Products 12.5mCi/ml; specific
activity 1250Ci/mmol) at 6pl per 6pmol probe and incubated at 37 °C for 30 minutes
with TdT enzyme (Promega). The reaction was stopped and the labelled probe was
purified through Sepadex G-50 gel. The purified probe was counted on a beta
counter and diluted to a concentration of 1.2xl06 cpm/lOOpl in hybridisation buffer
containing for most of the experiments 50% formamide, 4x SSC buffer with 0.05mM
DTT (see table 3.2.4.2 for solution compositions). 100 pi of solution was used per
section. Slides were covered with glass cover slips and then placed in lidded
incubation trays containing filter paper soaked in 50ml of 50% formamide with
4xSSC to prevent drying out. Sections were then hybridised over night in a sealed
oven at the appropriate temperature.
Calculation ofhybridisation temperature:
The hybridisation of a riboprobe to sample RNA is controlled by the melting
temperature of the probe. The ideal temperature for hybridisation is one sufficiently
high to maintain specificity but not so high that the probe becomes damaged.
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Melting temperature is influenced by 1) length of probe 2) base composition 3)
extent of sequence homology 4) composition of hybridisation and wash solution.
The formula below describes the interaction of these factors (Davis et al., 1986):
Tm = 16.6logl0 (molarity of monovalent cations) + 0.41 (%GC content of
probe) + 81.5 - (% of mismatches) - (675/length of probe in bases) -
0.65(%formamide in solution)
Incubation and washing are performed at temperature = Tm-15 °C.
Using this formula and the information in Table 3.2.4.1, conditions were chosen to
provide the optimum temperature by altering the molarity of monovalent cations in
the hybridisation solution. Table 3.2.4.2 describes the conditions used to detect
human and mouse RNA.




human Human only 50% 2x 37
human Human/mouse 50% 4x 33
mouse Mouse 50% 4x 34
Table 3.2.4.2 Composition of hybridisation buffer and conditions used for the detection of human
and mouse RNA in mouse brain sections. SSC =(sodium chloride / sodium citrate
buffer - composition see appendix 1)
After hybridisation coverslips were removed in lxSSC. Slides were the washed
three times in hot SSC (See Table 3.2.4.3 for conditions) for 20 minutes and twice at
room temperature for lhour. All solutions were DEPC treated.
Wash conditions are also dependent upon the formula above. During washing there
is no formamide present in order to facilitate the removal of non-specific bound
probe. The higher the concentration of SSC solution in the buffer the higher the
concentration of monovalent-cations. At higher concentrations of cations the bonds
formed between RNA are stronger and so decreasing the concentration of SSC








human Human only 0% 0.25x 55
human Human/mouse 0% lx 55
mouse Mouse 0% lx 55
Table 3.2.4.3 Composition of washing solution and conditions used.
Slides were rinsed in water to remove any salts and dried before being exposed to
Betamax film for 4 weeks. Image analysis was by computer-based image analysis
program (MCID/M4, Imaging Research Inc) and Microsoft Excel.
After background subtraction, optical density (OD) values were converted to pCi.g"1
tissue equivalent using standard curves of OD versus radioactivity in pCi.g"1 from
standards exposed to the same film. OD measurements were made by selecting a
suitable measuring tool, or box, of appropriate dimension, overlaying the structure of
interest, and measuring the optical density of that area. Measurements were made
bilaterally on 2-three sections for each mouse and each set of conditions.
Significance was defined as p<0.05 in a student t-test after F-test for analysis of
variance between mice in each group
3.3 Results
3.3.1. Tissue localisation ofhuman andmouse RNA
3.3.1.1 Tissue localisation in wild-type animals
RT-PCR analysis of tissue samples shows that wild-type animals express 5-HTT in
the midbrain and brainstem regions that, in this dissection, contain the raphe nuclei.
There was no detectable expression in the cortex, hippocampus, hypothalamus, basal
ganglia or cerebellum (Figure 3.3.1.1). In none of the RT-PCR or solution





Figure 3.3.1.1 RT-PCR detection of 5-HTT RNA expression in tissue samples from
the brain of wildtype mice. A) hippocampus, B) frontal cortex, C) brainstem, D)
hypothalamus, E) cerebellum, F) midbrain, G) basal ganglia, H) JAR cells 0.5pg ,1)
JAR cells lpg
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mice, except the midbrain and brainstem areas. In the dissection used the substantia
nigra and globus pallidus, which have been shown to express 5-HTT RNA in mice,
were not assayed separately.
3.3.1.2 Tissue expression in transgenics
All transgenic animals show 5-HTT expression in the brainstem region, which here
includes both midbrain and brainstem raphe. When the cDNA product was digested
with BanI endonuclease (Figure 3.3.1.2), which cuts human DNA, transgenic
samples show the product of smaller bands at 342 and 172 bp which is consistent
with the expression of the human 5-HTT in lines A102.3, A102.5, A104 and A145.1
but not A 102.2. Not all of the DNA was digested, showing the existence of
endogenous 5-HTT. When Hinfl endonuclease, which digests only mouse DNA, is
used, the expected bands are also seen in all lines (Figure 3.3.1.3). The endonuclease
Hpall cuts both human and mouse DNA with different size products. Human
295,166 and 52bp and mouse 447 and 52 bp. When the cDNA is digested with this
enzyme, 5 bands rather than the expected 4 are seen even when the enzymatic
digestion is allowed to continue for longer than necessary for complete digestion of
DNA from wild-type animals (Figure 3.3.1.4). This is probably as a result of
hybridisation occurring between human and mouse sense and antisense strains to
produce a double stranded DNA that does not contain restriction endonuclease sites.
Thus the enzymes which cut only a single species, BanI and Hinfl, can not be used
for quantification as the residual band may contain both hybrid and undigested DNA
and so not provide a true measure of expression for one species.
Transgenic mice also show 5-HTT expression in the cortex that was not seen in wild-
type mice. This was completely digested by BanI endonuclease showing that this is
due to specific transgenic expression of the human RNA and not to up-regulated
endogenous expression (Figure 3.3.1.5).
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Figure 3.3.1.2 BanI digest of cDNA from cortex (A-E ) and brainstem (F-J ) of




Figure 3.3.1.3 Hinfl digest of cDNA from cortex (A-E ) and brainstem (F-J ) of












Figure 3.3.1.4 Hpall digest of cDNA from Brainstem of: B=wildtype, C=A 102.2,
D= A102.5, F= A145.1, G=A104
mouse
human
Figure 3.3.1.5 Hpall digest of RT-PCR products from a) WT cortex, b) 102.3
cortex, c) 102.5 cortex, d) 145.1cortex, e) 104 cortex, f) 102.2 cortex, g) wt
brainstem, h) 102.3 brainstem, i) 102.5 brainstem, j) 145.1 brainstem, k) 104
brainstem, 1) 102.2 brainstem, m) wt cerebellum
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All the lines tested show this cortical expression. However it is not consistently
present in every sample. This is most probably due to individual sample degradation
as repeat experiments with the same RNA sample detected 5-HTT expression.
The cerebellum and basal ganglia of wild-type mice do not show 5-HTT RNA
expression (consistent with previous work: Bengel et al., 1997). The basal ganglia of
line 102.3 also do not show 5-HTT expression of either human or mouse gene. The
cerebellum of some transgenic lines shows slight 5-HTT RNA expression. Lines
102.2 and 102.3 have the highest levels whilst 102.5, 145.1 and 104 do not appear to
have 5-HTT RNA in these areas. There is very little 5-HTT expression in the
cerebellum of primates or rodents.
3.3.1.3 Summary of RT-PCR results
Thus RT-PCR detects the presence of human 5-HTT expression in the cortex ofmost
transgenic mouse lines, though this is much smaller in A102.2, and confirms that
endogenous mouse 5-HTT is not detectable in the cortex ofwild-type animals.
Transgenic animals also show expression of both human and mouse 5-HTT in
brainstem tissues.
3.3.1.4 Proportion of h5-HTT expression.
Analysis of RT PCR results using Kodak image analysis software to measure
proportional luminosity of ethidium bromide staining shows considerable variation
in expression between wild-type and transgenic mice (a 1.4-6 fold increase), and also
between the different transgenic lines, with 145.1 and 104 having the greatest
increase and 102.2 the least. Cortical expression is also greatest in 145.1 with
smaller amounts in 102.3 and 104, again with 102.2 the lowest of the expressing
lines and 102.5 showing low expression in the cortex (Table 3.3.1.1). However the
use of ethidium bromide as a stain is inaccurate because of the steep concentration-
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Cortex Brainstem
Human Mouse Human Mouse
Wildtype N/A NP N/A 1
A102.3 5603 NP 5.8±0.07 1
A102.5 NP NP 1.6 1
A102.2 5763 NP 1
A145.1 7053 NP 7.8±3.1 1
A104 NP NP 9.3±1.6 1
Table 3.3.1.1 Human and Mouse RNA expression in the cortex and brainstem of
wildtype and transgenic mice by RT-PCR with labelled primers.
N/A =not applicable NP = not present. Cortical amounts are absolute measurements of
RNA expression-^Ci.^g"1. The brainstem measurements are given as the ratio of human
to endogenous mouse in each line. N=3
luminosity curve. A comparison of products using radio-labeled probes is more
accurate. For RT-PCR to be semi-quantitative an internal control consisting of a
modified sample DNA sequence, which produces a smaller product to allow
comparison of the products, is required. In the protocol described here the presence
of the mouse form of the transporter provides an in-built control for the expression of
human 5-HTT in the brainstem region.
Table 3.3.1.1 lists the concentration of human and mouse RNA in the brainstem of
different lines of transgenic animals and in the wild-type. All the transgenic lines,
except A 102.2, express the human 5-HTT in the brainstem in addition to the mouse
form the expression varies from 1-4 fold and is greatest in lines A102.3 and A145.1.
In addition transgenic mice, with the exception ofA 102.5, express the human 5-HTT
in the cortex.
3.3.2 RNase protection assays.
RNase protection assays are as sensitive as RT-PCR but easier to quantify, though
they require larger amounts of sample RNA. RNase protection concurs with RT-
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PCR that there is no 5-HTT mRNA expression in the cortex of wild-type mice.
5-HTT mRNA was expressed in the cortex of all the transgenic lines tested (except
A102.5 and A104) and in the brainstem (Figure 3.3.2.1).
There were three products in the brainstem - coinciding with the size of the human
and two mouse, protected fragments. The ratio of human to mouse RNA expression
was 1-4 fold in the brainstem.
3.3.3 Localisation and expression of mouse 5-HTT RNA in wild-type and
transgenic mice
In situ hybridisation was used to provide a more specific localization of the h5-HTT
expression in transgenic line 102.3 and wild-type mice than that obtained by tissue
analysis. Three sets of conditions were used: A mouse specific probe to detect
mouse 5-HTT. A human specific probe at high stringency to detect only human
5-HTT RNA and finally the same human probe at low stringency where it also
detected mouse 5-HTT to compare the total level of 5-HTT RNA expression.
Coronal sections of the wild-type mouse brain at various levels of the neural axis
including the frontal cortex, hippocampus, striatum and raphe areas showed a
distribution of 5-HTT RNA consistent with that typically seen for serotonergic
neurons. 5-HTT RNA was found only in the mesencephalic raphe nuclei (Table
3.3.3.1). The highest signal was found in the dorsal raphe with less in the median
raphe (Table 3.3.3.1) and DRVL (data not shown). This is consistent with the
hybridization expression pattern seen in mice (Bengel et al., 1997). There was no









Figure 3.3.2.1 Representative RNAse protection assay using RNA from brainstem
ofwild type (wt) and transgenic line A102.3 (tg) mice.
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Raphe Nuclei (mouse probe)
Dorsal Median
TgA 102.3 1498+164 531±72
Wild-type 1498±359 572+125
Table 3.3.3.1 The expression of endogenous mouse 5-HTT RNA in the raphe nuclei of wild-type
and transgenic mice. Data expressed as pCi/g tissue compared to standards n=6
±SEM
There was no difference in mouse 5-HTT RNA levels in transgenic animals
compared to wild-type as detected with the m5-HTT specific probe (Table 3.3.3.1).
The distribution of 5-HTT RNA was identical to that seen in wild-type mice and no
expression was seen outside the raphe area. There was no change in level of
expression in either the dorsal or median raphe. Thus the regulation of endogenous
mouse 5-HTT is not affected by the inclusion of human 5-HTT promoter regions in
the transgene and so any alterations in level or distribution of 5-HTT RNA
expression detected with the human probe under low stringency conditions results
from the production of h5-HTT RNA.
3.3.3.1 Expression ofHuman 5-HTT RNA in transgenic mice
The human 5-HTT riboprobe when used under low stringency conditions detects
both human and mouse 5-HTT. This probe was also used under high stringency
conditions (see Section 3.2.4) but under these conditions a higher level of damage to
the sections occurred reducing the available measurements in the brainstem.
Therefore the data presented are from experiments under low stringency conditions.
As mentioned above there is no alteration in mouse 5-HTT RNA in transgenic
animals so any alterations seen with the human probe are because of human 5-HTT
expression.
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Tg A 102.3 2578±266** 938±164 1118±161 *
Wild-type 890+71 521±37 539±60
Ratio mouse:human 1:1.9 1:0.8 1:1
Table 3.3.3.2 The expression of 5-HTT RNA in the raphe nuclei ofwild-type and
transgenic mice *=p<0.05 **= p<0.01. Data expressed as pCi/g tissue
compared to standards n=6 ±SEM
Sections used were adjacent to those used for the hybridisation with the mouse probe
described above. In the brainstem area there is a significant increase in 5-HTT RNA
levels in the raphe nuclei of transgenic mice (Figure 3.3.3.2, Table 3.3.3.2). The
increase is 1.8 fold in the median raphe, 2 fold in the DRVL and 2.9 fold in the
dorsal raphe. Thus for each copy of the endogenous mouse 5-HTT there are 0.8-1.9
copies of the human 5-HTT RNA.
3.3.3.2 Expression of 5-HTT RNA outside the raphe
In addition to increased expression in the raphe nuclei transgenic animals also show
low-level expression in areas outside the brainstem area to which it is confined in
wild-type animals.
Transgenic animals show h5-HTT hybridization in the hippocampus throughout
CA1-CA3 and dentate gyrus (Figure 3.3.3.3, Table 3.3.3.3). This expression is at a
much lower level between 1/12th to 1/16th of that seen in the raphe with the same
probe. It is not possible from these results to identify a specific cell type that
expresses the RNA. The same probe at high stringency conditions shows similar
results and there is no significant difference between the two (Table 3.3.3.4).
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Figure 3.3.3.2 Localisation of 5-HTT RNA expression in the raphe nuclei of
transgenic (A) and wildtype (B) mice. Detection with a human 5-HTT probe under
low stringency conditions.
76
Figure 3.3.3.3 Localisation of h5-HTT RNA in the hippocampus of transgenic (A)





CA1 CA2 CA3 Dentate
gyrus
Tg A102.3 13 8±7 143±10 160±10 207+14
Wild type ND ND ND ND
ND = Not Detected
Table 3.3.3.3 Expression of 5-HTT in the hippocampus of transgenic mice. Data expressed as
pCi/g tissue compared to standards n=6 ±SEM
Hippocampus (High stringency
human probe)
CA1 CA2 CA3 Dentate
gyrus
Tg A102.3 166±9 182±7 205+13 278±12
Wild type ND ND ND ND
Table 3.3.3.4 Expression of human 5-HTT in the hippocampus of 5-HTT transgenic mice using a
human specific probe at high stringency. Data expressed as pCi/g tissue compared to
standards n=6 ±SEM
Further to this expression; low level 5-HTT RNA expression is also found in the
piriform cortex and granular cell layer of the olfactory nucleus of transgenic animals
(Figure 3.3.3.4). These areas do not show 5-HTT RNA expression in adult mice but
do in embryos (Hansson et al., 1998).
3.4 Discussion
The mouse form of the 5-HTT mRNA was found throughout the brainstem raphe
nucleus but not in the cortex or hippocampus in both control and transgenic animals.
This is consistent with previous published studies (Bengel et al., 1997). 5-HTT
mRNA, detected with a h5-HTT probe under high stringency conditions, was found
in raphe; hippocampus CA1-CA3, and dentate gyrus; piriform cortex; and the
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Figure 3.3.3.4 Localisation of h5-HTT expression in the granular layer of the
olfactory nucleus (A) and piriform cortex (B) of transgenic mice and wildtype mice
(C, D). Detection is with a human 5-HTT probe under low specificty.granular layer
of the olfactory nucleus. The same probe under low stringency conditions found
5-HTT mRNA in the same regions.
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There was no difference in level ofm5-HTT expression in transgenic and wild-type
mice thus any increase seen with the low stringency human probe is the result of an
additional expression of h5-HTT m RNA. Transgenic mice show a 1.8-2.9 fold
increase in mRNA in the raphe nuclei. The hippocampus shows no detectable
expression in the wild type mice consistent with the results of Bengel et al (1997)
and a low level in transgenic animals (ca 1/16th of the maximum expression seen in
the raphe). There is some evidence for the presence of 5-HTT mRNA in the
hippocampus in adult rats (Lesch et al., 1993) and Hansson et al (1998) show that in
adult rats the dentate gyrus shows a low number of 5-HTT positive cells. However,
there are also a relatively high number of 5-HTT binding sites in the hippocampus of
raphe origin (Sur et al., 1996). It is therefore interesting that these transgenic
animals express transporter RNA in this area. It has been shown that 5-HTT RNA is
expressed in the hippocampus CA1-CA3 and Dentate gyrus during development
(Hansson et al., 1998), and it is possible that excess RNA at this time alters the
configuration or long term expression in the hippocampus or that the normal level of
expression in mice is so low as to be undetectable except by more sensitive
techniques such as RT-PCR. The detected level was very low and it is possible that
contamination from blood or other sources could have occurred during dissection.
However, it is also possible that increased RNA in the raphe leads to axonal transport
and like the 5-HTT protein this RNA is of raphe origin. It would be possible to test
this by lesioning the raphe-hippocampal projection and re-analysing for RNA
expression. However it is unlikely that even a 3-fold increase in RNA level would
be sufficient to cause this effect.
Lesch et al (1993) also report RT-PCR detection of 5-HTT RNA expression in the
cortex of rats. However in situ hybridisation studies have not detected expression in
mice (Bengel et al., 1997) and this RT-PCR also consistently failed to detect 5-HTT
RNA in the cortex of control animals. In situ studies also show that in wild type
mice there was no expression in the cortex. In transgenic animals both the piriform
cortex and olfactory nucleus show 5-HTT RNA expression. It is possible that
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expression here occurs at very low levels or under certain physiological situations in
these areas in wild-type animals and that this expression is an increase of a normally
present phenomenon. It is also feasible that as both these areas have a serotonergic
input (Hansson et al., 1998) the hypothesis mentioned above for the hippocampus
applies and a disturbance in expression during development produces an alteration in
adult RNA expression. Possibly the normal off-switch fails.
These results show that the human transgene is being expressed in these mice and
confirms that the expression of the 5-HTT is targeted to certain regions. The
presence of the extra DNA leads to increased RNA production suggesting that the
expression of the 5-HTT is not regulated at this level (although it is possible that the
extra RNA is not translated). It is also possible that the pattern of expression differs
slightly in humans and mice, particularly in the cortex.
The expression of the human 5-HTT protein is studied in the next chapter.
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Chapter 4
Pharmacological characterisation of 5-HTT protein
expression
4.1 Introduction
The previous chapter described the expression of human 5-HTT RNA in transgenic
mice, but this expression does not necessarily mean that the RNA is translated into
5-HTT protein. Three possible scenarios could affect protein expression:
1) the human protein is not expressed;
2) the human protein is expressed and the endogenous mouse protein is
downregulated so that total 5-HTT protein levels remain constant; or
3) the human protein is expressed in addition to normal endogenous expression.
This last case is probably the most likely and would be the most useful model for
serotonergic disturbance. However, the 5-HT system has many regulatory elements
that may prevent over expression.
Two strategies were used to study 5-HTT protein expression. Firstly, the expression
was quantified in membranes from the cortex and brainstem of transgenic and wild-
type mice. The tritiated form of the SSRI citalopram ([3H]citalopram), which has a
high specificity for the 5-HTT, was used to measure 5-HTT protein expression in
membranes. Citalopram recognises both human and mouse protein; therefore, in
order to confirm human expression a pharmacological profile strategy was used.
Since the human, mouse and rat 5-HTT have slightly differing affinities for
antidepressants (Barker and Blakely, 1998; Barker et al., 1994; Tatsumi et ah, 1997),
the pharmacological profile and inhibition constants for different drugs in wild-type
and transgenic mice can be compared, thus providing information about human
5-HTT protein expression and allowing the contribution of the human protein to be
estimated. The affinities of antidepressants for the 5-HTT are described in the
introduction (Section 1.2.1). Finally, the binding of [3H]citalopram to the 5-HTT
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was localised in brain sections from wild-type and transgenic mice to provide an
expression pattern for the mouse and human protein, respectively.
Competition studies were used for the membrane binding and pharmacological
profiles. Done at equilibrium conditions, these studies use a fixed concentration of
radio-labeled ligand and sample tissue in the presence of a varying concentration of
unlabelled drug, which binds to the same site as the ligand. Thus, as the
concentration of competing drug increases, by the law of mass action, more of it
binds to the protein and less radio-labeled ligand is bound (see Section 4.2.5).
In order to find the drugs with different affinities for human and mouse protein a
comparison was first made between human, mouse and rat proteins. Assays were
done on membrane preparations from mouse brains. As human brains were not
available for comparison, human platelets were obtained (with thanks to the Rayne
Laboratory, University of Edinburgh). To ensure that the comparison between
platelet membranes and brain membranes was valid, platelets were also extracted
from rats and the pharmacology compared to that in rat cortex. Because of technical
constraints, it was not possible to obtain platelets from mice.
Saturation studies with increasing concentrations of unlabelled citalopram in the
presence of a fixed quantity of [3H]citalopram were then used to study the level of
protein expression and the dissociation constant (Kd) of citalopram, which was found
to differ between human and mouse proteins. Competition curves with other
unlabelled antidepressants were also used to compare the pharmacology in transgenic
and wild-type mice.
4.2 Methods
4.2.1 Membrane preparation from mouse and rat brain
Animals were killed by cervical dislocation followed by decapitation. Brains were
removed, placed immediately in ice-cold 0.9% saline, then dissected as quickly as
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possible. Regions taken were a) the cerebral cortex, b) brainstem and midbrain, and
c) cerebellum. Tissues were rolled on filter paper to remove blood vessels and the
tissue samples weighed. Rat brain samples were pooled but individual mouse brains
were processed separately in case transgenic animals had variable expression levels.
All solutions were kept on ice.
The tissues were homogenised (800 rpm) with a glass-teflon homogeniser (with
80pm clearance) in 10 (v/w) of 50mM Tris HC1 (pH 7.4), diluted to 50 volumes with
50mM Tris HC1 (pH 7.4) and centrifuged at 30000g for 10 minutes at 4 C to isolate
the membrane fragments. The pellet was resuspended (50mM Tris HC1, pH 7.4),
centrifuged (30000g, 10 minutes at 4 c), resuspended as before and incubated at 37 c
for 15 minutes to remove endogenous bound 5-HT. The membranes were
centrifuged as before and re-homogenised in 25 vols of 50mM Tris HC1, pH 7.4 and
aliquoted before storage at -20 C. Membranes were stored for at least 1 week before
use and for no longer than 6 weeks.
4.2.2 Preparation ofratplatelet-rich plasma
Platelet-rich plasma (PRP) was obtained by adaptation of the method of Gordon and
Olverman (Gordon and Olverman, 1978). Six female Spraque Dawley rats were
anaesthetised with 4% halothane in oxygen and nitrous oxide (30:70 v:v). Blood,
obtained by puncture of the vena cava into syringes primed with tri-sodium citrate,
was mixed with one part 3.1% tri-sodium citrate per nine parts of blood to prevent
coagulation. Blood samples were centrifuged at 2300 rpm (800g) for 2 minutes at
room temperature (RT) and the top layer containing PRP removed carefully. This
procedure was repeated twice more, and the PRP thus obtained was pooled. 7-9 ml
of blood was obtained per rat, which generated approximately 3-5 ml of PRP.
4.2.3 Preparation ofmembranes from rat and human PRP
Rat PRP was obtained as above. Human PRP was obtained from the blood of
volunteer control subjects as a by-product of lymphocyte extraction in the presence
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of heparin as an anticoagulant, (Rayne Laboratory, Department of Biomedical
Sciences, University of Edinburgh). Approximately 75 ml samples of PRP were
obtained.
Rat PRP was then centrifuged in a microfuge at 15,000 rpm for 20 minutes. The
pellets were re-suspended in Tris buffer (lOmM Tris HC1, 5mM EDTA) at 200pl per
10 ml of original sample. Human PRP was centrifuged at 17,000g or 14,500 rpm for
20 minutes and the resulting pellet re-suspended in Tris buffer at 50 ml per 50 ml
PRP. The resulting pellets were then homogenised on ice using an Ultra-Turrax
homogeniser for 10 seconds, twice. Samples were incubated on ice for 1 hour to lyse
the platelets, frozen for at least 30 minutes or overnight at -20 C to complete the
lysis, thawed on ice and made up to 15 ml (rat) or 50 ml (human) with ice-cold
50mM Tris HC1.
Membranes were prepared as for brain membranes described above except that the
incubation at 37°C to remove endogenous 5-HT was extended to two incubations of
30 minutes each. Membranes were isolated by centrifugation (10 minutes x
18000rpm for rat or 30000g for human samples. These conditions were used
throughout.) and re-suspended by homogenisation in 5 ml (rat) or 50 ml (human) of
50mM Tris HC1. Rat samples were further diluted to 10 ml for ease of handling.
The centrifugation and re-suspension steps were repeated and followed by a cycle of
incubation at 37°C for both human and rat platelet membranes (37°C, 30 minutes),
centrifugation (10 minutes, 18000 rpm/30,000g), and re-suspension (10ml 50mM
Tris HC1) to remove endogenous 5-HT. This incubation and centrifugation cycle
was repeated. The incubation at 37°C was increased from the 10 minutes used for
brain membranes described above as this was insufficient to release all the
endogenous bound 5-HT from the platelets, which inhibited [3H]citalopram binding.
After the second incubation at 37°C and centrifugation, the platelet membranes from
individual rats were re-suspended in a final volume of 5 ml 50mM Tris HC1 per 9 ml
of original blood, and the human platelet membranes were re-suspended in 10 ml 50
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mM Tris HC1 per 50 ml PRP. Samples were frozen as 1 ml aliquots at -20 c until
needed. On the day of assay the membranes were thawed on ice and diluted as
necessary in assay buffer. Rat membranes were diluted to 50-60 volumes, mouse
membranes to 40-50 volumes and human and rat platelets to 30 volumes.
4.2.4 Protein assays
The amount of protein was determined by the Bradford protein assay (Bradford,
1976). A serial dilution of bovine serum albumin (BSA) 10-200 pg/ml was used to
generate a standard curve. 250 pi of Bradford reagent (0.1% Coomassie blue (w/v),
5% of 95% ethanol (v/v), 10% of 85% orthophosphoric acid, twice filtered through
Whatman filter paper and stored at 4°C) was added to a 50 pi sample of the
standards, or test sample, in a 96-well plate (Corning). The plates were incubated in
the dark for 30 minutes before reading. A Dynatech plate reader was used to
measure absorbance; samples were shaken for 20 seconds to mix and the absorbance
was measured at an optical density of 595 nm (OD 595). OD 595 measurements for
the BSA standards were fitted through the linear part of the curve to a straight line
(Origin 41 for Windows). The amount of protein in each sample was then measured
by interpolation.
4.2.5 fH/Citalopram binding assays
These studies had three objectives: firstly, to compare the pharmacological profiles
of the human, rat and mouse transporters using cortical and platelet derived
membranes; secondly, to compare [3H]citalopram binding in wild-type and
transgenic mice to determine 5-HTT protein expression levels; and thirdly, to
compare the pharmacological profiles of wild-type and human 5-HTT (h5-HTT)
transgenic mice to determine the contribution of human transporters.
Competition studies are carried out in the presence of a fixed concentration of radio¬
ligand and membrane under equilibrium conditions. The concentration of the
competing drug is varied. Thus, as the concentration of competing drug increases
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the amount of radio-labeled drug bound decreases, such that occupancy by labelled
ligand A and competitive antagonist B can be defined by :
PA= - (1)
xa/Ka+Xb/KB+ 1
where Pa = occupancy by radio-labelled ligand; x\ = concentration of radio-ligand;
xq = concentration of inhibitor; K\ = equilibrium constant for the labelled ligand; and
Kb equilibrium constant for the inhibitor.
Stock solutions (10 mM) of the drugs used, sufficient for all the experiments, were
made in dFEO and stored at -20°C until diluted in assay buffer on the day of the
experiment. [ HJcitalopram (New England Nuclear) was diluted in dFEO and stored
under liquid nitrogen in aliquots sufficient for one experiment until needed. Assays
consisted of duplicate tubes to determine total and non-specific binding and ten sets
of duplicate tubes of competing drug at increasing concentrations. The binding
assays were carried out in 5 ml round bottom polypropylene tubes (Sterilin (RT35),
UK).
Membrane binding assays were carried out by pre-incubating 100 pi of buffer or test
drug, 300 pi of assay buffer (50mM Tris HC1, 120mM NaCl, 5mM KC1, pH 7.4),and
100 pi of [3H]citalopram (0.25 nM, 82-85 Ci/mmol) for 2 minutes at 25°C. Non¬
specific binding was determined in the presence of a concentration of the test drug at
least 100-fold the affinity of the drug for the transporter. Binding was initiated by
the addition of 500pl of the diluted membrane suspension to give a final volume of 1
ml. Incubation was continued for 1 hour to ensure that equilibrium was reached
(equilibrium for citalopram was 30 minutes). Bound and free ligand were separated
using a Brandel harvester over Whatman GF/B filters pre-wetted for 1 hour in assay
buffer containing 0.05 % polyethyleneimine (PEI). Following two rapid 2 ml washes
with assay buffer, the filter disks were transferred to scintillation vials and incubated
for at least 10 minutes with 100 pi of 100% formic acid to aid dissolution.
Emulsifier safe scintillant (2.5 ml) was added and equilibrated overnight.
Radioactivity was determined in a Packard 2500TR scintillation counter with
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automatic quench correction (counting efficiency approximately 50%). Samples
were counted for 4 minutes and results expressed as disintegrations per minute (dpm)
per sample. The concentration of the ligand for each binding assay was calculated
from eight samples of the radioactivity added to the assay.
To compare the pharmacological profiles of the transgenic and wild-type mice,
several competing drugs were used (see Table 4.2.1). In general a range of dilutions
of half a log unit were used and the range of concentrations was selected to bracket
the IC50 of the competing drug for the 5-hTT. Where possible, more closely space
dilutions of the competing drug were included around the IC50 value to reduce the
experimental error. When the competing drug is the unlabelled form of the radio¬
ligand used, in this experiment unlabelled citalopram, the graph of displaced binding
versus concentration of competing ligand is a saturation curve. The data from these
curves allow the calculation of the equilibrium dissociation constant (AT>) and
number of binding sites (5max). Data was analysed with GraphPad Prism 3 (Mac)
using non-linear regression analysis for curve fitting with the equation:
7=bottom +(top-bottom)/(l+10A((log IC50-A) x Hill Slope)) (2)
where the top and bottom are the Y values at the top and bottom plateaus of the
curve. Results were a logistic fit if the Hill slope equaled 1, which would be
consistent with a one-site fit. To calculate the K&, the dissociation constant at the
5-HTT and 5max, the density of the available binding sites for citalopram, the
following equations were used. /C50 (the concentration of ligand at which 50% of
the maximal binding occurs) is an experimentally defined parameter, measured from
the competition curve. As this constant depends upon the concentration of labelled
ligand present, it can be converted to a measurement of the dissociation constant as
follows:
Ko = IC50 - [3H]ligand concentration (3)
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where the IC50 is that of the unlabelled ligand and the [3H] ligand concentration in
the assay determined from the standards.
The density of binding sites (Bmax values in fmol/mg protein) were calculated by
converting the specific binding (dpm) of the radio-ligand bound into the number of
moles using the specific activity of the [3H]citalopram and the following equation:
Bmax = (bx /C50) / ([3H]-[ligand] x Pr) (4)
where b is the specific binding in fmoles at the [3H] citalopram concentration used in
the assay in the absence of inhibitor, IC50 is the concentration of the unlabelled
ligand giving 50% inhibition, [3H]-[ligand] is the concentration of radio-ligand in the
assay and Pr is the amount of protein in the assay in mg.
As the /C50 is an experimentally derived parameter, where possible, an inhibition
constant (K;), which is dependent on radio-ligand concentration, was calculated
according to the Cheng-Prussoff approximation for all inhibitors other than the cold
form of the ligand (Cheng and Prusoff, 1973):
IC
K' ~
l + ([\H~\-\ligand]Kd) ^
A Hill coefficient far away from 1 indicates there is not one binding site, and is
evidence for the presence of two sites. However, if it is not possible to separate into
two sites, then the K\ value will appear to be altered and this would not be a valid
measurement. In this case, the IC50 is determined.
Data analysis was by GraphPad prism 3(Mac) and Instat 2.03 using ANOVA
followed by the appropriate test as recommended by prism- Dunnet's post analysis
where one transgenic line was compared to control and Tukey's test where more
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4.2.6 Localisation of 5-HTT protein expression in the brain of transgenic mice
by in vitro autoradiography with f3HJcitalopram
In order to study the possible change in 5-HTT protein expression in the cortex of
transgenic mice, [3H]citalopram autoradiography was used in coronal sections of
transgenic mouse brain. The method and results described are from a preliminary
experiment with a range of [3H]citalopram concentrations, a picture of the
localisation pattern in the cortex was attained and thus some of the experimental
results are included in this thesis.
4.2.7 In vitro autoradiographic [3HJcitalopram method and analysis
Six wild-type and six A 102.3 mouse brains were processed, and coronal sections cut
using a cryostat as for in situ hybridisation (See section 3.2.4). Sections were
maintained at -70°C until used. Three adjacent sections were used for each
concentration, two as duplicate determinations of total binding and one as non¬
specific binding
For autoradiographic studies, sections were allowed to equilibrate to RT. Slides
were preincubated at RT for 15 minutes in assay buffer (see Table 4.2.2) and
incubated in the presence of [3H]citalopram for 1 hour (non-specific binding was
measured in the presence of 10"6M imipramine (which at this concentration blocks
the 5-HTT as well as NET and DAT), on adjacent sections on a separate slide. The
slides were then dipped in buffer at 4°C to remove excess ligand, and washed twice
for 10 minutes in buffer at 4°C. Any salt deposit was then removed by dipping the
slides in distilled water at 4°C before drying them in a cold air stream. Slides were
3 • 3then apposed, along with [ H]-microscales calibrated to nCi/mg (Amersham) to [ H]-
o
.
sensitive Hyperfilm (Amersham), in X-ray cassettes for 8 weeks at 4 C. Films were
developed according to the manufacturer's instructions and concentrations in
fmol.mg"1 were calculated by the image analysis software using the specific activity
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Table 4.2.2 Conditions for [3H]citalopram autoradiography
Autoradiograms were analysed using a computer-based image analysis program
(MCID/M4, Imaging Research Inc). After background subtraction, optical density
(OD) values were converted to fmol.mg"1 tissue equivalent using standard curves of
OD versus radioactivity in fmol.mg"1 from the tritium standards. OD measurements
were made by selecting a suitable measuring tool, or box, of appropriate dimension,
overlaying the structure of interest, and measuring the optical density of that area.
Measurements were made bilaterally on two sections for each concentration. The
same overlay was then used on the adjacent non-specific binding section. Specific
binding was determined by subtraction of non-specific binding from the respective
totals.
4.3 Results
4.3.1 Comparison of the pharmacological profiles of human, mouse, and rat
5-HTT.
The transgenic mice contain both human and mouse RNA. It was therefore
necessary to establish the pharmacology of both the human and mouse transporters in
isolation. As human brain tissue is difficult to obtain, platelet transporters with a
high degree of pharmacological similarity to those in the brain were used. Since
mouse platelets could not be obtained easily, membranes from rat cortex and
platelets were compared to confirm that the 5-HTT in platelets and brain tissue is
interchangeable. All experiments were conducted in parallel.
There was no significant difference between the binding affinities for 5-HTT for any
of the drugs tested in rat brain and platelets (Table 4.3.1.1). Taken together with
previously published studies in human tissue and expressed cell lines, this finding
92


































































Table4.3.1.1Ph rmacologyof[ H]citaloprambindinim use,r tndhu an. Theaffinityvalu sweredetermin dfrotinhibit of0.25 M[3H]citaloprambindi gme branesfrr tcort x, platelets,humanlateletsandouscor x.Disexpres edme±SEM.tatisticalan lysisANOVAfollowb Student-Newman-KeulsorTukeysmultiplpair-wiseanalysi*=p<0.05**= 1*=p .001c mp redouswh r figureswereavailablesingInstat2.03.(2)=nWhereoSEMigiv n=l.
confirms that platelet transporters are sufficiently similar to those in the CNS for use
as a model of human transporter function.
Whilst there were no significant differences in the affinity of citalopram between the
rat and mouse 5-HTT or between the rat cortex and platelets, there was a slight but
statistically significant change in the affinity for citalopram between human and rat
or mouse 5-HTT. The human transporter has a higher Kd (3.53 nM) compared to the
mouse (1.34 nM), a difference that was significant (p<0.01). The increase in Kd was
small, but the slight reduction in affinity for citalopram is important, as a shift toward
the human Kd in transgenics will indicate expression of the human variant.
However, such an increase will also affect the possible analysis of the competition
studies as the inhibition constant K; is derived from the Kd value of the labelled
ligand. In transgenic mice where the Kd is altered, the K\ cannot be determined
accurately.
A range of amine uptake inhibitors was tested in all species (Table 4.3.1.1). The
SSRI paroxetine had the highest affinity, with a K, value of 0.1-0.2 nM. The other
SSRIs, citalopram and fluoxetine, were also potent but the dibenzazepine
clomipramine, which has affinity for both the 5-HTT and noradrenaline (NA)
transporter, was more potent than fluoxetine. Desmethylimipramine (DMI), which
has affinity for both NA and 5-HT transporters, was less potent than the SSRIs as
was the selective NA uptake inhibitor, nomifensine. For all the tissues tested, the
order ofpotency for inhibition of [3H]citalopram binding (K\) was
Paroxetine>Citalopram>Clomipramine>Fluoxetine>DMI>Nomifensine.
The inhibition constants for fluoxetine, DMI and nomifensine had possibly differed
between human and mouse transporters in the preliminary study (Figure 4.3.1.1).
Two of these drugs were tested further (n=4-6) - fluoxetine and DMI. Further
studies indicated that only DMI had a significantly different inhibition profile in the
mouse and human (K\ = 237±21 and 66±21 nM, respectively; p< 0.001.) (Table






















Figure 4.3.1.1 Correlation of affinities of [ H]Citalopram binding in human platelet
and mouse cortical membranes. Affinities for Inhibition were determined from at least
two experiments (table 4.3.2.1). The correlation coefficient 9r0 obtained by linear
regression and correlation analyses of the data was 0.9227 p<0.01 with a slope of
1. 1±0.18 which was not significantly different from one.
95
I I I I I I
-1 0 1 2 3 4 5
log10[DMI] (M)
Figure 4.3.1.2 inhibition of [3H]citalopram binding by DMI in
membranes from human, mouse and rat tissues.
* — rat cortex 4 = rat pit ■ =human 4 — mouse
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(Table 4.3.1.1, Figure 4.3.1.2) for inhibition of [3H]5-HT binding by DMI in rat and
human transporters in heterologous expression systems (Barker and Blakely, 1998),
where the tricyclic antidepressants imipramine and DMI were found to be more
potent at the human versus the rat transporter.
All the drugs used bound to a single site. The Hill coefficient did not deviate
significantly from unity. This finding is important as it might be expected that the
Hill coefficient would be less than one in transgenic animals if the K\ were
significantly different in the two species. Those drugs with different affinities for the
human and mouse transporter, such as DMI, are useful for identifying the presence
of both human and mouse protein in the transgenics as a shift in the affinity towards
that of the human suggests that any extra protein present is the human form.
4.3.2 Affinityfor citalopram and binding site density in the cortex and brainstem
membranes ofwild-type and transgenic mice.
In wild-type animals the Kd for citalopram was 1 nM and the Hill coefficient did not
differ from unity, showing the presence of only one binding site. The 5max in the
cortex was 868 fmol.mg"'protein. There was a small (non-significant) increase in the
disassociation constant (AT>) for citalopram in the cortex of both lines of transgenic
mice tested compared to wild-type animals. This finding suggests a shift towards the
human value and thus the presence of the human transporter. In addition to the
change in Kd, the Hill coefficient (nH), which is a measure of the slope of the curve,
was less than unity in the transgenic mice. This observation is consistent with the
presence of two binding sites with different affinities.
There was a 2-3 fold increase in the 5max (available binding sites) in both transgenic
lines tested compared to wild-type mice, confirming that the 5-HTT is over-
expressed in these transgenic mice. This increase is greater in line A 102.3 than
A 102.2, suggesting that the two lines express different amounts of the human
protein. A102.2 expresses 50% human, 50% mouse, whilst line A102.3 expresses







F1 (4) 868±309 1.19±0.44 1.05±0.16
A102.2(6) 1829±388 1.28±0.29 0.74±0.09
A 102.3(4) *2790±571 1.60±0.26 0.58±0.05
Table 4.3.2.1 Affinity and binding site density for [3H]citalopram in the cortex of wild-type and
transgenic mice. * p<0.05, ** p<0.01 by ANOVA followed by Dunnet's pair-wise
comparison. Data are expressed as the mean ± standard error (n= 4).
Figure 4.3.2.1 shows a model that explains the effect of two binding sites with
different affinities on the binding curve. When two sites are present, the curve
generated is the product of two curves, one for each site, added together. If the
difference in affinities for the two sites is less than an order ofmagnitude, as in this
case, the two curves cannot be separated by a two-site fit. However using a logistic
fit and looking at the Hill coefficient as an indirect measure; the slope of the curve is
altered, becoming flattened, and the slope is reduced from one.
There were no significant differences between the Ku and Bmax of brainstem tissue
from wild-type and transgenic mice. Although these values increased, their






F1 2821±627 1.29±0.21 1.03±0.08
A102.2 3108±290 1.34±0.28 0.85±0.15
A102.3 3848±552 1.75±0.14 0.89±0.11
Table 4.3.2.2 Affinity and binding site density for [3H]citalopram in the brainstem of wild-type and
transgenic mice. * p<0.05, ** p<0.01 by ANOVA followed by Dunnet's pair-wise
comparison (Instat 2.03). Data are expressed as the mean ± standard error of at least 4
animals.
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Figure 4.3.2.1 Model showing the effect of the presence of two binding sites with
different affinities for the ligand on the shape of a saturation curve. Site A has and
KD = 1 and site B a kD = 10. Both have hill coefficients of 1. When the two sites
are expressed in the same system at equal levels (A+B) it can be seen that the
curve becomes flattened. In this example the measured kD of A+B is 4.39 and the














Figure 4.3.2.2 Binding site density in A) the cortex and B) the brainstem of
transgenic and wildtype mice.
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The expression of 5-HTT in the brainstem of wild-type mice is significantly higher
than in the cortex, which could possibly mask any changes in AT> or Bmm (Figure
4.3.2.2.)- The cortex has 5-HTT protein from DRN neurons in the brainstem as well
as the additional expression indicated by the presence ofRNA in the piriform cortex.
Thus two factors may be involved in the 5-HTT increase seen in the cortex. Further
experiments will concentrate on the cortex where the expression is easiest to isolate.
There was no detectable signal in any of the cerebellar membranes of wild-type or
transgenic mice.
4.3.3 Pharmacology of antidepressant binding in the cortex and brainstem of
wild-type and transgenic mice
The presence of two sites with differing affinities for the [3H]citalopram results in a
slight change in the Ko. This change in itself is not significant, but as the inhibition
constant for the competing drug is related to the Kd it may cause apparent shift in the
it is therefore possible only to compare the /C50 values for the competing drugs and
not the K\ values. Tables 4.3.3.1 and 4.3.3.2 show the pharmacological profile for
cortex and brainstem membranes, respectively.
In both wild-type mice and in transgenic lines A102.2 and A102.3, the order of
potency remains the same with clomipramine > fluoxetine > DMI. In cortical
membranes the affinity of DMI was higher in transgenic mice than in wild-type
controls (p<0.05). Like the change in affinity for citalopram, this increase was
slightly higher in line A102.3 than A102.2. There was no significant change in the
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In the brainstem there was no significant difference between wild-type and
transgenic mice in the IC50 any of the drugs tested. However, the 5max and Afi for
citalopram were increased in transgenic animals and the Hill slope was not far off
unity, yet not quite one, suggesting that two sites are present. Nonetheless, the
proportion of human 5-HTT expression may be lower in the brainstem than in the
cortex. These changes were similar to those in the cortex and towards the human
values. However, unlike the cortex there was no increase in the affinity of DMI in
the brainstem of transgenic mice
4.3.4 In vitro localisation ofcortical [3H]citalopram binding.
The saturation curve for [3H]citalopram was not very successful. There are several
probable reasons. Firstly, the mouse brain is very small and so there was a
considerable amount of variation in binding density as the first and last sections were
not within the same brain areas. Secondly, since the same solution was used for all
the sections and was thus re-used, at low ligand concentrations there was probably
some ligand depletion by the end of the experiment. Three batches of slides were
treated in each dish. Thus though there was a trend to increased binding in
transgenic animals, the errors masked any likely significant result.
However, the main aim to localise [3H]citalopram binding was achieved in both
transgenic and wild-type mice. Figure 4.3.4.1 shows sections from the cortex of
transgenic and wild-type mice. The pattern of binding was similar in both genotypes
and was consistent with the published pattern of expression of 5-HT neurons. None
of the cerebral cortical areas without 5-HTT expression in wild-type mice showed
expression in transgenic mice. The piriform cortex did not show 5-HTT protein
expression (Figure 4.3.4.1b) and the granular cell layer of the olfactory nucleus
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4.4 Discussion
4.4.1 Comparison ofhuman platelet andmouse 5-HTT
As a result of the recent generation of knockout mice without a functional 5-HTT,
there is a large body of published information on the effects of reduced 5-HTT
activity and its interactions with 5-HT autoreceptors in mice. The 5-HTT knockout
mouse is often cited as an animal model for human antidepressant use. There is also
a long-used assumption that the platelet transporter is functionally interchangeable
with the cerebral form, though considerable evidence suggests that regulation of the
platelet 5-HTT does not necessarily reflect that in the brain. Despite this evidence,
very few studies have directly compared mouse and human 5-HTT pharmacological
profiles.
The results of this thesis research confirm that platelet and cortical membranes have
identical pharmacology for all of the amine uptake inhibitors tested, in agreement
with the literature. The comparison of all three species in parallel experiments had
not been made prior to this study although rat and human 5-HTT have been
compared in several studies. There is no difference between the pharmacological
profile of the rat and mouse 5-HTT. There was, however, a difference between the
affinities of some of the tricyclic antidepressants (TCAs) used for human and rodent
transporters. In particular, the dibenzazepine DMI and possibly clomipramine had
greater affinity for the human transporter, though this was not tested in detail. This
finding agrees with previous studies in native platelet preparations (Wielosz et al.,
1976) where clomipramine and imipramine were found to be more potent in human
than rat platelets. More recent studies also found that the tricyclic antidepressants
were more potent at binding to the human than the cloned rat transporter in a
heterologous system where human and rat 5-HTT were transiently transfected into
HeLa cells (Barker and Blakely, 1998; Blakely et al., 1991; Ramamoorthy et al.,
1993a).
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4.4.2 Comparison oftransgenic and wild-type mice
Cortical membranes from transgenic mice exhibited a shift in the Kb of citalopram
towards the human affinity rather than the mouse. There was a shift in the Hill
coefficient away from unity, consistent with the presence of two sites with different
affinities for the ligand. In addition there was an increased density of 5-HTT binding
sites, which confirms an increased expression of 5-HTT in transgenic mice. The
density of 5-HTT binding sites was greater in transgenic line A102.3 than A102.2,
suggesting that the two lines express the protein at different levels in the cortex (Bmax
2:1, 1.6:1, respectively). Consistent with this over-expression being due to the
human protein, and in addition to the change in the Hill coefficient suggesting two
sites, the pharmacological profile showed a shift in the potency K; of DMI and
clomipramine in the cortex towards the human values and significantly different
from that in wild-type animals. As the tritiated ligand is specific for the 5-HTT, the
change in DMI potency is not due to a change in NA transporter activity.
These differences were less pronounced in line A102.2 than A102.3. This
observation agrees with the mRNA data, which showed that line A102.2 expressed
5-HTT mRNA at lower levels than A102.3. Although there are several possible
reasons for the variability of expression, the most likely explanation is that the
incorporation of different copy number of the YAC occurred in the different
transgenic lines. It is also possible that the loss of part of the YAC in the transgene
incorporated in line A 102.2 is sufficient to influence expression. Additionally, the
site of integration of the transgene into the mouse genome influences transgene
expression.
In the brainstem, there was a trend towards increased expression, but less than that
seen in the cortex. The less pronounced changes in the brainstem may be because
the cortex has several sources of 5-HTT protein as it receives input from the DRN in
the brainstem, as well as the hypothalamus and other forebrain regions. In studies of
[3H]citalopram binding in 5-HT lesioned animals (Lawrence et al., 1993),
hippocampal binding was abolished but cortical binding was only reduced by 50%,
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suggesting that there is more than one source of 5-HTT protein in the cortex. In
addition, in situ hybridisation studies (see Chapter 3) indicated that there was ectopic
expression of the 5-HTT transgene in the cortex, but not in the brainstem. In the
| TI]citalopram autoradiographic experiments, protein expression was not seen in the
same areas as human RNA localisation, suggesting that either the RNA is not
functionally transcribed or that it is located only in the somatic regions of cells which
may project elsewhere in the cortex. In dissecting the brain for tissue samples, care
was taken to remove the hippocampus and striatum from the cerebral cortex sample.
The density of [3H]citalopram binding sites was also lower in the cortex of wild-type
mice than the brainstem sample. This finding agrees with the published reports on
the distribution of the 5-HTT in rats (Lesch et al., 1993). It is possible that the
different brain areas have different capacities for increasing 5-HTT expression. Such
putative differences may be important in studying the effects of increased 5-HTT on
the behaviour and neurochemical effects of 5-HTT over-expression. An additional
factor may be that the human 5-HTT is targeted differently and may be found in the
cortex.
Though these studies show that 5-HTT protein is over-expressed in transgenic mice
at nearly twice the endogenous level and that the protein is successfully targeted to
the membrane, the findings do not guarantee that the protein is fully functional. On
the other hand, the successful citalopram binding does suggest that at least part of the
protein has normal conformation. These studies also do not provide any information
about protein turnover or levels of cytosolic or malformed protein.
4.4.3 Summary
5-HTT transgenic mice over-express the 5-HTT protein (2.1-3.2 fold in the cortex
and 1.1-1.3 fold in the brainstem). The shifts in Ku value and Hill coefficient away
from unity and altered pharmacological profile show that this over-expression is due
to the human form of the protein.
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4.4.4 Further work
The localisation of the 5-HTT protein using saturating concentrations
[3H]citalopram autoradiography is continuing. In addition to this effort, 5-HT
uptake studies to show that the over-expressed protein is definitely functional and
immunocytochemistry with antibodies specific to human and mouse 5-HTT would
help complete the picture of the human 5-HTT expression.
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Chapter 5
Characterisation of the serotonergic neurochemistry
of h5-HTT transgenic mice
This chapter reports the measurement of the concentrations of 5-HT, dopamine and
their metabolites 5-HIAA and DOPAC in brain tissue samples from transgenic and
wild-type mice. The aim was to see whether increasing the expression of the 5-HTT
had any consequences for the animals' neurochemistry. Any changes seen in the
5-HT system would help to clarify the role of the transporter in regulation of
serotonergic function and explain any behavioural changes observed in the over-
expressing mice and in models of human depressive disorders. Such changes may
also help to explain why increased 5-HTT levels have been linked to depression
(Dahlstrom et al., 2000).
5.1 Introduction
The major proportion of 5-HT concentrations in tissue samples is in intracellular
stores and is therefore dependent upon the interactions among 5-HT synthesis, re¬
uptake and storage, and metabolism. The following summarises the comprehensive
description of 5-HT metabolism given in Chapter 1.
5-HT is synthesised within the neuron from the amino acid tryptophan, with the rate-
limiting step being is the conversion of tryptophan to 5-Hydroxytryptophan by the
enzyme tryptophan hydroxylase (Grahame-Smith, 1964). Tryptophan hydroxylase is
not saturated at physiological conditions so the synthesis of 5-HT can be altered by
the availability of tryptophan as well as alterations in enzyme activity (Hamon et al.,
1981; Hamon and Glowinski, 1974). Tryptophan levels are mainly dependent upon
dietary intake and are not easily regulated. The activity of tryptophan hydroxylase is
regulated by both Ca2+/calmodulin-dependent (Hamon et al., 1981; Kuhn and
Lovenberg, 1982) and cAMP-dependent (Foguet et al., 1993) protein kinases that
convert the non-active form tryptophan hydroxylase to the active enzyme.
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This activation can be altered by 5-HT autoreceptors. 5-HTiA receptors are
negatively linked to adenyl cyclase but also to Gj-protein-regulated K+_ or Ca2+-
dependent ion channels and so may act through either protein kinase system (Starke
et al., 1989; Williams et al., 1988). The terminal autoreceptor 5-HTiB also inhibits
5-HT synthesis. Stimulation of the 5-HTiB receptor markedly inhibits synthesis, and
the blockade of 5-HT)B receptors increases synthesis, indicating that endogenous
5-HT exerts a tonic effect on synthesis via this receptor (Moret and Briley, 1997a;
Moret and Briley, 1997b; Stenfors et al., 2000; Stenfors et al., 2001). Both 5-HTia
and 5-HTiB receptors can regulate synthesis independently under experimental
conditions (Barton and Hutson, 1999) but they are probably not the only receptors
involved physiologically. SSRIs and tricyclic antidepressants increase extracellular
5-HT and inhibit pre-synaptic neuronal firing and 5-HT synthesis (Aghajanian, 1972;
Carlsson and Lindqvist, 1978; Corrodi and Fuxe, 1969; Fuller et al., 1974; Gartside
et al., 1995; Hjorth, 1993; Hjorth and Sharp, 1993; Hjorth et al., 1995; Invernizzi et
al., 1992; Svensson, 1978). This acute effect depends on the presence of 5-HT and is
not prevented by blockade of 5-HTia, 5-HTiB or a combination of both receptors
(Moret and Briley, 1997b; Stenfors et al., 2001). This suggests that there is another
mechanism by which 5-HT release inhibits synthesis.
5-HT is stored in vesicles before release and on re-uptake 5-HT is either transported
by the VMAT2 from the cytoplasm into vesicles and re-stored or broken down by the
monoamine oxidase A/aldehyde dehydrogenase pathway (Cases et al., 1995; Celada
et al., 1992). The most stable and easily measured product of this process is
5-Hydroxyindole-3-acetic acid (5-HIAA). 5-HT metabolism is controlled by the
activity of the monoamine oxidase A (MAO-A) pathway. Increasing 5-HT
concentrations in the cytoplasm will increase the amount of 5-HT metabolised by the
enzyme. 5-HT itself may regulate MAO activity (Tyce, 1990). There is also some
evidence that a polymorphism in MAO-A may differentially effect serotonin
metabolism (Tyce, 1990). Mice in which monoamine oxidase A has been knocked
out have up to nine times greater than normal tissue 5-HT concentrations (Cases et
al., 1995), and MAO inhibitors increase 5-HT levels whilst reducing 5-HIAA levels
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in rodents and humans. 5-HIAA can be measured in tissue samples with relative
ease. The absolute concentration of 5-HIAA but more usefully the ratio of
5-HIAA/5-HT is a used as a measure of 5-HT turnover and activity.
The 5-HT and dopamine systems interact at several levels; it was therefore possible
that altered 5-HT neurochemistry in turn affects dopamine concentrations. The most
stable and easily measured metabolite of dopamine is 3,4-dihydroxyphenyl acetic
acid (DOPAC), which was therefore included in the assays. If there were any
apparent changes in DOPAC concentrations, then dopamine and DOPAC tissue
concentrations were assayed together in a different assay.
Measuring the concentrations of both transmitter and its metabolites provides
considerable information about the state of the transmitter system, particularly the
feedback state. In the 5-HT system a decrease in absolute transmitter levels indicates
either 1) a reduced reuptake efficiency, 2) a reduction in synthesis or 3) greater
metabolism. A concurrent increase in 5-HIAA would suggest that greater
metabolism was a factor. An increase in the ratio of 5-HIAA/5-HT would indicate
greater 5-HT turnover and therefore greater release. It is thus of interest to compare
the effect of 5-HTT over-expression on transmitter and metabolite concentrations to
provide information about the status of, and the feed back in, the 5-HT system.
5.1.1 5-HT and 5-HTT concentrations in knockout mice
On neuronal stimulation in 5-HTT knockout mice, the release of 5-HT has been
shown to be severely reduced and re-uptake abolished, in addition tissue 5-HT is
depleted by 60-80%. A small, though statistically significant, increase in 5-HIAA
(Bengel, 1998) was also seen, which further indicates the importance of 5-HTT in
5-HT homeostasis. 5-HT is usually metabolised by monoamine oxidase within the
cell, but monoamine oxidase within the synaptic cleft has some affinity for 5-HT and
may be the cause of the increased 5-HIAA. In 5-HTT knockout animals dopamine
and noradrenaline (NA) and their metabolites were unaffected by the change in
5-HT, possibly due to adaptations during development. These 5-HTT knockout
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animals survive but show other alterations in the 5-HT system: decreased 5-HT!A
receptor RNA and protein levels in the raphe nuclei and regional-specific reduced
5-HTib expression (Fabre et al., 2000); and regional-specific adaptive reduction of
5-HT2A receptor expression (Rioux et al., 1999). The 5-HTT knockout mice also
show abolition of the pharmacological induced decrease in 5-HT turnover caused by
the 5-HTia agonist isipirone, and loss of the 5-HT release caused by 5-HTib/id
antagonists (Fabre et al., 2000). Attenuation of the locomotor responses to ecstasy
(Bengel, 1998) in these knockout mice confirms the marked alterations of both
autoreceptor and postsynaptic receptor function and suggests a possible effect on the
DA system in knockout mice. The knockout animals have been suggested as a model
for chronic antidepressant treatment as the 5-HTT is blocked; however, 5-HT is an
important developmental signal and so the lifetime loss of 5-HTT activity will lead
to adaptive changes that are different from adult onset of 5-HTT blockade with
antidepressants. Therefore, whilst the changes in receptor function in knockout mice
are interesting as a study of 5-HT system, the comparisons with depressed patients
have to be drawn with circumspection. 5-HT2A receptor expression is a case in point:
there are important periods during development where the ontogeny of 5-HT2
receptors can be affected (Morilak and Ciaranello, 1993). In SSRI-treated rodents
5-HT2A receptors are increased whilst in 5-HTT knockout animals 5-HT2A receptor
expression is decreased.
5-HT metabolism is also altered in depression where an increase in 5-HIAA
(Martensson et al., 1989) and a decrease in 5-HT levels are seen in the CSF of
patients. The most effective drugs for treating depression, TCAs and SSRIs, increase
the level of 5-HT in rodents. This observation, along with the evidence of altered
5-HT metabolism in depressed patients, formed the basis of the working hypothesis
that the biochemical basis of depression is a deficiency in the levels of available
brain serotonin, particularly in the hippocampus, an area greatly involved in the
regulation of mood and which receives high levels of serotonergic input from the
DRN and MRN.
113
Recent evidence that 5-HTT levels are increased in some types of depressive patients
(Dahlstrom et al., 2000) implies that transgenic animals over-expressing the 5-HTT
may be a better model than knockout animals for changes in the human 5-HT system
that lead up to clinical depression. In this research the concentration of 5-HT, its
metabolite 5-HIAA and the dopamine metabolite DOPAC were measured in
transgenic animals using high pressure liquid chromatography (HPLC) with
electrochemical detection.
5.2 Methods
5.2.1 Dissection oftissue samples
Mice were killed by cervical dislocation and their brains quickly removed. Tissue
samples from the cerebellum, brainstem, midbrain, basal ganglia, hypothalamus,
hippocampus and frontal cortex were dissected quickly (about 10 minutes per
mouse) and frozen on dry ice. Samples were stored at -70 C until required. Eight
male h5-HTT transgenic mice, from line A102.3, with eight age-matched controls
were used per group. The tissue areas were chosen to cover 1) the originating nuclei
of 5-HT pathways (brainstem, midbrain), 2) forebrain regions with 5-HT inputs
(hippocampus, frontal cortex, hypothalamus), 3) regions with low 5-HTT expression
as a control (cerebellum), and 4) a region where the 5-HT system might alter
dopamine (basal ganglia).
An initial coronal cut was made immediately anterior to the cerebellum and followed
by a second cut to separate the brainstem and cerebellum. Care was taken to prevent
contamination of the cerebellum sample with brainstem or spinal cord. The midbrain
was then dissected away from the forebrain and the hippocampus identified and
removed. Next a block of hypothalamic tissue, which extended from the anterior
edge of the optic chiasm to the caudal edge of the mamillary body and laterally to the
hypothalamic sulci, was removed. Finally an area corresponding to the basal ganglia
and basal forebrain was removed according to stereotaxic co-ordinates in the mouse
atlas of the brain (Franklin, 1997). This area includes the accumbens nucleus, ventral
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pallidum and median forebrain bundle, islands of Calleja, and magnocellular preoptic
nucleus.
5.2.2 HPLC detection of5-HT, 5-HIAA and DOPAC
A maximum of four samples were processed at a time to avoid oxidative degradation
of the amines. All samples from one brain region were analysed on the same day as
HPLC machines are sensitive to daily fluctuations in temperature and pressure. 5-HT
and 5-HIAA were assayed together to ensure that comparisons could be drawn
between them. The assay conditions also produced a visible peak corresponding to
DOPAC, which was also measured. Dopamine could not be measured in this assay.
Samples were analysed according to a variation of a previously reported method for
the detection ofmonoamine metabolites (Zaczek and Coyle, 1982). Briefly, samples
were weighed whilst frozen, then thawed in 500 pi cold 0.1M perchloric acid.
Tissues were homogenised by ultrasonication for 30 seconds or by using a Ultra-
Turrax homogeniser (for three 10-second bursts). The cerebellum was more difficult
to homogenise and the process was therefore repeated for this region. The
homogenate was centrifuged for 5 minutes to remove any solid matter and the top
200 pi of supernatant was removed and stored on ice to prevent solid matter re-
suspending and clogging the column; the supernatant was protected from light to
prevent degradation. An aliquot (50 pi) of this supernatant was then analysed for
5-HT, 5-HIAA and DOPAC by HPLC with electrochemical detection. 5-HT,
5-HIAA and DOPAC were resolved in the same run using a Microscorb column
(CI8 ODS 2, Rainin) and detection was by a BAS (LC-4) potentiometer with a
working electrode set at +0.7 Volts. De-gassed mobile phase (methanol 12.5%,
EDTA 0.03%, NaH2P04 127mM, octane sulphonic acid 15mM, pH 4.0) was pumped
at 1.2 ml/min using an HPLC pump.
Calibration was by an external standard (5 pmol each 5-HT, 5-HIAA, DOPAC in 0.1
M perchloric acid) and fresh standards were made each day from concentrated stock.
Stock solutions of 10 mM for each of 5-HT, 5-HIAA, and DOPAC were dissolved in
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dH20 and stored at 4°C. Stock solutions were made fresh each week and were
diluted on the day by serial dilution in 0.1M perchloric acid.
5.2.3 HPLC detection ofdopamine, DOPAC and 5-HJAA
Those basal ganglia samples that showed a change in DOPAC concentrations in the
5-HT analysis described above were re-analysed for dopamine content in a separate
assay. Supernatant from the tissue preparation was stored at 4°C overnight, then
diluted 1/5 in 0.1 M cold perchloric acid. A 50pl aliquot of diluted supernatant was
then assayed for DA, DOPAC and 5-HIAA using similar apparatus to that described
for the 5-HT assay, but different mobile phase. Mobile phase composition was
methanol 16.7%, EDTA 0.03%, NaH2Po4 116mM, octane sulphonic acid 24mM, pH
3.85. De-gassed mobile phase was pumped at 1.2 ml/min using an HPLC pump.
Calibration was by an external standard (5 pmol each DA, 5-HIAA, DOPAC in 0.1
M perchloric acid) and fresh standards were made each day from concentrated stock.
Stock solutions of 10 mM for each of DA, 5-HIAA, and DOPAC were dissolved in
dH20 and stored at 4°C. Stock solutions were made fresh each week and were
diluted on the day by serial dilution in 0.1M perchloric acid.
5.2.4 Data analysis
All results were analysed using Microsoft excel and Instat2.03. Data are expressed as
absolute amount of monoamine per mg wet weight of tissue and comparison of data
was by ANOVA followed by multiple pair-wise comparison using Bonferroni
multiple comparison test for selected pairs of columns. Statistical significance was
identified as p< 0. 05.
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5.3 Results
5.3.1 5-HT and 5-HIAA concentrations in different brain regions of the mouse.
Results are expressed as pmol/mg wet weight of tissue and, where applicable, as a
percentage of the value in wild-type mice.
5.3.1.1 5-HT, 5-HIAA and 5-HIAA/5-HT concentrations
The midbrain and hypothalamus had the highest 5-HT concentrations (6 pmol/mg
wet weight tissue) in both wild-type and transgenic animals (Table 5.1). The
midbrain area in this dissection contains the raphe nuclei and so a high proportion of
serotonergic cell bodies is not unexpected. The 5-HT concentrations of the midbrain
also had the highest error values of all the parameters measured. This error was
probably due to differences in dissection and the possible loss of some of the raphe
area as well as individual variation between animals. The high levels of 5-HT in the
raphe area and hypothalamus are consistent with the published literature for both
mice and primates although absolute values vary between species and investigators
(Azmitia and Gannon, 1986). The order of 5-HT concentration in the other regions
(highest first) was basal ganglia > hippocampus > brainstem > frontal cortex. These
regions, as measured, all have a 5-HT concentration around 2-2.5 pmol/mg wet
weight tissue.
The midbrain and hypothalamus also have the highest levels of 5-HIAA in
proportion to their 5-HT concentrations. The ratio of 5-HIAA/5-HT in the
hippocampus of transgenic mice is significantly higher (p <0.01) compared to each
of the other measured regions except the cortex (ANOVA followed by Dunnets
pairwise comparison). There are no significant differences between any of the other
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5.3.2 5-HT and 5-HIAA concentrations in h5-HTT transgenic mice
Transgenic mice have reduced 5-HT concentrations in all brain areas compared to
wild-type animals (Table 5.1, Figure 5.1). The decrease was 14 - 40% of wild-type
values and was greatest in areas with the highest level of 5 -HT turnover:
hippocampus (40%) > cortex (33%) > brainstem (31%) >midbrain (21%) >
hypothalamus (17%) > basal ganglia (14%). The cerebellum of transgenic animals is
included as a control as it has low levels of 5-HT and 5-HTT expression, and no
measurable increase in 5-HTT expression (see Chapter 4). There is no significant
alteration in any parameter measured in the cerebellum.
There is a slight but non-significant increase in 5-HIAA levels in over-expressing
mice, 6-42% in most areas compared to wild-type mice. (Figure 5.2).
5.3.3 5-HIAA/5-HT ratio and 5-HT turnover in h5-HTT over-expressing mice
Transgenic mice show an increase in all brain regions (27-121%) in the ratio of
5-HIAA/5-HT compared to wild-type mice (Table 5.1, Figure 5.3). Again, this
increase was not significant in midbrain or cerebellum. The frontal cortex had the
highest increase (121%). The hippocampus, brainstem, midbrain and basal ganglia
all show changes of similar magnitude (40-50%). However, the increase (27%) in the
hypothalamus was considerably lower than that in other regions and not much higher
than that in the cerebellum. Increased 5-HTT expression consistently decreased total
5-HT levels and increased 5-HT turnover. The slight regional specificity of these
effects may be relevant in the behavioural analysis and receptor studies.
5.3.4 DOPAC and dopamine
There was no alteration in the levels ofDOPAC in mice over-expressing the 5-HTT.
In one experiment there was a change in the DOPAC levels in the basal ganglia in
the 5-HT assay. The dopamine levels were therefore analysed in basal ganglia
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[5-HT] in wlldtype and h5-HTT mice
8l
cortex midbrain brainstem basalganglia hippocampus hypothalamus
Brain region
Figure 5.1 Tissue concentrations of 5-HT in different brain regions of
wildtype and h5-HTT mice.
Data shown as mean± sem of 8 animals *=p<0.05 **=p<0.01 ***=p<0.001
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[5-HT] in wildtype and h5-HTT mice
8
cortex midbrain brainstem basalgangiia hippocampus hypothalamus
Brain region
Figure 5.1 Tissue concentrations of 5-HT in different brain regions
wildtype and h5-HTT mice.
Data shown as mean± sem of 8 animals *=p<0.05 **=p<0.01 ***=p<0.001
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[5-HIAA] In control and h5-HTT mice
cortex midbrain brainstem basalganglia hippocampus hypothalamus
brain region
Figure 5.2 Tissue concentrations of 5HIAA in different brain regions
wildtype and h5-HTT mice
Data shown as mean± sem of 8 animals *=p<0.05
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5HIAA/5HT in wildtype and h5-HTT mice
1.4.
midbrain brainstem basaiganglia hippocampus hypothalamus
Brain region
Figure 5.3 5-HT /5HIAA and 5-HT turnover in wild type and h5-HTT mice.
* p<0.05 ** p<0.01 ***p<0.001 n=8
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samples. However there were no significant alterations in DA or DOPAC
concentrations (Figure 5.4) or DOPAC/DA ratio and the original finding was not
repeatable. Thus, it would appear that the increase in 5-HTT and decrease in 5-HT
levels does not in turn alter dopamine metabolism, at least at the tissue level
measured here. It is possible that alterations do occur at the synaptic level, which are
not reflected in the tissue as a whole. Further investigations are needed before any
definitive statement can be made.
5.3.4 DOPAC and dopamine
There was no alteration in the levels of DOPAC in mice over-expressing the 5-HTT.
In one experiment there was a change in the DOPAC levels in the basal ganglia in
the 5-HT assay. The dopamine levels were therefore analysed in basal ganglia
samples. However there was no significant alterations in DA or DOPAC
concentrations (Figure 5.4) or DOPAC/DA ratio and the original finding was not
repeatable. Thus, it would appear that the increase in 5-HTT and decrease in 5-HT
levels does not in turn alter dopamine metabolism, at least at the tissue level
measured here. It is possible that alterations do occur at the synaptic level, which are
not reflected in the tissue as a whole. Further investigations are needed before any
definitive statement can be made.
5.4 Discussion
5.4.1 5-HT turnover and 5-HT concentrations
Transgenic mice contain the same levels of endogenous mouse 5-HTT as wild-type
animals, with an additional over-expression of the human 5-HTT at about two times
the level of the endogenous mouse form. Transgenic mice have reduced 5-HT
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[DOPAC] in wildtype and hS-HTT mice
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Figure 5.4 Tissue concentrations ofDOPAC in different brain regions of
wildtype and h5-HTT mice.
Data shown as mean± sem of 8 animals *=p<0.05 **=p<0.01 ***=p<0.001
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concentrations in all tissues measured and an increase in the concentration of the
metabolite 5-HIAA though these do not reach significance. The increase in 5-HIAA
is not as great as the reduction in 5-HT concentrations, implying that more 5-HT is
being metabolised but that stimulation of the metabolic pathway is not the only
factor involved in the decline in tissue 5-HT. For the 5-HT transmitter to enter the
metabolic pathway it must first be released from vesicular storage and be taken up by
the 5-HT transporter. The increased metabolic product and the increased 5-HIAA/
5-HT ratio, which is used as a measure of turnover, suggest that more 5-HT is being
released from the neurons of transgenic mice than would occur in wild-type animals.
Microdialysis studies of extracellular 5-HT concentrations are needed to confirm this
observation. The decrease in 5-HT brain concentrations in transgenic mice (14-40%
of the concentration in the corresponding area in wild-type mice) is significant in
most areas, but considerably less than the 70-90% decrease seen in 5-HTT knockout
mice (Bengel et al, 1998). In 5-HTT knockout mice the loss of re-uptake prevents
recycling of 5-HT and so tissue 5-HT is dependent upon the synthesis of new
transmitter. This mechanism can not cause the decrease in 5-HT in the animals over-
expressing h5-HTT.
A decline in tissue 5-HT concentration could be due to a change in any of three
general areas: increased metabolism; reduced storage; reduced synthesis; or to a
combination of these factors. These points will be considered below. The 5-HT
system is tightly controlled at the level of autoreceptors on both soma and terminal
regions as well as more directly by 5-HT within the neuron. It is therefore probable
that there are many changes which interact and can not be separated at this level of
analysis. An attempt is made to consider the possible explanations and to indicate the
areas most likely to be involved in these particular transgenic animals.
There are two possible states of the 5-HT system of transgenic mice: first, the status
of the neurons is the same as wild-type animals except for the increase in transporter
sites; second, over-expression of the transporter leads to adaptive changes in 5-HT
receptors and neuronal function during development. Possible explanations for how
increased 5-HTT leads to a decline in tissue 5-HT could be a direct effect of
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increased uptake coupled to autoreceptor activity, altered pattern of transporter
expression, adaptive changes in receptor-mediated control, and developmental
changes in synthesis.
If we assume that the 5-HT system is unchanged except for the increased 5-HTT
expression, then the slight increase in 5-HIAA concentrations and the increase in
5-HIAA/5-HT ratio indicates an increase in 5-HT turnover. This increased turnover
suggests that greater release balances the increase in available uptake sites and that
this extra release leads to a greater proportion of transmitter being broken down by
MAO. This effect on metabolism can be simply explained by the increase in 5-HTT
levels causing an increase in availability of uptake sites, thus increasing the rate of
uptake so that more 5-HT enters the neuron in the time immediately following
release. This chain of events will lead to greater intracellular 5-HT concentrations
and greater activation of, and availability of substrate for, the MAO pathway. It is
important to remember here that the over-expression of the 5-HTT has been present
throughout life. The parameter measured is therefore the final product of all the
adjustments in the system that have occurred to maintain 5-HT function at the
optimum level. For transmitter release, and consequently metabolism, to be increased
but synthesis reduced, an imbalance in the regulatory control must occur. Several
receptor subtypes have been shown to influence 5-HT synthesis and release; both the
somatic 5-HTia and terminal 5-HTib receptors act to reduce synthesis, firing and
release of 5-HT. The 5-HTia receptor is probably not tonically active, so reduced
extracellular 5-HT would not increase release via this receptor. The terminal 5-HTjb
receptor is tonically active and so altered 5-HT will affect release and synthesis via
this receptor. Increased 5-HT transporter could alter synthesis through three stages.
In wild-type mice 5-HT synthesis is under the control at the level of tryptophan
hydroxylase activity by 5-HTib, possibly 5-HTia and end product control by
intracellular 5-HT concentration (Hamon and Glowinski, 1974). When 5-HTT is
increased, uptake is enhanced, the extracellular 5-HT concentration ([5-HT])
decreases and intracellular [5-HT] increases faster in the time after release. This will
reduce the 5-HT)B tone compared to wild-type and decrease the inhibition of release
and synthesis. It may also reduce inhibition via 5-HTiA or increase 5-HTiA
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sensitivity by preventing down-regulation. Increased intracellular [5-HT] will act to
inhibit synthesis by reducing tryptophan hydroxylase activity, whilst metabolism of
5-HT via MAO to 5-HIAA is increased. The reduced inhibition leads to increase
release. The increased release compensates for the augmented uptake and [5-HT] is
maintained at nearer the wild-type level. The total amount of 5-HT transported into
the neuron also increases, further inhibiting TPH activity. This receptor model may
be all that is required to explain the altered 5-HT neurochemistry in these transgenic
animals. However, it is likely that 5-HTia will be more involved. Recent evidence
also indicates that 5-HTib receptors are found on the soma as well as terminal
regions and that 5-HT2 receptors found on 5-HT cell bodies in the raphe nucleus may
have opposite functional effects to 5-HTia receptors, causing hyperpolarization.
However, their physiological role and effectiveness has not yet been characterised. It
is possible that the two opposing receptor subtypes are activated at different [5-HT]
and as such the balance may be shifted in transgenic mice.
A further point to consider is that the protein expression detected by [JH]citalopram
binding in cortical and brainstem membranes shows a much greater proportional
increase in the cortex than brainstem. Transgenic mice may therefore have an
imbalance in 5-HT uptake in the terminal and cell bodies, leading to unequal
stimulation of different receptor subtypes. However, in the normal mouse, there are
almost certainly different excesses of transporter available in different areas of the
brain , because the increase in 5-HT concentration in the raphe nuclei and ventral
hippocampus reaches maximum at a lower dose of fluoxetine than that needed in the
frontal cortex (Malagie et al., 1995). Thus over-expression will increase this 5-HT
pool, but may not have an effect proportional to the increase. This may also help to
explain why a transgenic mouse with two to three times the endogenous transporter
does not show an equivalent two-thirds reduction in total tissue 5-HT. In summary,
more release will occur at normal activity levels in the neuron. A greater proportion
of this 5-HT than usual is broken down by MAO, as suggested by the increase in
5-HIAA concentrations, but the increased intracellular [5-HT] and lack of
autoreceptor stimulation prevents a compensatory increase in synthesis and so a
decline in total 5-HT concentrations in the tissue would occur.
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The only brain region where the change in 5-HIAA concentration is significant is the
frontal cortex. This may be due to differences in the increased expression in the
different regions or to the availability of monoamine oxidase to break down 5-HT or
to the availability of the enzymes and acid transport to further break down 5-HIAA
in different areas. The cortex, which has the lowest 5-HT and 5-HIAA levels in wild-
type animals, may have insufficient capability to remove extra 5-HIAA generated
which then builds up. It may also be due to the different proportions of 5-HT which
go to storage or breakdown in different areas possibly due to more expression or
differences in MRN or DRN neuronal expression and innervation. The DRN and
MRN have different autoreceptor reserves (Larsson et al., 1998; Malagie et al., 1996)
and SSRIs have region differences in activity (Le Poul et ah, 2000). The frontal
cortex receives serotonergic innervation almost solely through the dorsal raphe
cortical tract whilst other areas receive several serotonergic pathways.
The above explanation for the decline in tissue 5-HT concentrations assumed that
there were no changes in the expression of other parts of the 5-HT system due to the
presence of the transgene during development. It is not confirmed that the protein is
expressed at higher than normal levels during development though the increase in
adult brain would strongly suggest that it is. 5-HT is an important developmental
signal and 5-HTT expression is seen both in 5-HT neurons and in non-serotonergic
cells where the 5-HT that enters the cell is a trophic factor. Treatment of expectant
mothers with drugs that vary 5-HT levels leads to developmental malformations.
Knockout mice which have increased 5-HT levels during development, show 5-HT
uptake via DA and NA transporters (Cases et al., 1998) and have altered
development of the barrel field of the somatosensory cortex (Cases et al., 1996;
Vitalis et al., 1998). Most knockout mice where a part of the 5-HT system is affected
show adaptive changes, particularly in receptor function and expression. 5-HTia and
5-HTib receptor knockout mice have altered 5-HT and dopamine metabolism, (Ase
et al., 2000) and 5-HT]A receptor knockout mice have altered GABA(A) receptor
expression. 5-HTT knockout mice have reduced 5-HT concentrations (Bengel, 1998)
and altered 5-HTia expression and function (Fabre et al., 2000; la Cour et al., 2001;
129
Li et al., 1999a), 5-HTib expression (Fabre et al., 2000), and 5-HT2A expression
(Rioux et al., 1999) as well as altered adenosine receptor function (Mossner et al.,
2000). MAO-A knockout mice have altered adenosine receptor function (Mossner et
al., 2000). It is therefore probable that the 5-HTT over-expression will also cause
adaptive changes in receptor function during development. These changes will
probably be brain region-specific and may differentially affect 5-HT synthesis and
release. It is impossible to say at this stage what changes are to be expected.
An additional facet of increased 5-HTT expression which must be mentioned is the
possible change in transporter location on the neurons. Zhou et al. (2000) showed
that the 5-HTT is found on the cell body and on axons close to the terminal bud, but
probably not directly on the synaptic bud itself. Increasing 5-HTT expression may
have any of four effects on positioning. Firstly, the transporters may be in the same
position but very close together (a 2-3 fold increase is not extreme); this may reduce
the expected effect of the increase on 5-HT levels as each receptor may inhibit the
removal of 5-HT by the others. Secondly, the transporters may extend further
towards the synaptic cleft, increasing the likelihood of transport and faster removal
of 5-HT, thus limiting the area of diffusion and activity. Thirdly, the transporters
may extend further from the site of release, removing more of the 5-HT which
diffuses from the release site, limiting the area stimulated and possibly subtypes of
receptor, and thus altering the regulation. Fourthly, the transporters may be located a
long way from the cleft or additionally on non-neuronal cell types such as glia, thus
increasing the amount of 5-HT lost from the neuron and possibly the state of the glia
cells. These possibilities would provide opportunities for further study.
This model would imply greater synaptic release but the same duration of action and
a reduction in total neuronal 5-HT level. Under these conditions, the autoreceptors
would not be greatly altered, but it is possible that increased release would increase
the concentration in the synaptic cleft at the onset of the stimulus, thus increasing the
intensity of postsynaptic receptor stimulation. This stimulation, in turn, would lead to
greater desensitisation/down-regulation postsynaptically and so reduce either the
normal response or, depending upon the number of spare receptors in each area, the
130
response to an increase in prolonged 5-HT activity, such as may occur in response to
external stimuli.
Another factor mentioned above is that the position of the increased protein
expression may be important. If the increased 5-HTT expression has a greater
proportional effect at the cell body level in the raphe, then the sensitivity of the
autoreceptor may be altered. In rats there is now considerable evidence that the raphe
nuclei contain a pool of extracellular 5-HT and that the somatic autoreceptors are not
normally activated by baseline release but only by excessive stimulation (Adell and
Artigas, 1998). Thus the removal of 5-HT by excess transporter may reduce the
concentration of the extracellular pool and so increase the sensitivity of the 5-HTiA
receptors
5.4.2 5-HTT expression and depression
Some recent evidence suggests that SSRIs are more effective in depressed adult-
onset patients with a double copy of the longer 5-HTT promoter allele, which has
been linked to higher 5-HTT protein expression. Also recent work by Dahlstrom et
al. (2000) has found that in drug-nai've adolescents and children with depression
there is an increase in 5-HTT in the hypothalamic/midbrain area. Chronic SSRI
treatments, which cover the delayed period of onset of therapeutic activity, have been
shown to reduce transporter levels and although there is some confusion as to the
mechanism, it appears that mRNA decreases (Lesch et ah, 1993) so regulation of
transcription is likely. This regulation may be mediated by receptor activation or
intracellular mechanisms. These factors suggest that increased 5-HTT expression
may be a factor in depressive illness.
The results of neurochemical analysis in 5-HTT over-expressing mice suggests that
one of the ways by which higher expression of 5-HTT may pre-dispose to affective
disorders is by causing a decrease in total 5-HT concentrations. This decrease could
occur in three possible ways. Firstly, the decrease in 5-HT may not be the direct
cause of the disorder but lead to a predisposition due to changes in the feedback of
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the 5-HT system, making an external trigger factor more likely to initiate a clinical
manifestation. Secondly, it is also a possible that lower 5-HT concentrations
diminish available 5-HT for release upon prolonged neural stimulation. A third
option may be that compensatory increases in 5-HT release inhibit or alter
postsynaptic functions. A study of the receptor sensitisation and levels both post- and
presynaptically, as well as microdialysis studies of 5-HT release would help clarify
these questions.
If depression can result from increased expression of the 5-HTT, the therapeutic
effects of SSRIs would not be due to the acute effect of augmented extracellular
5-HT but to another area of the 5-HT system which has been affected by the increase
in 5-HTT. This explanation would be consistent with the delay of onset for the
therapeutic actions of SSRIs and with the apparent, though not consistent, effects of
5-HTia receptor antagonists on therapeutic activity of antidepressants (Blier and
Bergeron, 1998; Blier et al., 1998; Dawson et al., 2000). Whilst much more work is
needed to clarify this model, it is possible that these mice will provide a suitable
animal model for studies of depression in humans.
In summary, over-expression of 5-HTT decreases tissue 5-HT concentrations
throughout the brain. There is a slight increase in 5-HIAA concentration and 5-HT
metabolism, but the reduction in 5-HT concentration is probably mainly due to an
inhibition of 5-HT synthesis, probably mediated via compensatory increases in 5-HT
release and autoreceptor activity. It is possible that these mice may provide a better




Behavioural analysis of the response of transgenic
mice to MDMA
6.1 Introduction
The serotonin system has been linked to many behavioural and developmental
functions, including sleep (Hilakivi, 1987; Monti and Monti, 2000), circadian
rhythms (Morin, 1999), sexual function (Rampin and Giuliano, 2000; Uphouse,
2000), appetite (Leibowitz and Alexander, 1998; Meguid et al., 2000), addiction
(Koob, 2000), and locomotor function (Schmidt and Jordan, 2000), as well as
memory impairment (Buhot et al., 2000) and psychiatric diseases (Delgado, 2000).
It was therefore expected that mice over-expressing the h5-HTT, with disturbed
5-HT neurochemistry, would have an altered behavioural phenotype. This
disturbance might be robust, similar to 'the serotonin syndrome', or a less overt
propensity to respond to anxiogenic or pharmacological stimuli.
6.1.1 Behavioural studies in transgenic mice
Transgenic mice provide an excellent model for studying the effects of single genes
on behaviour, but there are several considerations that must be remembered when
planning and analysing these experiments. The genetic modifications in transgenic
animals are present throughout life (long-term), so there is always the probability
that compensatory modifications occur. Such a compensation has been seen in
5-HTT knockout mice, where homozygous knockout mice develop normally despite
the important role of 5-HT as a developmental signal (Lauder, 1990; Lauder et al.,
2000; Lauder et al., 1983).
In addition, transgenic animals used in these experiments are the product of many
generations of breeding. As caging and food supply can also change behaviours, all
the animals used were from cages with more than one animal, in case solitary
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housing has any affect on 5-HT function. A preliminary screen (Irwin, 1968),
carried out to check for any major behavioural abnormality, detected no obvious
change in phenotype in 5-HTT transgenic mice. In 5-HTT knockout animals, which
have been studied as a model of disturbed 5-HT function, no obvious changes in
behavioural phenotype have been reported, although the locomotor effect ofMDMA
was lost (Bengel, 1998). Therefore, the effect of MDMA on temperature and
locomotor activity was studied in the transgenic animals as a comparison with the
knockout mice and to probe the effects of 5-HTT over-expression on the 5-HT
system.
6.1.2 5-HT and thermoregulation in mice
The hypothalamus is the major centre for temperature regulation in the majority of
mammals studied (Arancibia et al., 1996; Bligh and Hensel, 1974; Feldberg, 1969;
Van Tienhoven et al., 1979). 5-HT is a major putative transmitter system in
temperature regulation as intra-cerebroventricular injections of 5-HT cause
hypothermia in some models (de Roij et al., 1979; Yamada et al., 1988; Yamada et
al., 1987) and 5-HT concentrations vary with body temperature during heating and
cooling in primates (Myers and Beleslin, 1971; Myers and Waller, 1975) and rats
(Lin, 1978). There is conflicting evidence for the roles of DA, NA, acetylcholine
(ACh) and 5-HT in thermoregulation, with different investigators and methods
producing apparently contradictory results. For instance, intracranial injections of
5-HT have produced both a rise and fall in core body temperature (Cox et al., 1980;
Crawshaw, 1972; Lin et al., 1981). Sheard and Aghajanian (Sheard and Aghajanian,
1967) found that intra-hypothalamic injections of 5-HT or electrical stimulation of
the dorsal raphe increased colonic temperature in the rat, whilst Lin et al. (1983)
found that electrical stimulation of the dorsal raphe or intra-hypothalamic injections
lowered colonic temperature. However, a wide range of doses and methods were
used in these studies. A high dose of 5-HT can cause a sharp fall in temperature (de
Roij et al., 1979), perhaps because of activation of presynaptic 5-HT]A receptors
which leads to a decrease in neuronal firing. 5-HTiA receptor stimulation by 8-OH-
DPAT has long been known to cause hypothermia and it is often used as a measure
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of 5-HTia activity (Goodwin et al., 1985; Hjorth, 1985). In addition to saturating
5-HT receptor sites, high doses of 5-HT can also interact with the catecholamine
receptors that mediate the peripheral heat loss pathway (Ruwe and Myers, 1982).
More recent evidence from microdialysis experiments (Lin et al., 1998) using
different pharmacological tools to increase or decrease 5-HT in the hypothalamus
found that drugs which increased extracellular 5-HT (fluoxetine, 5-HTTP, and
potassium) caused hyperthermia (measured as core body temperature) and increased
metabolic rate. Drugs that reduced 5-HT levels, such as the 5-HT]A agonist 8-OH-
DPAT, caused hypothermia. This hypothermia, induced by reduced 5-HT in the
extracellular compartment, was brought about by a decrease in the metabolic rate and
an increase in skin temperature. The alteration in 5-HT level was parallel to, but in
advance of, the change in temperature. DOI, a 5-HT2a/c receptor agonist, also
induced hyperthermia. The hyperthermic effect of DOI is mediated via 5-HT2A
stimulation (Salmi and Ahlenius, 1998) and is enhanced by 5-HTia antagonists,
suggesting a functional interaction between the two receptors and the possible
involvement of the 5-HTiA receptor under normal conditions. In general, 5-HTia
receptor stimulation causes hypothermia and 5-HT2A receptor stimulation causes
hyperthermia (Gudelsky et al., 1986; Nash et al., 1989).
Changes in body temperature induced by changes in the 5-HT system can therefore
be mediated via altered central 5-HT receptor balance, as a result of either increased
5-HT release activating different receptor subtypes or changes in receptor
expression. In addition to its central actions, 5-HT can cause hypothermia via
stimulation of peripheral 5-HT2 receptors (Sugimoto et al., 1991). The hypothermia
was prevented by ketanserin, a 5-HT2 antagonist with greatest selectivity for 5-HT2A
receptors, and so is probably acting via 5-HT2A receptors in the vasculature, possibly
to increase heat loss.
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6.1.3 5-HT and dopamine interactions in thermoregulation in mice
The dopamine (DA) system has also been implicated in temperature changes in mice
and rats (Cox et al., 1980; Yamada et al., 1988). The hypothermia induced by
stimulation of 5-HTja receptors is inhibited by dopamine receptor antagonists
(Yamada et al., 1988), suggesting that dopaminergic systems are involved in 5-HT-
induced hypothermia in mice. Dopamine D1 and D2 receptors mediate different
effects on temperature in mice; D1 receptors mediate hyperthermic and D2 receptors
hypothermic responses (Costentin et al., 1990; Salmi, 1998; Salmi et al., 1993;
Sanchez, 1989; Zarrindast and Tabatabai, 1992). Dopamine D2/D3 receptor agonists
induce hypothermia in mice (Salmi, 1998). This effect that almost certainly occurs
via D2 receptor stimulation as D2 receptor knockout mice do not show either the
hypothermic or hypo-locomotor effects seen in wild-type animals (Boulay et al.,
1999a), whilst D3 knockout animals have similar responses as wild-type mice
(Boulay et al., 1999b). D2 antagonists such as halperidol prevent the hypothermia
induced by non-selective dopamine agonists, whilst D1 receptor antagonists do not.
The loss of both locomotor and temperature effects of MDMA in knockout mice
implies that the same neurotransmitter system may be involved in both and that the
hypothermia may be in part because of reduced locomotor activity. D1 receptor
stimulation reduces the hypothermia caused by dopamine released by reserpine, and
D1 agonists induce hyperthermia (Nunes et al., 1991; Vasse et al., 1990; Zarrindast
and Tabatabai, 1992). The hyperthermic effect is masked when D2 receptors are
also stimulated (Costentin et al., 1990). The hypothermia induced by MDMA may
therefore be partly mediated via changes in dopamine receptor activation or balance
of the receptor subtypes as well as direct effects on dopamine release induced by
5-HT receptor activation.
5-HT2a, 5-HT2B, 5-HTia and 5-HT)B receptors have been implicated in the control of
dopamine neurons in vivo. Both 5-HT2a and 5-HT2b receptors tonically inhibit
dopamine release in rats (Di Matteo et al., 1998; Millan et al., 1998). 5-HTib
receptors mediate the locomotor effects ofMDMA, probably via activation of DA
neurons. 5-HTib knockout mice have attenuated locomotor response to MDMA
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(Scearce-Levie et al., 1999) and decreased DA levels resulting from increased DA
turnover (Ase et al., 2000). 5-HTiA receptor knockout mice have augmented 5-HT
release and turnover and show reduced inhibition of DA neurons (Ase et al., 2000).
Any changes in 5-HT receptor expression resulting from adaptive changes in
transgenic mice may therefore affect both locomotor and temperature effects via the
dopaminergic system.
6.1.4 Role ofother transmitter systems and ofcorticosterone in thermoregulation
Noradrenaline has also been implicated in hypothermic responses in mice (Leroux-
Nicollet et al., 1988) and primates (Myers and Waller, 1975). The primate study also
found that the 5-HT-induced hyperthermia was concurrent with an increase in ACh,
suggesting that 5-HT activates a cholinergic pathway which transmits efferent
signals for heat production. Recent evidence that MDMA alters ACh release via
histamine receptors (Fischer et al., 2000) may therefore be a factor in the response to
MDMA in transgenic mice.
Corticosterone reduces the hypothermia induced by 8-OH-DPAT stimulation of
5-HTia receptors, probably via direct attenuation of 5-HTia function (McAllister-
Williams et al., 2001). This is probably of less importance than the major transmitter
systems, 5-HT and dopamine, is mentioned for the sake of completeness.
6.1.5 Responses ofmice to MDMA exposure
MDMA in mice causes an acute release of 5-HT and DA from nerve terminals. This
release of 5-HT has both carrier-mediated (imiprimine-sensitive) (Gu and Azmitia,
1993; Gudelsky and Nash, 1996) and Ca2+-dependent components (Crespi et al.,
1997). Fluoxetine abolishes 5-HT release and attenuates DA release. MDMA
causes an increase in locomotor activity, decreases exploratory behaviour and
disrupts startle response. In 5-HTT knockout mice, the increase in locomotor
activity evoked by MDMA is abolished, and a brief paradoxical reduction in activity
occurs after MDMA administration. These mice have a pronounced reduction in
5-HT levels throughout the brain (see Introduction) that may cause this change in
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response. However, the heterozygous mice have similar 5-HT levels to wild-type
animals, but show a 50% reduction in locomotor activity that correlates with the
level of transporter expression (Bengel, 1998). 5-HTib knockout mice also have
abolished locomotor response to MDMA (Scearce-Levie et al., 1999), probably as a
result of lack of stimulation ofDA release in the striatum.
In addition to MDMA's locomotor effects, considerable evidence indicates that
MDMA alters core body temperature in rodents, though few studies have detailed
these effects in mice. Treatment regimes where multiple doses ofMDMA are given
to mice cause both hypothermia and hyperthermia, depending upon dose and time
after injection. Multiple doses (4 repeated doses of 20 mg.kg"1 at 2 hourly intervals)
caused a short-term hyperthermia in mice (Miller, 1994; O'Callaghan, 1994), which
returned to baseline after the last dose. The same dose (20 mg.kg"1) given 3 times at
3 hourly intervals caused a brief hypothermia after the first dose, followed by
hyperthermia after the second dose which was maintained for several hours (until
recording stopped) (O'Shea, 2001). At a higher dosing regime (3 doses of 30 mg.kg"1
at 3 hourly intervals), a short-term hyperthermia occurred after the first dose,
followed by hypothermia an hour after the last dose. A lower dose (10 mg.kg"1)
caused only hypothermia for the first 2.5 hours and no further change (O'Shea,
2001). This study suggests a biphasic, dose-dependent effect of MDMA on body
temperature. Although effects of MDMA in these studies were described as
prolonged and long-term, there were no studies of 24-hour temperature
measurements in mice after single doses ofMDMA. With multi-dose regimes it is
difficult to ascertain the concentration of MDMA in the plasma or at the site of
action or to control the secondary effects of reduced 5-HT availability. At low doses,
5-HT release may be sub-maximal (such that only a proportion of 5-HT stores is
released). A second dose at the lower concentration then has a greater effect than
repeated dosing at a higher dose where 5-HT stores may be depleted more quickly.
The one study that used radio-telemetric methods to monitor body temperature over a
long period (Dafters R.I, 1998) found that 4 single daily doses ofMDMA given to
rats on consecutive days produced a thermogenic response that depended on ambient
temperature and caused long-lasting alterations in thermoregulatory mechanisms.
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MDMA use in humans is known to produce hyperthermia that, combined with
dehydration, is often considered to be one of the possible causes of ecstasy-related
deaths (Burgess et ah, 2000; Dar and McBrien, 1996; Mallick and Bodenham, 1997).
Considerable evidence from studies on rats suggests that preventing MDMA-induced
hyperthermia by restraint or pharmacological means reduces 5-HT neuronal toxicity
(Broening et ah, 1995; Colado et ah, 1998; Colado et ah, 1993; Malberg et ah, 1996;
Sabol and Seiden, 1998). Several studies, however, suggest that there is another
pharmacological, but non-temperature-sensitive component (Colado et ah, 1998;
Malberg et ah, 1996). In mice there is no 5-HT nerve toxicity at low doses of
MDMA though there is striatal DA neuronal toxicity (Logan, 1988; Stone, 1987).
There is some evidence that reducing body temperature, either by pharmacological
means (MK-801 or ethanol) or restraint, prevents DA toxicity (Miller, 1994).
However, another study found that pretreatment with fluoxetine to prevent the
MDMA-induced temperature changes did not prevent toxicity, whilst the dopamine
reuptake inhibitor GBR 12909 was neuroprotective but did not prevent temperature
change (O'Shea, 2001). MDMA causes long-term neurotoxicity to the 5-HT system
in humans and primates (see introduction).
The aim of the studies described in this chapter was to provide a preliminary
characterisation of the possible effects of increased 5-HTT expression on the
behavioural phenotype of transgenic mice and their behavioural responses to
pharmacological challenge. MDMA was used to probe the 5-HTT system's activity
in the transgenic mice in order to determine whether increased 5-HTT levels,
accompanied by moderately reduced 5-HT levels, alter locomotor behaviour. The
effects of increasing doses of MDMA on core temperature in the mouse were also
investigated. A dosage regime was chosen to include the range of doses used in the
literature to induce maximal locomotor activity in mice (Bengel, 1998; Scearce-
Levie, 1999) as well as a lower range in case the over-expression of the 5-HTT sites
increased sensitivity to MDMA. The use of radio-telemetry implants rather than
rectal temperature probes allowed the 24-hour monitoring of both locomotor activity
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and temperature. The neurotoxicity of MDMA in mice is dose- and frequency-
dependent (O'Shea et al., 1998).
We predicted that over-expression of the human 5-HTT in the transgenic mice might
lead to 5-HT nerve terminal loss and long-term 5-HT disturbance. This possibility
was considered as it is known that 5-HT and 5-HIAA levels return to baseline after
24 hours in wild-type mice (Logan, 1988) and so disturbance after this washout
period would indicate a neurotoxic action. Mice were left for 72 hours after the last
dose ofMDMA before tissue samples were taken for HPLC analysis. Because the
number of animals tested was small, only preliminary telemetry data are presented.
6.2 Methods
6.2.1 Irwin Screen
The Irwin screen is a comprehensive assessment of the behavioural, neurological,
and autonomic state ofmice, allowing one to distinguish the effects of psycho-active,
neurologic and autonomic drugs between different strains of mice, and the different
effects of drugs in the same class (Irwin, 1968). This screen was used as a basic test
of the phenotype of transgenic mice. This screening process is most sensitive at
detecting behavioural changes induced by pharmacological challenges. However, it
can also measure behaviour related to arousal and anxiety and has been used to
detect differences between strains of mice. It is in some senses a very crude system,
but covers a broad range of behaviours and should pick up any major behavioural
differences between transgenic and wild-type mice.
The complete method has been previously described (Irwin, 1968). Briefly, six to
eight second-generation transgenic +/- males from lines A102.3 and A145.1 (one line
using each YAC construct and both with high expression of 5-HTT RNA) were
compared to non-transgenic littermates and, where littermates were not available, to
second-generation wild-type mice to provide a similar background. Tests were done
in a separate room from the home room by a trained observer who was blind to the
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genetic status and line of the animals tested. Mice were tested with a series of simple
behavioural paradigms to measure: spontaneous activity, motor-affective response,
sensori-motor response, posture, muscle tone, equilibrium and gait, CNS excitation,
appearance of eyes, secretion and excretion, and general behaviour. The order in
which tests were carried out minimised the handling stress and the more provocative
tests were done last.
It had been observed during routine handling that transgenic mice had a tendency to
be smaller and more resistant to handling. We considered the possibility that mice
over-expressing the 5-HTT would have altered 5-HT receptor expression that might
lead to increased anxiety or aggression. In this case a change in the motor-affective
responses or startle response would be expected. These responses cover general
state, responses to new environments, stimuli, and aggressive challenge. For
example, vocalization and urination-defecation are responses which give information
on general state; transfer arousal and alley progression give information on response
to new environment; and provoked biting and grasp-irritability on aggressive
impulses.
Analysis was by ANOVA followed by Dunnett post-test's analysis of each
transgenic line to the wild-type where such tests were possible (see results).
6.2.2 Telemetry apparatus
The freely moving telemetry system (Data Sciences International) uses a transmitter
and monitor pill inserted into the peritoneal cavity. The monitor sends a signal to a
receiver attached to a data analysis system (Data Quest) that stores the data. The
monitor used here measured body temperature and horizontal locomotion.
Telemetry provided a convenient way to measure activity and temperature without
the need for restraint to insert rectal temperature probes. The monitors also measure
horizontal rather than running-wheel activity, which is important as MDMA-induced
locomotor activity tends towards an increasing straight line pattern of locomotion
(Gold et ah, 1988), accompanied by reduced exploratory behaviour and low pattern
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variability. Telemetry monitoring also allows 24-hour continuous measurement,
which is important in the long-term measurement of temperature, and which provides
a measure of circadian variations as it covers both the light and dark periods.
6.2.3 Dosing regime
Transgenic heterozygous males, 4-6 months old, were compared to their non-
transgenic littermates. Animals were treated with MDMA or saline, in groups of
eight, consisting of a random mixture of wild-type and transgenic animals. To
measure body temperature and horizontal locomotor activity, telemetry pills
(PhysioTel Implants, Data Sciences International) were surgically implanted into the
peritoneal cavity under general anaesthesia and the animals allowed to recover for 3-
4 days before being placed in the experimental homecage. Mice were individually
housed in polycarbonate cages (Eurostandard Type 2L, 365 x 207 x 140 mm), each
equipped with a running wheel (240 x 80 mm from Techniplast UK Ltd, UK).
Ambient temperature was maintained at 22°C. Deep litter bedding (40 mm depth)
was provided in each cage; food and water were available ad libitum. Running-
wheel activity was monitored by means of reed relays, magnetically sensitive
switches, activated by four miniature magnets positioned 90° apart on each wheel.
One count was equivalent to 189 mm traveled horizontally. The detectors were
monitored continuously by Dataquest ART system (DSI, MN, USA) that collated
activity counts into ten-minute time bins across the duration of the experiment.
Animals were allowed to acclimatise to the experimental environment for 1 week (12
hr.-12 hr. light/dark cycle, 7.00am/7.00pm). A total of 7-8 age-matched animals for
each genetic background were treated either with saline or MDMA (one animal died
after implantation of the monitor pill).
Animals were allowed to adjust to the homecage for 24 hours for baseline recording.
On the second day the animals were injected with MDMA or saline at hour 4 of the
circadian cycle (1 lam). MDMA was dissolved in 0.9% saline and doses were given
subcutaneously in a ramped regime: on day two, lmg.kg"1; day three, 3mg.kg_1; day
four, lOmg.kg"1; and day five, 30mg.kg"'. Monitoring was maintained throughout.
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Animals were then monitored for another 72 hours before culling. This range of
doses was chosen to cover the doses in the literature which gave maximal locomotor
effects in different strains of mice (Bengel, 1998; Scearce-Levie, 1999) and to see
whether transgenic animals responded at lower doses. As mentioned in the
introduction , compared to humans and rats , mice are resistant to the toxic effects of
chronic MDMA treatments. The presence of the human transporter in the transgenic
mice may increase their susceptibility to the toxic effects of high doses ofMDMA.
The mice were culled 72 hours after the last dose and it was not possible to measure
any parameters of neuronal cell death. This must be kept in mind we analyzing the
results from the later doses. However it is possible that the resistance to MDMA is
due to another variable in the mouse neuron and is not related to the 5-HTT. The
short time between doses and the lack of any residual effects of the MDMA at 72 hrs
post treatment suggests that neuronal toxicity is probably minimal under this regime.
Statistical analysis was by two-way ANOVA or least squares, followed by Student-
Newman-Keuls test.
6.3 Results
The data presented are a preliminary analyses of temperature and horizontal activity.
Statistical analysis with thanks to Dr Hugh Marston, FINE, Edinburgh.
6.3.1 Irwin screen
The results of behavioural observations, grouped according to the key factors they
provide information about, are shown in Table 6.3.1. As the screening process
covers many variables which can be seen in different mouse lines, some variables,
such as eye colour, were not appropriate for this line of mice and are therefore not
listed in the results.
This form of analysis was used as a preliminary screen to catch any gross phenotype
and to suggest areas for further study. As many of the variables are scored on an
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Wild-type 102.3 145.1
Spontaneous activity locomotor activity 3.7 3.5 4.1
bizarre behaviour 0 0 0
Motor- affective response alley progression 37 63.5 48
transfer arousal 4 4 4
touch-escape 5.3 7 4.9
posit, struggle 3.3 4.25 1.38
grasp-irritability 3.2 3.38 1.25
provoked biting 1.3 4.29 3.75
provoked freezing 0.2 0 0
finger withdrawal 0.2 0.25 1.4
finger approach 1.3 1.4 1.4
posit.passivity 0.2 0.25 0.13
vocalization 2.33 3.13 3.38
urination-defecation 0.5 0.63 0.38
Sensoro-motor response visual placing 7 6 4.5
tail-pinch 3.3 4.9 4
toepinch 6 5.9 5.6
corneal 4.7 4.25 4
pinna 5.8 6.5 5.1
startle 3.8 3.8 2.8
Posture pelvic elevation 4 4 4
tail elevation 1.8 2.25 2
limb rotation 0 0 0
Muscle tone body tone 5.2 5.3 5
abdominal tone 4.7 6.1 4.6
limb tone 3.8 4.1 3.5
grip strength 5 4.9 5.8
wire manoeuvre 1.5 1.5 0
Equilibrium and gate righting reflex 0 0 0
ataxic gate 0 0 0
hypotonic gate 0 0 0
gate other _ _
total incapacity 0 0 0
Secret. & excret. salivation 0 0 0
lacrimation 0 0 0
diarrhoea 0 0 0
General hypothermia 0 0 0
piloerection 0 0 0
skin colour
_
respiratory rate 3.7 3.75 4
Table 6.3.1 Results of Irwin screen in transgenic and wild-type mice. Results are
expressed as the mean of 6-8 animals .102.3 & 145.1= transgenic line A102.3 and
A145.1
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arbitrary, non-continuous scale, it provides a largely quantitative rather than
qualitative analysis. It is also a characteristic of this sort of analysis that some of the
measurements, such as alley progression, have high potential for inconsistent results.
Results are therefore best analysed by comparing all measured behaviours which
would be consistent with a particular system or area being affected by the transgene.
Neither line of transgenic mice had an overt behavioural phenotype when compared
to wild-type animals. Nor was there a difference when both transgenic lines were
combined. These measurements were all taken during the light period of the diurnal
cycle and do not cover the onset or intensity of normal locomotor activity during the
dark period.
6.3.2 Baseline activity and temperature in transgenic and wild-type mice
Transgenic mice from line A102.3 were compared to wild-type animals. Line A145.1
was excluded because of space limits. The telemetry apparatus was used to measure
both temperature and locomotor activity throughout the 24-hour period. Baseline
conditions were measured on day one in the absence of handling or injection. Data
were sampled automatically with one measurement taken every 10 minutes. This
frequency provided too much data to be easily analysed, therefore the measurements
were pooled first as 30-minute then as 2-hour periods after injection. This time
frame fitted the response profile.
Figures 6.2 and 6.3 show baseline measurements for wild-type and transgenic mice.
There are two groups of each, which were later treated either with saline or MDMA,
but here are drug-naive. Wild-type and transgenic mice do not have significantly
different body temperatures under baseline conditions (p<0.05). Transgenic animals
show similar activity to wild-type animals during the light period but are less active
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6.3.3 Effect ofMDMA on temperature in wild-type and transgenic mice
Data were pooled before graphing as follows. First the results, which were absolute
values without subtracting baseline (recorded on day one), were pooled into groups
of recordings from each 30-minute period. The next stage of analysis was to
calculate the mean ofmeasurements for each animal during the 30-minute or 2-hour
window. Finally, the mean of all animals in each group was calculated for each time
period. This is the result shown on the graphs.
At the two lowest doses ofMDMA there was no significant alteration in the body
temperature of transgenic mice or wild-type mice. Statistical analysis of temperature
differences was by two-way ANOVA of the minimum temperature attained in the
two hours following MDMA administration at the two highest doses (10 mg.kg"1 and
30 mg.kg"1) which confirmed that there were significant factors of genotype
(p=0.004) and drug treatment (p=0.039) on temperature and an interaction between
the two factors (p=0.013). This analysis was followed by a Student-Newman-Keuls




Table 6.3.2 Minimum core body temperature (°C) attained by transgenic and wild-type mice in the
two hours after injection with MDMA (pooled 10 and 30 mg.kg"1 n=8). *Significantly different from
MDMA-treated wild-type, p<0.001; fSignificantly different from saline, p<0.001
There were no significant differences in body temperature between untreated wild-
type and untreated transgenic animals (Table 6.3.2). MDMA treatment did not
significantly alter the core body temperature of wild-type mice. Transgenic mice
showed a significant decrease in body temperature in response to MDMA (p<0.001)
compared to saline-treated controls. The response to MDMA was significantly
different (p<0.001) between wild-type and transgenic mice. Thus MDMA lowered
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the temperature of transgenic mice compared to the wild-type and non-treated
transgenic mice.
The shape of the thermoregulatory response is shown in Figure 6.4. In both wild-
type and transgenic animals MDMA treatment (10 mg.kg"1) led to a slight (non¬
significant) hyperthermic response of 1-2°C following a brief hypothermia in the first
hour after injection. This transient hyperthermia was probably because of increased
locomotor activity and was followed only in the transgenic mice by prolonged and
increasing hypothermia, which started 4 hours after injection and reached up to -5°C
6.5 hours after injection. The temperature then slowly increased and returned to
baseline by 16 hours post-injection.
At a dose of 30 mg.kg"1 in wild-type and transgenic mice (excluding one mouse with
a prolonged hypothermia), MDMA evoked a slight hypothermic response for the first
hour after injection, which was quickly reversed (Figure 6.5). A slight hyperthermic
response of + 2°C occurred, which peaked at 4.5 hours and was maintained until 7
hours after injection and the onset of activity during the dark period. The data
include one transgenic animal that did not show a hypothermic response at 10 mg.kg"
1
, but did respond at 30 mg.kg"1. In animals which responded at the high dose the
hypothermic response was similar, in onset and duration, to that seen at the lower
dose (10 mg.kg"1). Data were pooled before graphing, as described for the
temperature measurements above.
6.3.4 Effect ofMDMA on locomotor activity in wild-type and transgenic mice
Both transgenic and wild-type mice start exhibiting locomotor responses to MDMA
at 10 mg.kg"1 (p<0.05). The duration of the locomotor effects over a 24-hour period
are shown in Figures 6.6 and 6.7. In wild-type and transgenic animals, MDMA at 10
mg.kg"1 led to an increase in horizontal activity after injection, which declined after
the first 4 hours but remained slightly greater than baseline. This decline lasted until
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Figure 6.6 Effect of a single dose of lOmg.kg"1 MDMA on core body temperature
and horizontal activity in transgenic and wildtype mice.
Data is expressed as pooled data for each two hour period after injection and the
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the onset of circadian night, when activity returned to normal. The MDMA-induced
increase was greater in transgenic than wild-type mice.
Immediately following injection of the higher dose of MDMA (30 mg.kg"1), wild-
type animals exhibited an increase in locomotor activity that lasted for 6 hours
(Figure 6.8). There was a similar response of the same duration in transgenic
animals, but unlike the response to the lower dose ofMDMA, the response was less
pronounced in transgenic animals than in wild-type animals (Figures 6.8 and 6.9).
The locomotor response peaks during the first three hours after injection. Two-way
ANOVA was therefore used to compare the cumulative activity over the three hours
following MDMA administration on all five treatment days; group, treatment and the
interaction were all significant factors (p< 0.001). Figure 6.10 shows the locomotor
response to MDMA across the five treatment days. The dose-response curve for
MDMA in transgenic animals shows a shift to the left, with the peak locomotor
response to MDMA occurring at 10 mg.kg"1 in transgenic animals, but at 30 mg.kg"1
in wild-type animals. Least square means followed by Student-Newman-Keuls
comparison showed that drug-naive transgenic animals were no less active than wild-
type animals and that MDMA increased the activity in both groups (p<0.05). The
locomotor response to MDMA at 10 mg.kg"1 was significantly increased compared to
saline-treated controls for both transgenic mice (p<0.001) and wild-type mice
(p=0.003). At this dose there is no significant difference in the effect of MDMA
between the two genotypes. At 30 mg.kg"1 both wild-type (p=0.001) and transgenic
(p=0.026) mice show significant increases in locomotor activity compared to saline-
treated controls. There is also a significant difference (p=0.04) between transgenic
and wild-type mice in the response to MDMA.
One further consideration in differences between the transgenic and wildtype mice at
high doses ofMDMA is the possibility of increased neurotoxicity in transgenic mice
due to the presence of the human transporter. No neurodegenerative markers could
be analysed in these experiments , however it is possible that loss of available 5-FIT
neurons after 10 mg.kg"1 MDMA might inhibit or alter the apparent behavioural
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Figure 6.9 Affect of a single dose of 30mg.kg-l MDMA on core body temperature
and horizontal activity in transgenic and wildtype mice.
Data is expressed as pooled data for each two hour period after injection and the
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Figure 6.10 Mean locomotor activity in the 2hr period after injection of MDMA in
wild-type and transgenic mice.
Treatment was by a singie i.p. injection of MDMA or saline once daily. Increasing
doses were given on subsequent days. Control = drug naive mice
*
= wild-type -saline * = wild-type MDMA transgenic saline
transgenic MDMA
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effects of the higher dose. Further analysis by HPLC or immunocytochemical
analysis of the 5-HT pathways of transgenic mice after a single dose would further
clarity this argument. However the quick return to baseline behaviour for transgenic
mice after 72 hrs washout suggets that any degeneration iss minor.
6.3.5 Other behavioural observations during the experiment
Mice were weighed before the experiment and during the week of the injections in
order to accurately dose the animals and to monitor their welfare. The mice were
age-matched and compared to their littermates. Transgenic mice were consistently
and significantly lighter than their non-transgenic littermates (wild-type = 31.2 ± 1.1
grams, transgenic = 26.9 ± 0.48 grams, p<0.01). Mice were observed at intervals
during the hypothermic response to check on their welfare.
6.4 Discussion
The temperature results can be interpreted by assuming a biphasic effect ofMDMA
on body temperature, with doses of MDMA up to 10 mg.kg"1 evoking a dose-
dependent reduction in body temperature and higher doses reversing this effect (See
Figure 6.11, a hypothetical model of temperature-dose response for MDMA in mice.)
This interpretation would explain why many of the transgenic animals responded
maximally to lOmg. kg"1 MDMA and with a smaller hypothermic response to higher
doses of the drug. Among those animals that displayed a hypothermic response only
at the highest dose of MDMA, some may have variations in brain 5 -HT
concentrations that led them to respond to MDMA only at higher doses.
6.4.1 MDMA effects in wild-type mice
MDMA caused temperature and locomotor effects in wild-type mice that were dose
dependent. The time course and magnitude of these responses corresponded with




Figure 6.11 Model ofMDMA induced dose-response in mice
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(Miller and O'Callaghan, 1995; O'Callaghan J, 1994; O'Shea E, 2001) or where an
increase in horizontal locomotor activity and a slight hypothermia occurred, followed
by hyperthermia (Miller D, 1994; Miller and O'Callaghan, 1995; O'Callaghan J,
1994; O'Shea E, 2001).
6.4.2 MDMA and locomotor activity in transgenic mice
In drug-nai've transgenic mice there was a distinct reduction in the level of horizontal
locomotor activity during the dark period of the diurnal cycle. The increase in
locomotor activity in response to MDMA was similar to that in wild-type mice but
peaked at a lower dose of MDMA. In contrast, in 5-HTT knockout mice, the
locomotor affect is abolished, though there are no reports of the effects ofMDMA on
body temperature in these animals (Bengel, 1998). This reports confirms that the
locomotor effects of MDMA are dependent upon the presence of the 5-HTT and
probably on carrier-mediated 5-HT release rather than absolute 5-HT levels, which
are reduced in both transgenic and knockout animals.
Transgenic mice had a tendency to be smaller than their non-transgenic littermates,
despite their reduced locomotor activity. Reduced body weight is a common non¬
specific characteristic of many transgenic mice, but in combination with reduced
activity levels lower body weight might indicate an alteration caloric intake by these
5-HTT over-expressing mice. The possible role of hypothalamic 5-HT in appetite
(Hernandez et al., 1991) and eating disorders (Kaye et al., 1998), and the
controversial use of the 5-HT-releasing amphetamine fenfluramine as an appetite
suppressant ( Curzon and Gibson, 1999; Garattini et al., 1986), suggest that these
mice may provide an animal model for studies on eating disorders.
6.4.3 MDMA and thermoregulation in transgenic mice
In wild-type mice, treatment with moderate doses of MDMA causes 5-HT release
and increased extracellular 5-HT, which normally causes a hyperthermic response
mediated via postsynaptic 5-HT2 receptors. However, very high MDMA doses cause
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a massive 5-HT release, which may have the same effect as injections of high doses
of 5-HT to the hypothalamus, thus stimulating 5-HTiA autoreceptors and overriding
5-HT2-induced hyperthermia (de Roij et al, 1979).
In transgenic mice with over-expression of the 5-HTT there are more sites for
carrier-mediated 5-HT release, thus increasing the likelihood of 5-HT release at
lower concentrations ofMDMA. Transgenic mice have a slightly altered affinity for
MDMA as their temperature response peaks at 10 mg.kg"1 but is still increasing at 30
mg.kg"1 in wild-type animals. Neither wild-type nor transgenic mice responded to
the next lower dose ofMDMA (3 mg.kg"1).
The pattern of the hypothermic response in transgenic mice could result from one or
more of a number of factors. Firstly, 5-HT receptor balance could be altered as a
result of either greater 5-HT release or adaptive changes in 5-HT receptor expression
or sensitivity during development. Secondly, 5-HT could be depleted because of
greater carrier-mediated release. Thirdly, 5-HT could interact with, or change, other
transmitters, such as DA and NA. Fourthly, peripheral responses could be altered,
either directly in the heat regulatory system or indirectly through corticosterone
production. Finally, one parameter may be behavioural changes in the response of
the animal to heat-challenge, as seen with the hyperthermia induced by MDMA.
MDMA induces locomotor activity; increased activity may lead to heat loss through
vasodilation, causing the animals to curl up and stay still to preserve heat though no
observations were made during this time period. At the higher dose ofMDMA, it is
possible that the cold effect is reduced (locomotor activity is reduced) or the signal
received more quickly and so the heat preservation behaviour occurs, preventing
prolonged hypothermia. This alteration may be caused by any of the above factors,
particularly alterations in peripheral thermoregulation and vasodilation. 5-HT is
vasoconstrictive in large vesssels via 5-HT2 receptors, but also vasodilatory through
other non-5-HT2 receptors (Van Nueten et al., 1984). 5-HT2 receptor stimulation in
the periphery can also cause hypothermia in mice. Here, both possible changes in
peripheral 5-HT receptors and altered central feedback could be involved. The
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observation that transgenic mice with hypothermia showed piloerection and
symptoms of high blood pressure (e.g., raised intraocular pressure) would suggest
that peripheral changes are occurring. It would be of interest here to study the
response to a heat challenge in transgenic mice. Part of the hypothermic response
may not be a direct effect of 5-HT or dopamine release on 5-HT or dopamine
receptors, but an altered sensitivity to heat. MDMA has been shown to alter
thermoregulatory responses to heat in rats (Dafters RI, 1998). These mice may be
responding to the thermogenic action ofMDMA with a compensatory hypothermia.
Central nervous system control of thermoregulation may also be involved in the
response to MDMA. In the brain of transgenic mice, the balance of 5-HTia and
5-HT2A receptor activation may be perturbed by increased carrier-mediated release of
5-HT through the 5-HTT. This perturbation may be sufficient to stimulate 5-HTia
receptors to induce hypothermia and override the 5-HT2A-mediated hyperthermia. In
addition, the balance of expression of the two receptors may be altered by the
transgene such that the reduction in 5-HT levels in these animals sensitises 5-HTiA
receptors or desensitises 5-HT2 receptors. In 5-HTT knockout mice the
desensitisation of 5-HTia receptors in the raphe is different from that in the
hippocampus, despite a drastic decrease in 5-HT in all areas (Li et al., 2000; Li et al.,
1999a). These findings indicate that it would be possible for the 5-HTia receptors in
transgenic mice to also be differentially affected. The exact cause of 5-HTia
receptor desensitisation in 5-HTT knockout mice has not been determined but may
result from the decline in 5-HT or a direct effect of the 5-HTT on the expression.
However, it is plausible to predict that the increase in 5-HTT has caused a
commensurate increase in 5-HTia levels because of increased transport and so
reduced feedback. There is some discussion as to whether 5-HTia presynaptic
receptors are active under baseline conditions (see Introduction) If not, 5-HTia
receptors may have a greater capacity to respond to change as a feedback system
than postsynaptic receptors.
In addition to increases in 5-HTia sensitivity or expression, the postsynaptic 5-HT2
receptors may be desensitised. As discussed in the previous chapter, an over-
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expression of 5-HTT may lead to greater release at the level of the synaptic cleft,
which in turn may desensitise postsynaptic receptors. Either or both of these
receptor changes would predispose 5-HTT transgenic mice to hypothermia in
response to 5-HT release. This effect would be more pronounced when combined
with augmented MDMA-induced 5-HT release
The higher dose (30 mg.kg"') of MDMA did not cause such prolonged or severe
hypothermia in those transgenic mice that responded at the lower dose (10 mg.kg"1).
This may attributed either to desensitisation of the 5-HT1A receptors or to a depletion
of available 5-HT. High doses of MDMA may cause depletion of 5-HT stores, as
these mice probably have greater release than normal at the 10 mg.kg"1 dose, but
there is possibly not as much 5-HT available for release at the higher dose of
MDMA. It is also possible that stored 5-HT levels have not recovered after the
MDMA-stimulated release, but the 6- to 24-hour period before recovery of 5-HT
levels in normal mice after 5-HT release (Logan, 1988; Stone, 1987) gives only
qualified support to this hypothesis. Here it is possible that the presence of the
human transporter may be a contributing factor; in primates 5-HT recovery is slower
than in mice (Slikker et al., 1989).
In addition to exerting direct effects on the 5-HT system, MDMA stimulates central
DA release via 5-HT stimulation of 5-HTib receptors in mice; this response is
attenuated in both 5-HTT (Bengel, 1998) and 5-HTib knockout mice (Scearce-Levie,
1999). 5-HT2A and 5-HT2B receptors tonically inhibit dopamine release in rats (Di
Matteo et al., 1998; Millan et al., 1998), which may be altered in transgenic mice and
so alter metabolic rate and locomotor activity. These changes in metabolic rate and
locomotor activity may be sufficient to counteract a centrally induced hypothermia.
The increased locomotor activity after injection with MDMA may also explain the
late onset of the hypothermia, which coincides with the activity returning to baseline.
In summary, these results show that over-expression of the 5-HTT reduces baseline
locomotor activity in mice during the circadian night and disturbs the
thermoregulatory response to MDMA. Transgenic mice have a profound
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hypothermic response to MDMA, in contrast to the very slight hyperthermia seen in
wild-type animals. Transgenic mice have an increased sensitivity to MDMA, with a
peak locomotor response at lower dose than wild-type mice. There are several




This thesis has described the production of transgenic mice over-expressing the
human 5-HTT. These mice express 2-3 times the total 5-HTT protein of wild-type
mice, in a pattern similar to that of the endogenous protein in mice and humans. This
over-expression leads to a reduction in total 5-HT levels of the brain, as well as
altered behavioural and pharmacological responses to MDMA.
7.1 5-HT knockout mice
Studies of 5-HTT knockout mice have provided a wealth of information about the
functions and regulation of the 5-HT system. These mice have no 5-HTT expression
and hence no specific 5-HT uptake. The removal of the 5-HTT is not fatal but has
several effects on the 5-HT system. Knockout mice had vesicular 5-HT stores
reduced by about 95% (Bengel, 1998) because of a loss of released transmitter. The
knockout mouse had extracellular 5-HT levels about six-fold higher than those seen
in wild type littermates, similar to those seen in wild type animals after citalopram
treatment (Bengel, 1998; Fabre et al., 2000). Concentrations of 5-HIAA were
slightly decreased in the knockout mice in most brain areas tested, but the decrease
in 5-HIAA was not of the same magnitude as the decrease in tissue 5-HT, so that the
5-HIAA/5-HT ratio was 130-180% of wild type. The 5-HTT heterozygous mice
expressed the 5-HTT at levels 50% of those in wild type animals, but did not have
altered 5-HT levels, suggesting that feedback systems are able to compensate for a
decrease in 5-HTT expression.
The knockout of the 5-HTT altered the expression of several 5-HT receptor subtypes
(5-HTia 5-HTib and 5-HT2) in the brain, although it is not known whether this
resulted from the effects of altered 5-HT concentrations, or from developmental
compensations. Many of the 5-HT receptors are expressed during development;
5-HTT itself is expressed well before the formation of neurons and in non 5-HT
producing cells, where the transporter probably takes up 5-HT as a mitogenic factor.
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The alterations in 5-HT receptor expression seen in 5-HTT knockout mice are brain
region- and gender-specific. In the case of the 5-HTja receptor, several studies
(Fabre et ah, 2000; Li et al., 2000; Li et ah, 1999a) have shown that the receptor
density and mRNA is reduced in the dorsal raphe and that this reduction is greater in
knockout than in heterozygous mice. In contrast, the hippocampus shows a slight
increase in 5-HTia expression of equal magnitude in both knockout and
heterozygote, whilst other brain areas show no changes. The behavioural and
neuroendocrine effects of 5-HTiA agonists are also significantly reduced in knockout
mice (Li et ah, 2000; Li et ah, 1999a) but not in heterozygotes. Electrophysiological
studies of the 5-HT system showed that 5-HTT deletion increased the recovery time
of the firing rate of hippocampal CA(3) pyramidal neurons following iontophoretic
applications of 5-HT (Gobbi et ah, 2001). Whilst both 5-HTT knockout mice and
heterozygous mice have desensitised presynaptic 5-HTia receptors, only the
knockout mice display any post synaptic 5-HTia receptor desensitisation (Gobbi et
ah, 2001; la Cour et ah, 2001). The 5-HTib autoreceptor is also reduced in the
knockout mouse in the substantia nigra but not other brain regions. 5-HT2A receptors
are also altered in a brain region- specific manner, with decreases in the cerebral
cortex and lateral striatum and a new zone of expression in the outer striatum.
In addition to changes in the expression of 5-HT receptors, the 5-HTT knockout
mouse exhibits altered behavioural and pharmacological responses to drug challenge,
with a reduced locomotor response to MDMA. (Bengel, 1998) and an increased
cocaine place preference (Hall et ah, 2002; Sora et ah, 1998). The locomotor effects
of MDMA are also abolished in 5-HTib receptor knockout mice, suggesting that this
effect in transporter knockout mice may be due to receptor desensitization as much
as to direct effects on 5-HT in the synapse.
The regional specificity of the changes in receptor expression and the fact that the
heterozygote, although showing a 50% reduction in transporter, does not have
reduced tissue 5-HT concentrations or an altered neuroendocrine response to 5-HTiA
receptor agonists, suggests the involvement of a complex loop in the regulation of
the 5-HT system.
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7.2 The 5-HTT over-expressing mice
The 5-HTT knockout mouse shows reduced tissue 5-HT concentrations, increased
extracellular 5-HT, desensitised 5-HTja and 5-HT2 receptors and reduced locomotor
response to MDMA. It might be expected that increased 5-HTT expression in the
transgenic mice would lead to changes opposite to those seen in 5-HTT knockout
mice: increased intracellular 5-HT and decreased extracellular 5-HT, coupled with
increased 5-HTiA receptor sensitivity and increased 5-HT2A and 5-HTiB receptor
sensitivity. As the changes are brain region specific it would be expected that the
5-HTT transgenic mice would show the greatest variations in 5-HT levels in the
DRN and hippocampus.
The expected increase in 5-HT did not occur in the over-expressing mice; indeed,
they showed a reduction in total brain 5-HT. This reduction is not completely
unexpected for several reasons. The total ablation of the 5-HTT in knockout mice is
a major perturbation compared to the 2-3-fold increase in 5-HTT expression seen in
transgenic mice. The decrease in brain 5-HT concentrations associated with a small
increase in transporter protein would suggest that, whilst the expression of the
5-HTT is required for 5-HT uptake and storage, a minor disturbance in 5-HTT
expression has complex effect on 5-HT homeostasis. Such a complex effect is
probably mediated through several interlocking pathways. One hypothesis is that an
acute increase in the 5-HTT leads to reduced 5-HT in the synapse. At the soma
extracellular 5-HT is probably also reduced by increased 5-HTT activity. As a
consequence, the presynaptic autoreceptors at both the synapse and soma receive less
stimulation, leading to increased 5-HT release upon nerve stimulation. This
feedback mechanism, which compensates for the reduced 5-HT due to increased
transporter activity, is present in transgenic mice from conception. This hypothesis
agrees to some extent with pharmacological data. Chronic SSRI treatments to block
the 5-HTT have very different effects on the 5-HT system, including neuronal firing,
than acute treatment (Benmansour et al., 2002). Evidence shows that chronic SSRI
treatments achieve much of their therapeutic effect after a lag period of 21 days, due
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to down regulation of the 5-HTT rather than to acute increases in synaptic 5-HT
levels(Benmansour et ah, 2002). Another factor contributing to reduced 5-HT levels
as in the knockout mouse may be direct effects of the increased 5-HTT on
autoreceptors, possibly due to changes in developmental expression.
One of the aims of this type of research is to provide a model for studying the effects
of a single factor on possible behavioural and psychiatric states in humans. By
comparing the genetic, neurochemical and behavioural effects of various agents in
animal models with the known psychiatric or disease states in humans, researchers
can extrapolate from animal data which areas of genetic or neurochemical
disturbance might be involved in human disease. The findings of this thesis research
show that increased 5-HTT expressions have far-reaching effects on pharmacological
and behavioural responses in transgenic animals. The effect of MDMA on
locomotor function and temperature regulation in transgenic mice may be direct
(through the 5-HTT) or indirect (via variations in receptor sensitivity or dopamine
release). These effects in transgenic mice are different to those in wild-type mice.
This difference alone does not mean that the baseline state in transgenic mice is
altered compared to wild-type mice, just that the two strains respond differently to
challenges. The reduced circadian locomotor activity in transgenic mice in the
absence of MDMA treatment is better evidence that 5-HTT over-expression is
sufficient to alter behaviour and possibly therefore disease.
Although there are few other models of over-expression in the 5-HT system, mice
over-expressing the 5-HT3 receptor have been produced and studied (Allan et al.,
2001). This receptor is thought to be involved in the reward pathway, by controlling
DA release in the mesolimbic system. Transgenic mice over-expressing the 5-HT3
receptor were made in order to study the receptor's role in addiction. Like their
5-HTT over-expressing counterparts, the 5-HT3 over-expressing mice had a
relatively small increase in receptor expression, which produced altered
pharmacological responses. Their sensitivity to ethanol was enhanced (Engel and
Allan, 1999; Engel et ah, 1998) and their place preference for cocaine was reduced,
whilst their sensitivity to cocaine and DA release in response to cocaine were
168
increased (Allan et al., 2001). These findings are further evidence that significant
behavioural effects can result from changing gene expression only 2- to 3-fold. Such
relatively small changes, which could occur as a consequence of normal genetic
variation, are sufficient to cause neurochemical changes that could result in disease.
The monoamine hypothesis of depression and anxiety posits that affective disorders
are due to reduced activity of the 5-HT system, which could result from reduced
availability of 5-HT, or reduced responsiveness to the neurotransmitter, or its
increased removal. Evidence suggests that in some subsets of depressed patients the
5-HTT is increased (Dahlstrom et al., 2000), but considerable evidence from other
studies suggests that the 5-HTT is reduced (Malison et al., 1998; Staley et al., 1998).
These conflicting results can be explained by the different criteria for depression
used in these studies, as described in the Introduction (see Section 1.6.1).
The findings from this thesis research confirm that the role of the 5-HTT in the 5-HT
system is more complex than taking up extracellular 5-HT, thus terminating the
5-HT neurotransmission. In addition to the direct re-uptake from the synapse, the
transporter indirectly affects other elements of the 5-HT neuron, such as the receptor
changes suggested above. The development of the 5-HT system was not hugely
disturbed in the 5-HTT transgenic mouse, but a small increase in 5-HTT expression
was sufficient to cause measurable behavioural effects. Such disturbances could
explain why humans with slight variations in 5-HTT expression might be prone to
developing affective disorders. The transgenic mouse model used here provides
some insights into possible areas of interaction within the 5-HT system. For
instance, studies on the localisation and activity on both pre- and postsynaptic
receptors would provide information about the effects of changes in transporter
expression on receptor function. This information might be useful in understanding
and improving treatment of affective disorders, in which the 5-HTiA receptor agonist
pindolol has been implicated in enhancing SSRI treatment (Pineyro et al., 1994).
Studies with the 5-HTT over-expressing animal model might confirm this
interaction. Postsynaptic receptor function could also be examined in this model by
looking, for instance, at the localisation and sensitivity of the 5-HT2 receptors and at
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their downstream effects, such as temperature regulation or neuronal activity
(Morishima and Shibano, 1995; Nash et al., 1989; Sugimoto et al., 1991).
7.3 Future work
In this research the synaptic concentration of 5-HT in the over-expressing mice was
not determined. The use of micro-dialysis to analyse these levels would provide
more information as to which mechanisms are involved in reducing 5-HT levels.
Another factor contributing to reduced 5-HT levels may be direct effects of the
increased 5-HTT on autoreceptors, possibly due to changes in developmental
expression.
Further work on 5-HT receptor availability, receptor sensitivity, and synaptic
concentrations of 5-HT in these over-expressing mice would clarify the factors
involved in regulating the availability of 5-HT. Postsynaptic 5-HT receptors would
also be affected by altered synaptic levels of 5-HT, thus localization and expression
of 5-HTia, 5-HTib and 5-HT2A receptors at both the protein and RNA level would be
of the greatest importance in the understanding of the regulation of the 5-HT system.
One further useful study would be the autoradiographic localisation and
quantification of the 5-HTT in transgenic mice. Such a study is important for several
reasons. Firstly, the pharmacological binding data (Chapter 4) suggest that the
increases seen in the cortex are greater than in the midbrain, and therefore the soma,
which may be an important consideration in interpreting any behavioral and systemic
results. Secondly, the 5-HTT has been shown to be present in glia (Zhou et al.,
1998), and it is possible that some of the increased cortical expression seen in the
transgenic mice is partly in these cells rather than the neurons. A third consideration
would be the distribution of 5-HTT expression within individual neurons. Recent
electron microscopy studies (Zhou et al., 1998) suggest that the 5-HTT is found
perisynaptically, and increasing its concentration might alter its micro-localisation.
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A final matter of interest is the study of the developmental changes in early gene
expression which are altered in transgenic mice. This would be helpful in elucidating
both the role of the 5-HTT in brain development and the effects of over-expression
on the 5-HT system.
7.4 Use of transgenic mice as a tool for understanding the complex
interactions of the 5-HT system.
The over-expression of 5-HTT in transgenic mice offers a better animal model of
depression in man than the 5-HTT knockout mouse, though it cannot be considered
an appropriate model of all types of affective disorder. Transgenic mice over-
expressing the 5-HTT also provide a good model for further studies on interactions
of various parts of the 5-HT system, particularly those aspects that respond to SSR1
treatments. One example would be 5-HTiA receptor sensitivity (Pineyro et al.,
1994), where the effects of a lifetime change would probably differ greatly from
those of an acute pharmacological model.
5-HTT transgenic mice could also be useful for studying the interactions between the
5-HT system and other neurotransmitter systems, such as the dopaminergic system,
particularly in areas such as the striatum where 5-HTib receptors are known to
influence DA neuronal firing (Sarhan et ah, 2000). The evidence for locomotor
disturbance in the transgenic mice (see Section 6.1.2) and loss of locomotor
stimulation in response to MDMA in knockout mice (Bengel, 1998) suggests that
these or other dopaminergic neurons might also altered by variations in 5-HTT
expression. The transgenic model provides a good system to study these types of
interactions. Comparative studies on the localisation of the 5-HT projections areas
of the adult forebrain could be done with transgenic and wild type mice. If
differences are found, then localisation of 5-HT pathways could be studied
throughout development. Such localisation studies would enhance the understanding
not only of affective disorders, but also disturbances in serotonergic metabolism such
as anorexia nervosa. This eating disorder is a possible area of study as these mice
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appear to be smaller than their wild-type littermates, and recent evidence in 5-HTT
knockout mice has shown gastric disturbance (Chen et al., 2001).
7.5 Conclusion
In conclusion, this thesis research has produced a transgenic mouse model in which
the moderate over-expression of one gene has had important ramifications for the
whole animal, both at the neurochemical and behavioural levels. The RNA and
protein expression studies confirm the validity of this transgenic method as a reliable
model for human protein expression. The two main findings from this research are
that the over-expression of the 5-HTT leads to reduced total brain 5-HT stores and to
reduced locomotor activity and disturbed thermoregulation in response to MDMA.
These results have stimulated the generation of some hypotheses for how 5-HTT
over-expression might affect the 5-HT system as a whole, with implications for
possible roles of the 5-HTT in human affective disorders. This genetic manipulation
of the 5-HTT has produced an animal model that will be a valuable tool for further
studies in the 5-HT system.
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